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 Breast cancer affects 1 in 8 women worldwide.  The American Cancer Society 
estimates that in 2006, approximately 212,920 women will be diagnosed with invasive 
breast cancer, and an estimated 40,970 women will die from this disease (1).  As the 
medical world revolutionizes diagnostic equipment and medical therapies for the early 
detection and treatment of breast cancer, the underlying cause of breast cancer must be 
addressed and alternative therapies investigated.  Simply stated, breast cancer is a result 
of genetic mutation.  Mutations leading to altered gene expression spearhead the 
development and progression of breast cancer.  Our research focuses on several key 
genetic alterations in primary breast carcinoma cells, and via our proposed cancer 
therapy, we intend to decrease cancer cell division and/or induce cancer cell death.    
Breast carcinoma cells reach their immortalized state via several routes of 
deregulated gene expression and genetic mutations.  This research focuses on the several 
important genetic alterations detected in breast cancer.  First, the majority of cancer cells 
overexpress telomerase which promotes restoration of the telomeric DNA on 
chromosomal ends during cell division.  The catalytic subunit of telomerase, hTERT 
(human telomerase reverse transcriptase), is the rate-limiting enzyme responsible for 
synthesizing telomeric DNA.  Disruption of telomerase has been found to impede the
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recapping of telomeres, thus triggering pathways involved in cell senescence and/or 
apoptosis.  Second, in addition to overexpression of telomerase, at least 40-50% of breast 
cancers have mutations in the p53 tumor suppressor gene.  The p53 protein is the primary 
“gatekeeper” of the cell cycle; therefore, mutations in the p53 gene results in impaired 
cell cycle control thus promoting tumorigenesis.  Importantly, the E2F-1 transcription 
factor is a known repressor of hTERT transcription and transcriptional activator of p53 
and p53-homologue proteins.  In the presence of p53 mutations, the p53-homologue, the 
p73 tumor suppressor protein, can assume the responsibilities of wildtype p53.  To 
explore these two genetic alterations in breast carcinomas, we will be utilizing the E2F-1 
transcription factor.  Previously, the E2F-1 transcription factor has only been investigated 
using viral-based methodologies (i.e. adenoviruses and adeno-associated viruses) to 
introduce the E2F-1 transcription factor into cancer cells to study their impact on gene 
expression.  However, viral-based methodologies are often irreversible, do not affect 
100% of treated cells and the viral host vector could elicit an immune response.  We 
propose protein therapy with the E2F-1 transcription factor to impact all targeted cancer 
cells in a reversible manner.  We will be investigating an alternative protein therapy with 
the E2F-1 transcription factor to modulate expression of telomerase and induce 
expression of p73 and p21
WAF1/CIP1
 tumor suppressor genes in p53-mutated breast 
carcinoma cell lines.   Several p53-mutated cell lines will be investigated in our research 
due to the high prevalence of p53-mutations in breast cancer.   
 This research uses an alternative method of introducing the E2F-1 transcription 
factor into breast carcinoma cells by employing Tat-mediated protein transduction. 
Proteins attached to the HIV-1 Tat transduction domain have been found to transduce 
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100% of target cells (2, 3).  Once Tat fusion proteins enter cells, they have the 
opportunity to elicit their biological effect followed by degradation of the recombinant 
Tat proteins.  Importantly, transduction of the E2F-1 transcription factor into all the 
targeted cancer cells will facilitate a cellular response to our protein therapy.  It is 
anticipated that biologically active E2F-1 proteins will completely repress the expression 
of telomerase and effectively active p73 cell pathways in p53 mutated cell lines.  We 
anticipate greater levels of repression and/or activation of target genes versus viral-based 
methodologies due to the more effective introduction of active proteins versus viral-based 
methods that depend on the carcinoma cells to produce active proteins.  In addition, the 
proposed E2F-1 Tat fusion proteins would function as reversible therapeutic agents 
because once protein treatment is discontinued, the remaining proteins are degraded via 
native ubiquitin-proteosome pathways based on the half-lives of the proteins (2-4). 
 To investigate the biological effect of E2F-1 Tat fusion peptide treatment on 
breast cancer cells, it was necessary to produce protein expressing constructs and develop 
an efficient protocol for purifying the recombinant proteins.  The primary goal was to 
develop a successful technique to produce and purify recombinant E2F-1 Tat fusion 
proteins with greater than 95% transduction potentials.  The E2F-1 Tat constructs 
contained the HIV transduction domain, a hemagglutinin (HA) tag, 6-histidine tag, and 
the wildtype or mutant E2F-1 gene.  Therefore, the proteins translated from the mRNA 
transcribed from the E2F-1 construct cDNA would produce the following:  an E2F-1 
protein attached to the HIV-1 Tat transduction domain for efficient transduction of active 
proteins, a HA tag for detection via immunocytochemistry and a 6-histidine tag for 
purification via FPLC.  In general, the purification of Tat fusion proteins is highly 
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dependent on the solubility and stability of the proteins under specific physiological 
parameters (i.e. soluble proteins at final a pH range of 7.4-7.5) required for in vitro 
testing of cell lines.  To briefly summarize this phase of the research, it was necessary to 
generate constructs with the HIV-1 Tat transduction domain attached to E2F transcription 
factors in order to test their transduction potential and biological efficacy in carcinoma 
cell lines.  Expression vectors containing the wildtype E2F-1 gene and a mutant E2F-1 
gene, E132 (point mutation in DNA-binding domain), were obtained in order to clone the 
cDNA into the multiple cloning site (MCS) of the pTatHA expression vector to generate 
E2F-1/TatHA and E132/TatHA constructs.  The pTatHA vector already contained the 
HA tag and 6-histidine tag necessary for detecting and purifying the recombinant E2F-1 
proteins.  A bacterial expression system was utilized to produce the recombinant proteins, 
and our purification protocol was optimized by combining affinity chromatography, 
strong denaturants and FPLC to yield a large quantity of E2F-1 Tat fusion proteins.  
Therefore, we optimized a methodology to produce biologically active E2F-1 Tat fusion 
proteins to impact gene expression in breast cancer cell lines.  The following objectives 
summarize the goals of the first phase of this research: 
  
 A.  Develop an effective methodology to generate constructs with the HIV-1 Tat  
 transduction domain attached to E2F-1 transcription factors. 
 
 B.  Produce large quantities of purified, biologically active E2F-1/TatHA and      
 E132/TatHA proteins using a bacterial expression system followed by FPLC     
 purification and dialysis.   
 5 
 C. Verify transduction of the E2F-1/TatHA and E132/TatHA fusion proteins into 
 breast carcinoma cell lines.  
 
 The second phase of the proposed research investigates repression of telomerase 
activity in primary ductal breast cancer cells through transcriptional regulation of the 
catalytic subunit hTERT.  We hypothesize that inhibition of telomerase expression can be 
achieved via Tat mediated protein transduction of the repressor protein E2F-1.  
Telomerase, a ribonucleoprotein, synthesizes tandem repeats of the DNA sequence 
TTAGGG at the terminal ends of chromosomes permitting continuous genomic 
replication and cell division.  Telomerase includes an RNA component (hTR) that serves 
as the template for telomeric DNA and a protein catalytic subunit (hTERT) with reverse 
transcriptase activity (5).  Telomerase activity is regulated by transcription of hTERT 
which is detectable in 80-90% of malignancies and absent in most normal somatic cells 
(6).  Importantly, fine-needle aspirations of early stage malignant breast tumors revealed 
that 81% were positive for telomerase (7), and Hiyama et al. (2000) also reported that 
95% of advanced stage breast cancers express telomerase (8).   
We expect that efficient transduction of the E2F-1/TatHA fusion proteins will 
effectively repress hTERT expression in the primary ductal breast cancer cell lines 
HCC1937 and HCC1599.  E2F-1 has been identified as a transcriptional repressor of the 
hTERT gene via binding two separate sites (-174 bp and -98 bp) of the proximal hTERT 
promoter (9).  Efficient transduction of the E2F-1 protein via Tat mediated transduction 
should facilitate complete repression of hTERT gene expression.  Our in vitro 
experiments with breast cancer cell lines were designed to permit a thorough evaluation 
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of the overall effects of the E2F-1 repressor protein and its role in transcriptional 
repression of the hTERT gene.  It was hypothesized that complete repression of 
telomerase activity could be achieved in vitro via protein transduction with E2F-1 to 
ultimately decrease cell division and/or induce apoptosis.  This proposed study was also 
expected to provide a greater understanding of E2F-1 repressor proteins functioning as 
transcriptional repressors with a potential role in cancer therapeutics.  In summation, the 
primary objectives of the second phase of this research are as follows:  
  
 A.   Determine if the E2F-1 transcription factor can repress telomerase activity 
 in primary ductal breast cancer cells through transcriptional regulation of the       
 catalytic subunit hTERT. 
 
  B.  Achieve complete repression of hTERT in breast cancer cell lines following 
 transduction of wildtype E2F-1/TatHA proteins versus the control E132/TatHA 
 protein using real-time RT-qPCR methodologies. 
 
 The third phase of this research focuses on activation of the p73 tumor suppressor 
gene in p53-mutated breast cancer cell lines.  Common mutations that lead to diminished 
cell-cycle control in breast cancer include alterations in the p53 tumor suppressor gene.  
Approximately 50% of cancers, including breast cancer, harbor mutations of the p53 
tumor suppressor gene (12).  However, the p53-homologue, p73, is rarely mutated in 
carcinoma cells (13).  In cancer cells harboring a p53 mutation, multiple studies suggest 
that overexpression of the p73 tumor suppressor gene can induce apoptosis (14, 15).  In 
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the absence of p53, it is imperative that the proposed cancer therapy stimulates intact cell 
cycle pathways to inhibit cancer cell division or induce cancer cell death.  The p73 
pathway provides an alternate route through which apoptosis of cancer cells can be 
achieved since compelling evidence supports that p73 induction is associated with 
inducing downstream target genes controlling cell cycle arrest and apoptosis. 
 An important regulator of p73 expression, the E2F-1 transcription factor, has been 
found to activate p73 expression and induce cancer cell death (16, 17).  Activation of the 
p73 tumor suppressor pathway has been observed in adenoviral and retroviral studies 
transfecting the E2F-1 gene into carcinoma cells (16, 17).  Additionally, upregulation of 
p53-responsive genes has been observed in cells upon activation of p73 (18, 19).  
Stimulation of the p73 tumor suppressor gene has also induced p21
WAF1/CIP1
 expression 
leading to cell growth arrest and apoptosis (19, 20).  We hypothesized that our 
alternative, reversible methodology to induce p73 expression in breast carcinoma cells, 
utilizing protein transduction with E2F-1 Tat fusion proteins (TFPs), would effectively 
target and kill breast cancer cells.  We expected the E2F-1 Tat fusion proteins to 
effectively transduce the targeted breast carcinoma cells, activate transcription of p73 and 
induce apoptosis.   
 The p21
WAF1/CIP1 
gene functions as an inhibitor of cyclin-dependent kinases and is 
directly induced by the p53 tumor suppressor protein and its homologues.  The 
p21
WAF1/CIP1
 gene is an uncommon target for mutational inactivation in breast cancer 
(21); however, in the absence of p53, its innate role in controlling the cell cycle may be 
compromised.  Wildtype p53 directly induces expression of p21
WAF1/CIP1
 resulting in cell 
cycle arrest; therefore, in the absence of p53, this pathway controlling the cell cycle is 
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unstimulated.  Importantly, the induction of the p53-homologue p73 can stimulate 
activation of p21
WAF1/CIP1
 promoting cell cycle arrest in cancer cell division.  In 
combination to p73, p21
WAF1/CIP1
 gene expression in cells is also reportedly affected by 
the BRCA1 tumor suppressor protein (22).  Our study investigates the induction of 
p21
WAF1/CIP1
 via p73 overexpression using real-time RT-qPCR, and it is anticipated that 
our experiments will distinguish possible differences in BRCA1 (wildtype versus 
mutated) on p21
WAF1/CIP1
 expression and subsequent apoptotic activity.  We propose that 
the decreased expression of BRCA1 in the HCC1937 cell line (homozygous 5382C 
mutation) could impact the ability of p73 overexpression to activate p21
WAF1/CIP1
.  
Overall, we expect to observe increased fold induction of p73 in all cell lines tested with 
possible variation in p21
WAF1/CIP1
 expression based on the BRCA1 status of tumor cells.  
 The following points summarize our objectives for the final phase of this 
research.  
  
 A.  Following treatment with E2F-1/TatHA, E132/TatHA and TatHA control   
 proteins, monitor fold changes in gene expression of the p73 tumor suppressor 
 gene in breast cancer cell lines via real-time RT-qPCR. 
 
 B.  Determine if overexpression of the p73 tumor suppressor gene can activate    
 expression of the p53-responsive gene, p21
WAF1/CIP1
, in p53-mutated breast    
 cancer cell lines. 
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 C.  Following induction of p73 gene expression, distinguish differences in         
 p21
WAF1/CIP1
 expression in breast cancer cell lines with and without BRCA1 
 mutations. 
  
 D.  Assess apoptotic activity in breast cancer cells following E2F-1/TatHA, 
 E132/TatHA, and TatHA fusion peptide treatment.  
      
 In summary, the proposed research investigates the contributory role of specific 
genetic alterations in breast cancer research and possible avenues for therapeutic 
intervention.  In the following chapters, an effective methodology to produce and purify 
E2F-1 Tat fusion proteins is outlined.  The transduction of Tat fusion proteins into breast 
cancer cell lines will be demonstrated to illustrate the efficient delivery of biologically 
active proteins.  Chapter IV will investigate our hypothesis that E2F-1 transcription factor 
proteins can effectively repress hTERT in telomerase expressing breast cancer cell lines.  
Chapter V will investigate if Tat-mediated transduction of E2F-1 proteins into cells can 
also induce expression of the p73 tumor suppressor gene in p53-mutated cell lines.  We 
will also determine if the p53-responsive gene, p21
WAF1/CIP1
, can be upregulated via 
overexpression the p53-homologue, p73.   
Overall, the effects of E2F-1 Tat fusion protein treatment on breast cancer cell 
growth and apoptosis will be assessed in breast cancer cell lines.  It is anticipated that the 
objectives outlined above will lead to a greater understanding of the therapeutic potential 
of E2F-1 Tat fusion protein treatment as an adjuvant to current chemotherapeutic 
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 Breast cancer will affect 1 in 8 women worldwide in their lifetime and 1 in 33 will 
die from this disease (1).  In 2006, the American Cancer Society estimated that 212,920 
women were diagnosed with invasive breast tumors and approximately 40,970 women 
died from breast cancer (1).  The incidence of breast cancer appears to be increasing 
worldwide, in part because of better ability for diagnosis due to significant advancements 
in mammography and the advent of magnetic resonance imaging (MRI) as a screening 
tool for breast tumors (1-5).  However, despite advancements in the early detection and 
treatment of breast cancer, limitations in therapeutic options still exist because of drug 
side effects and poor tumor response to treatment.  Most chemotherapeutic and 
radioactive treatments have deleterious systemic effects in women undergoing therapy for 
breast cancer.  Conventional treatments for breast cancer target the uncontrolled growth 
of cancer cells while a primary source of disease, genetic mutation, is not understood 
enough to serve as a central target of cancer treatment plans.  The future of breast cancer 
treatment depends on the exploration of therapies targeting specific genetic alterations 
associated with the development and progression of breast cancer.  Therefore, our 
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research will explore a novel therapy targeting specific genetic alterations in breast 
carcinomas to impact gene expression and induce cancer cell death. 
 
BREAST CANCER REVIEW  
 
Detection, Diagnosis and Staging of Breast Cancer 
Breast cancer originates at the cellular level from genetic alterations.  As tumor 
cells proliferate, their presence manifests into a detectable form.  Detection usually 
occurs when women or their physician incidentally palpate a breast mass or a suspicious 
finding is identified via screening mammography.  The definitive diagnosis of breast 
cancer then depends on the pathology of a breast tumor (i.e. fine-needle aspiration of a 
breast tumor or evaluation of tissue from a lumpectomy) followed by surgical cancer 
staging.  Breast cancer staging requires an additional dissection of mammary lymph 
nodes to identify the sentinel lymph node and assess lymphatic spread of tumor cells.  
Metastatic disease is suspected based on the extent of lymphatic involvement in 
combination to physical diagnosis and testing for tumors in the lungs, liver, bones and 
brain.  Overall, breast cancer staging offers valuable information regarding disease 
activity and the most beneficial therapeutic intervention.  Table 1.1 outlines breast cancer 
staging as published in Harrison‟s Principles of Internal Medicine, 16
th
 edition (6).  The 
grading of breast cancer is performed according to the Scarff-Bloom-Richardson tumor 
grading system, and the histological grade of the tumor cells correlates with important 
prognostic factors.  Grade 1 indicates the breast tumor is well-differentiated, cells appear 
normal without rapid growth and cancer cells are arranged in small tubules (7).  Grade 1 
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breast cancers have a 95% 5-year survival rate (7, 8).  Grade 2 breast cancer refers to 
moderately-differentiated breast cancer cells with mixed characteristics between grades 1 
and  3 (7).  Grade 2 breast cancers are associated with a 75% 5-year survival rate in 
patients (7, 8).  Grade 3 breast cancer indicates the tumor cells are poorly-differentiated, 
cells do not appear normal and they tend to grow and spread more aggressively.  Grade 3 
breast cancer is associated with a 50% 5-year survival rate (7, 8).   
The staging and grading of breast cancer is applicable to our research when 
considering the tumor stage of the cell lines utilized for in vitro studies.  Table 1.2 
outlines the specific characteristics of the breast cancer cell lines evaluated in our studies.  
Importantly, 80% of breast cancers are classified as primary infiltrating or invasive ductal 
breast carcinomas.  The two primary infiltrating ductal breast cancer cell lines 
investigated by this research are HCC1937 and HCC1599.  The HCC1937 cell line is 
derived from a TNM stage IIB, grade 3 primary ductal breast carcinoma, and the 
HCC1599 cell line originates from a TNM IIIA, grade 3 primary ductal carcinoma.  
Additional metastatic breast cancer cell lines (stage IV) were examined in our work 
including MCF-7, MDA-MB-231 and MDA-MB-435S cells.  Several specific mutations, 
oncogenes, and staging for each of the breast cancer cell lines are listed in Table 1.2 (9-
17).  
 
Risk Factors Associated with Breast Cancer 
 Although breast cancer is a result of genetic alterations, multiple known risk 
factors are attributed to the increased risk of developing breast cancer.   Women have an 
increased breast cancer risk if they are Caucasian or if they have a positive family history 
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of breast cancer (18).  Increased risk of developing breast cancer is also associated with 
increasing age, and/or a previous medical history of endometrial cancer, mammary 
dysplasia or contralateral breast cancer (19).  Additionally, a greater incidence of breast 
cancer is associated with menarche before the age of 12 and late menopause after the age 
of 50 which are phenomena leading to increased total hormonal exposure of breast tissue 
(19).  Advanced age at first pregnancy and nulliparity are also attributed to increased 
development of breast cancer in women (19).  Oral contraceptive use is associated with a 
slightly increased breast cancer risk while postmenopausal hormone replacement therapy 
is attributed to a higher incidence of breast cancer (19).  Women who are determined to 
be at greater risk of developing breast cancer should be screened on a regular basis by 
their physician to ensure early detection and intervention of precancerous and cancerous 
breast lesions.  Genetic testing to detect predisposition to developing breast cancer in 
women with known risk factors may also become an accepted medical intervention in the 
near future to better develop treatment plans for these women.  Likewise, genetic 
screening for known mutations or aberrant gene expression associated with breast cancer 
could decrease mortality rates by allowing early detection and serve as a justification for 
gene therapy.   
 
ROLE OF GENETIC MUTATIONS IN BREAST CANCER 
 
Breast cancer is a result of genetic mutation.  The source of genetic mutation is 
variable and can be associated with germline mutations in known tumor suppressor genes 
or sporadic mutations due to radiation exposure, carcinogens, environmental factors 
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and/or other unknown causes.  Hereditary breast cancer is linked to mutations in tumor 
suppressor genes, and these women have an increased lifetime risk of developing breast 
cancer.  Knudson‟s two-hit hypothesis explains this predisposition to cancer and the 
occurrence of familial cancer syndromes (refer to Table 1.3 for specific examples).  
Knudson‟s hypothesis states that the first „hit‟ or genetic mutation is inherited due to a 
germline mutation in a cancer susceptibility gene, and the second „hit‟ occurs somatically 
in the other allele of the same gene (20).  Following the second hit, the person is 
predisposed to developing cancer due to the functional inactivation of a tumor suppressor 
gene or a gene involved in regulation of the cell cycle.   Table 1.3 demonstrates 
autosomal dominant and recessive hereditary cancer syndromes and their association with 
breast cancer, other malignancies and their respective genetic mutations (20-23). 
In breast cancer, mutations in the p53 tumor suppressor gene are present in 40-
50% of carcinomas (24, 25).  The p53 tumor suppressor gene is regarded as the 
“gatekeeper” of the cell cycle, and mutations can result in deregulated cellular growth 
resulting in cancer.  Gene mutations in breast cancer susceptibility genes 1 and 2 
(BRCA1 and BRCA2) are attributed to 3-8% of all breast cancer cases and 30-40% of 
familial breast cancer cases (26).  BRCA1 and BRCA2 also function as tumor suppressor 
proteins and numerous mutations in their genes have been detected and attributed to 
missense, truncating and silent mutations (27).  Mutations in the retinoblastoma (Rb) 
tumor suppressor gene are also linked to progression of breast cancer, and approximately 
20-30% of breast carcinomas are positive for a deletion or mutations of the Rb gene (28).  
The important role of tumor suppressor genes in breast cancer development will be 
discussed in greater detail in subsequent sections of this review.  In addition, the E2F-1 
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transcription factor and its association with tumor suppressor genes and its potential role 
in cancer therapeutics will be described.  We will also explore an alternative route of 
introducing the E2F-1 transcription factor into cells via protein transduction and discuss 
the therapeutic implications of our proposed methods.   
 
 
REVIEW OF THE E2F-1 TRANSCRIPTION FACTOR 
 
Family of E2F Transcription Factors  
 The E2F transcription factor family consists of three groups with six different E2F 
proteins.  Overall, the E2F family of transcription factors is multifaceted in its ability to 
both activate and repress target genes and reportedly promote and inhibit cellular 
proliferation (29).  Group one contains E2F-1, E2F-2, E2F-3; group two includes E2F-4 
and E2F-5; and group three only contains the E2F-6 protein.  Expression of group one 
E2F members is controlled by cell growth with significant accumulation at the G1/S 
phase boundary of the cell cycle.  The E2F-4 and E2F-5 transcription factors bind the 
Retinoblastoma (Rb) protein family members, but function as transcriptional repressors 
in conjunction with the p130 protein in G0 and G1 phase of the cell cycle.  The E2F-6 
transcription factor is unique because it does not contain the domains involved in 
transactivation of E2F target genes nor the domains that bind the Rb protein.   
 
Effects of E2F-1 on the Cell Cycle    
 The E2F-1 gene is located on chromosome 20q11.2 and the translated protein is 
approximately 47 kilodaltons in size.  The E2F-1 transcription factor is found within the 
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cell nucleus and plays an integral role in the G1- to S-phase transition in the cell cycle.  
E2F-1 forms a heterodimer complex with DP-1 (DRTF-1 polypeptide-1) to form the 
DRTF1/E2F-1 transcription complex which functions to bind the hypophosphorylated Rb 
proteins (30).  In mid to late G1 phase, Rb is phosphorylated and the DRTF1/E2F-1 
complex detaches from Rb, and E2F-1 is released to transactivate its target genes.  The 
transcriptional activity of native E2F- 1 is stimulated via phosphorylation by CDK2 and 
cyclin A-CDK2 in S-phase (31).  Following activation, E2F-1 binds specific promoter 
sequences in target genes to activate transcription, ultimately functioning to mediate both 
cell proliferation and apoptosis. 
 The level of native E2F-1 protein fluctuates in the cell cycle.  E2F-1 levels begin 
to rise in G1/S phase, and increase as cells progress into S-phase (32).  The S-phase of 
the cell cycle comprises the complete and accurate duplication of all genes in a cell, and 
excess E2F1 can activate an S-phase checkpoint (32).  It is important to control E2F-1 
levels throughout S-phase because it is apoptotic in excess.  In contrast, low levels of 
E2F-1 expression delay S-phase entry, decrease activation of E2F-1 responsive genes and 
diminish apoptotic activity in cells (32, 33).   In normal cells, feedback control, i.e. intact 
Rb tumor suppressor gene, exists to prevent overexpression of E2F-1 from inducing 
apoptosis.  However, it has been reported that virtually all human tumors exhibit 
alteration in the Rb pathway (32); thus the effect of E2F-1 overexpression on cell 
senescence and cell death warrants further investigation.   
  E2F-1 is the primary E2F family member directly involved in apoptosis.  
Apoptosis typically occurs following the synthesis of S-phase genes which subsequently 
activate apoptosis-related genes.  Numerous studies transfecting the E2F-1 gene into cells 
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revealed that apoptosis followed synthesis of S-phase enzymes and DNA after 
overexpression of E2F-1 (32).  Three different pathways have been identified to describe 
E2F-1-mediated apoptosis: 1) p53-dependent apoptosis via activation of the CDKN2A 
transcript p14
ARF
, 2) inhibition of survival signals thus making cells more susceptible to 
apoptotic signals such as TNF-alpha, 3) induction of p73 expression leading to activation 
of p53-responsive gene targets and programmed cell death (34).  Figure 2.1 illustrates 
several of the E2F-1 signaling pathways involved in cell cycle progression, cell cycle 
arrest and apoptosis (35).  Additionally, microarray analysis of E2F-1 induced apoptosis 
has revealed upregulation and downregulation of several key proteins involved in signal 
transduction, cell cycle regulation and apoptosis (36).  Jamshida-Parsian et al. (2005) 
performed microarray analysis of the gene expression associated with adenovirus-
mediated overexpression of E2F-1 in melanoma cells (36).  They reported at least 5.5-
fold induction of apoptosis-related genes BCL2L11 and CDKN1A (p21
WAF1/CIP1
) and 7.2-
fold repression of the MYC oncogene (36).  Other CDK inhibitor genes involved in 
regulation of cell proliferation were also induced following E2F-1 overexpression 
including CDKN2C (p18 CDK4 inhibitor), CDKN1B (p27, Kip1), CDKN1C (p57, 
Kip2), CDKN1C (p57, Kip2) and CDKN2A (p16, cell cycle checkpoint gene) (36).  
Microarray analysis also revealed a 6.3-fold upregulation in MAP3K5 (induces apoptosis 
by extracellular signals) and a 22.6-fold increase in the FGFR3 (fibroblast growth factor 
receptor 3) gene which is associated with cell growth and oncogenesis (36).  Overall, this 
study provided data supporting novel pathways to explain the mechanism of E2F-1 
mediated apoptosis thus supporting the therapeutic potential of the E2F-1 transcription 
factor. 
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Inherent Controls of E2F-1 Level in Cells 
 The level of E2F-1 expression in cells is both positively and negatively controlled 
by multiple factors.  Activation of E2F-1 has been observed via IGF-1 stimulation and 
positive regulation by cyclins D and E.  The expression levels of E2F-1 also increase in 
the presence of the c-myc oncogene and self-induction also occurs following stimulation 
of other S-phase genes.  Conversely, E2F-1 is inactivated by binding hypophosphorylated 
Rb protein and negatively regulated by cdk inhibitors p21
WAF1/CIP1
, p27, INK and TNF-
alpha.  In addition to complex regulation of E2F-1 levels, the E2F-1 protein is controlled 
via proteosomal degradation.  The stability of E2F-1 is modified by covalent 
phosphorylation, and the exact mechanism of degradation depends on kinases such as 
cyclin A/cdk2.  Regulation of E2F-1 protein levels ultimately occurs by the ubiquination-
dependent proteasome degradation pathway (37).  
 The E2F-1 transcription factor can activate or repress transcription of target 
genes, but its activity is dependent on a number of factors.  When E2F-1 interacts with 
the Rb protein, its transcriptional potential is negatively affected by recruiting a histone 
deacetylase complex and by contacting promoter-bound proteins (37).  Additionally, 
phosphorylation regulates the E2F-1/Rb interaction which is ultimately controlled by 
cyclin D/cdk4 at the G1/S transition of the cell cycle (37).  E2F-1 forms a heterodimeric 
complex with DP1 (DRTF proteins) proteins, and it binds the promoters of genes that 
contain E2F-responsive elements in order to activate transcription. 
 Activity of native E2F-1 is dependent on post-translational modification to 
increase activity of the protein.   E2F-1 is subject to modification by acetylation, and the 
acetylation domains are in close proximity to the DNA-binding domain (38).  P/CAF is a 
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p300/CBP-associated factor that functions to acetylate E2F-1 and affect its activity in 
several ways.  It increases the DNA-binding ability, activation potential and the protein 
half-life (38).  P/CAF and p300/CBP are more commonly known to acetylate histones 
associated with transcriptionally active DNA, but also function to acetylate other 
transcription factors such as p53.  Acetylation of E2F-1 by P/CAF results in an increased 
transcriptional activation capacity (38).  It is speculated that E2F-1 is not acetylated when 
bound to the Rb protein; however, when E2F-1 is unbound, acetylation serves to protect 
it from degradation as it functions as a transcriptional activator.  Overall, it appears that 
acetylation of E2F-1 by either P/CAF or p300/CBP can regulate the transcription activity 
of E2F-1(38).  Ianari et al. (2004) reported that the formation of E2F-1-P/CAF complexes 
in response to DNA damage supports a role for P/CAF HAT in E2F-1-dependent 
apoptosis because the protein is stabilized by acetylation (37).  Stabilization of E2F-1 
occurs in response to genotoxic stress via phosphorylation by ATM kinase, RAD3-related 
(ATR) kinase, and checkpoint kinase 2 (37).  DNA damage also results in the 
stabilization of E2F-1 via acetylation which boosts its ability to activate downstream 
targets (37).   
 A potential drawback to producing the E2F-1 proteins in a prokaryotic system is 
the possibility of proteins requiring post-translational modifications to elicit their 
biological actions.  It is possible that complete repression or activation of target genes 
would require the E2F-1 transcription factor to be acetylated.  If this proves to be the 
case, a eukaryotic expression system could be utilized to express the proteins.  It has also 
been proposed that acetylation protects E2F-1 from a ubiquitin-mediated degradation 
and/or proteolytic cleavage (37).  The biological activity of our proposed E2F-1 Tat 
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fusion proteins may require modifications such as acetylation to increase transactivation 
of target genes and to extend the protein half-lives.  Currently, the wildtype E2F-1 protein 
half-life is approximately 70 minutes (increases to 3 hours if degradation pathways are 
inhibited) (32); however, it is anticipated that the half-life of our E2F-1 fusion proteins 
would be significantly extended due to altered cellular trafficking and our alternative 
introduction of this transcription factor.   
 
ABERRANT GENE EXPRESSION IN BREAST CANCER- TELOMERASE 
 
The unique ability of immortalized cells to bypass normal controls of cellular 
proliferation is a phenomenon that is heavily investigated by physicians and scientists.  A 
part of this phenomenon is the increased expression of telomerase in tumor cells.  In 
human cells, telomeres are protein-DNA complexes that cap the ends of chromosomes. 
During cell divisions, the telomeric DNA shortens progressively until the Hayflick limit 
of the cell is reached (approximately 50-80 cell divisions), and cells enter a senescent 
state (39, 40).  Telomerase, a ribonucleoprotein, synthesizes tandem repeats of the DNA 
sequence TTAGGG at the terminal ends of chromosomes permitting continuous genomic 
replication and cell division.  Telomerase includes three primary components: an RNA 
component (hTR) serving as the template for telomeric DNA, a protein catalytic subunit 
(hTERT- human telomerase reverse transcriptase) with reverse transcriptase activity and 
telomerase associated proteins (41).  While telomerase is repressed in most human 
somatic cells, the majority of cancer cells exhibit reactivation of telomerase to maintain 
the length of telomeric DNA and protect chromosomal DNA during unlimited cell 
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divisions (42, 43).  The expression of telomerase is tightly regulated by expression of the 
hTERT gene; therefore, complete hTERT repression is the objective of potential cancer 
therapies.   The development of an effective telomerase inhibitor via hTERT repression 
would result in efficient telomeric DNA shortening and induction of cellular pathways 
triggering cell senescence and/or apoptosis. 
A significant proportion of breast cancers express telomerase which contributes to 
their immortalized state of growth.  Telomerase activity is detectable in 80-90% of 
malignancies and is absent in most normal somatic cells (44).  Fine needle aspirations of 
malignant breast tumors revealed that 81% were positive for telomerase (45).  Hiyama et 
al. (42) also reported that 95% of advanced stage breast cancers were positive for 
telomerase.  In addition, telomerase is currently being evaluated as a tumor marker for 
breast cancer and other solid malignancies (46). Due to the importance of telomerase 
maintaining the immortalized cell state, the development of effective telomerase 
inhibitors is an important area of cancer research.  Therefore, the second phase of our 
research focuses on the development of a novel telomerase inhibitor, the E2F-1 protein 
fused to the transduction domain of HIV-1, which should transduce target cells and 
inhibit expression of hTERT in multiple stages of breast cancer cell lines. 
 
Role of E2F-1 in Telomerase Expression 
Because telomerase activity is regulated by the transcription of hTERT, the 
cloning and characterization of the hTERT-promoter has permitted examination of 
elements controlling transcriptional activation and repression of hTERT (47).  The 
transcriptional effects of the E2F family of transcription factors on the hTERT promoter 
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have been investigated by several groups.  The E2F family of transcription factors 
mediates cell cycle progression, and they are released upon phosphorylation of Rb family 
proteins (48-50). While most of these factors are associated with inducing transcription of 
genes, E2F-1 has been identified as the primary E2F transcriptional repressor of the 
hTERT gene (48).  Won et al. recently reported that E2F-1, E2F-2 and E2F-3, but not 
E2F-4 and E2F-5, repress the hTERT promoter in human tumor cells (29).  In 2001, 
Crowe et al. reported the E2F-1 protein binds two sites (-174 bp and -98 bp) of the 
proximal hTERT promoter and functions as a transcriptional repressor (48).  In addition, 
a study that examined the apoptotic function of E2F-1 found that cell death generated by 
ectopic expression of E2F-1 was independent of the p53 regulatory pathway (49). 
Therefore, even in cells with intact p53 tumor suppressor gene function, overexpression 
of E2F-1 should inhibit transcription of the hTERT gene and potentially induce 
apoptosis.   
Several studies have investigated the role of telomerase inhibition resulting in cell 
death.  Saretzki et al. reported that ribozyme-mediated telomerase inhibition induced 
immediate cell death via a newly proposed “fast-track” mechanism (51).  Theoretically, 
inhibition of telomerase will result in apoptosis following sufficient cell divisions to 
shorten telomeres to a length that triggers inherent apoptotic pathways (see Figure 2.2).  
Saretzki et al. proposed two different mechanisms through which telomerase inhibition 
could induce cell death: 1) “fast track” mechanism not requiring telomere shortening via 
interfering with “capping” function of telomerase, and 2) “classical” mechanism of 
apoptosis triggered by slow telomere shortening in each cell division (51).  This proposed 
“fast-track” mechanism of apoptosis in ovarian cancer cells was observed with their 
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ribozyme-mediated telomerase inhibitor treatment 72 hours post transduction (51).  This 
study reported a 75% reduction in telomerase activity as detected via semiquantitative 
analysis and massive cell death following 3 days of treatment with their telomerase 
inhibitor (51).  These data support a novel route of apoptosis induced by a telomerase 
inhibitor associated with uncapped telomeres triggering arrest/apoptosis pathways (51). 
 As mentioned previously, telomerase is undetected in most normal somatic cells.  
A treatment targeting expression of telomerase would therefore have a negligible effect 
on somatic cells.  Germ cells (i.e. sperm) and stem cells do express telomerase; however, 
as Figure 2.2 illustrates, the long term effects of a telomerase inhibitor on hTERT would 
have a marginal impact, and the telomeric DNA of these cell types would most likely be 
regenerated following removal of the telomerase inhibitor (52).  Cancer cells have 
telomeres that appear shorter than normal cells due to telomere shortening during tumor 
development (52), thus the cells are predisposed to apoptosis following additional 
telomeric shortening in the presence of a telomerase inhibitor.  As demonstrated in Figure 
2.2, during a defined treatment time period with a telomerase inhibitor, such as our 
proposed hTERT repressor, E2F-1/TatHA, the germ and stem cells would recover 
following treatment, but the cancer cells would undergo apoptosis or cell senescence.   
 
E2F-1 Transcription Factor and Apoptosis 
The impact of the E2F-1 transcription factor in cancer cells is a developing area of 
research.  Several groups have reported induction of apoptosis in cancer cells following 
E2F-1 overexpression.  In 1999, Dong et al. first reported that E2F-1 overexpression at 
high doses (MOI= 100) induced apoptosis in melanoma cells (53).  In 2002, Dong et al. 
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reported that adenoviral-mediated overexpression of E2F-1 in combination to 
chemotherapeutic drugs in the melanoma cell lines SK-MEL-28 and SK-MEL-2 induced 
apoptosis (53).  The transfection of E2F-1 resulted in greater chemosensitivity of 
melanoma cells to the drugs roscovitine, etoposide and Adriamycin but not 5-FU, 
cyclohexamide and cisplatin (54).  Overall, they concluded a new chemosensitization 
therapy for melanoma was possible via adenovirus-mediated E2F-1 gene transfer in 
combination to Topoisomerase II poisons and other chemotherapeutic agents (54).   
The role of E2F-1 in cancer cell death has been explored by multiple groups.  
Henderson et al. (2000) revealed that E2F-1 suppressed cancer cell growth while 
decreasing telomerase activity in the Tu-167 SCCHN (squamous cell carcinoma head and 
neck) cell line (55).  They examined the effects of wildtype p16, p21
WAF1/CIP1
, E2F-1 and 
p53 transfection in 11 different SCCHN cell lines and concluded that E2F-1, p21
WAF1/CIP1
 
and p53 overexpression repressed telomerase expression (55).  Their work supports a role 
for E2F-1 in deregulated telomerase expression and cell senescence, but they did not 
propose a mechanism of action or quantitate the degree of telomerase repression.  
Adenoviral-mediated overexpression of E2F-1 also induced apoptosis in human breast 
and ovarian carcinoma cell lines (56).  Hunt et al. reported morphological changes 
consistent with apoptosis in four out of five cell lines tested within 48 hours of exposure 
to high concentrations of E2F-1 (56).  Apoptosis was also confirmed with DNA 
fragmentation analysis and FACs analysis (56).  Apoptotic changes were present in cell 
lines with mutant p53, thus supporting the role of E2F-1 induced cell death independently 
of p53, but no specific mechanism of action was suggested (56). 
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Although the above studies support a role for E2F-1 in cancer cell death, none of 
these adenoviral-mediated studies directly examined the repressive effects of E2F-1 
overexpression on hTERT transcription.  The correlation between decreasing telomerase 
activity via E2F-1 repression and the induction of tumor cell apoptosis has not yet been 
fully examined.  In addition, the mechanism by which E2F-1 induced apoptosis in the 
above studies has not yet been clearly deduced; therefore, the repressive effects of E2F-1 
on telomerase and induction of apoptosis must be examined to fully characterize the in 
vitro effects of E2F-1 (53, 55, 56).   
 
E2F-1 Functions as a Transcriptional Repressor 
The characterization of E2F-1 as a transcriptional repressor is a new role for this 
factor because it has traditionally been denoted as a transactivator of various genes.  
Hsieh et al. (57) reported that transcriptional repression rather than the transactivation 
function of E2F-1 is involved in the induction of apoptosis.  Zhang et al. (58) provided 
the first direct evidence that telomerase is required for maintaining the vitality of both 
human tumor and immortal cells.  Zhang et al. also reported that cell death in immortal 
cells was telomere-length dependent, and upon inhibiting telomerase in cells with short 
telomeres, the resulting damage to the chromosomes triggered apoptotic cell death (58).   
Interestingly, Yamasaki et al., (59) determined that E2F-1 null mutant mice developed a 
variety of malignant tumors, and Field et al. (60) indicated that E2F-1 functions in mice 
to promote apoptosis and suppress cell proliferation.  Tumor formation in the absence of 
E2F-1 was also suggested by Crowe et al. (48).  This study utilized E2F-1 expression 
vectors and liposomal transfection into SCC25 cells resulting in transcriptional repression 
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of hTERT via consensus binding in the hTERT-promoter at putative E2F-1 sites (48).  
Importantly, Crowe et al. reported that transfection of the E2F-1 constructs reduced 
endogenous hTERT mRNA levels by 4-fold, and the reduced hTERT mRNA levels were 
accompanied by decreasing telomerase activity (48).  This study was also one of the first 
to correlate the novel transcriptional repressive effects of E2F-1 on the hTERT gene 
promoter while monitoring subsequent telomerase activity (48).  However, the repressive 
effects of E2F-1 on hTERT must be further examined.  The liposome-mediated 
transfection of E2F-1 via the Lipofectamine kit (Invitrogen Life Technologies, Carlsbad, 
CA) as described in Crowe et al. does not guarantee transfection of 100% of the cancer 
cells (48), nor do any of the adenoviral-mediated studies previously mentioned (53, 55, 
56).  Therefore, to determine if E2F-1 can completely repress hTERT transcription, thus 
decreasing telomerase activity and inducing apoptosis, the E2F-1 protein must be 
effectively transduced into 100% of the cancer cells.  Our proposed methodology 
utilizing protein transduction with E2F-1 Tat fusion peptides will lead to the development 
of a transduction technique to completely transduce the cancer cells of interest.  The 
proposed research will also potentially generate a method to completely inhibit 
telomerase thus inducing cell senescence and/or apoptosis in cancer cells. 
 
Association between BRCA1, E2F-1 and Telomerase Expression 
In 2001, results published by Ho et al. (61) determined that E2F-1 and E2F-4 
protein levels were decreased in primary breast carcinomas, and 70% of the tumors 
expressed a low level of E2F-1.  Additionally, the metastatic nodal tissue examined 
revealed that 100% of the tissue samples had significantly low levels of E2F-1 as 
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compared to normal breast tissue (61).  Ho et al. also suggested that E2Fs act as tumor 
suppressors in breast cancer and their down-regulation may be important in the 
development of metastases (61).  Therefore, it would be important to determine the 
repressive effects of E2F-1 on hTERT transcription in tumor cells with and without the 
normal BRCA1 protein to determine any variance between BRCA1 status and inhibition 
of telomerase and induced apoptosis.  Recently, Wang et al. (9) determined that the 
BRCA1 promoter was transactivated in a dose-dependent manner by E2F-1 and served as 
a target for E2F-dependent transcriptional regulation.  Other studies have also 
demonstrated that BRCA1 is a potent inducer of apoptosis by binding directly to p53 and 
therefore stimulating transcriptional activation of pro-apoptotic genes such as BAX (58, 
62).   
Our research will utilize primary infiltrating ductal carcinoma cells, HCC1937 
and HCC1599, both with and without a BRCA1 gene mutation.  As described in Table 
1.2, the HCC1937 cell line tested in our studies has a BRCA1 mutation consisting of a 
homozygous mutation of the 5382C allele.  Therefore, telomerase inhibition and 
apoptosis in primary infiltrating ductal carcinoma cell lines with a BRCA1 gene mutation 








REVIEW OF TUMOR SUPPRESSOR GENES AND BREAST CANCER 
 
Review of the p53 Tumor Suppressor Gene and Breast Cancer 
 The p53 tumor suppressor protein serves as a cell cycle gatekeeper that functions 
to suppress cell growth by either cell cycle arrest or induction of apoptosis.  It also plays 
a crucial role in DNA repair, angiogenesis and cellular senescence.  However, in 50% of 
all cancers, including breast cancer, the p53 protein is mutated and unable to perform its 
normal biological actions (25, 28).  The p53 protein is encoded by the p53 gene located 
on chromosome 17p13 and contains 11 exons (22).  The p53 protein contains three 
functionally distinct regions which are the N-terminal region, a central DNA-binding core 
region and a basic C-terminal region (22).  The p53 tumor suppressor gene mutations that 
inactivate the p53 protein are commonly missense mutations or nonsense mutations in 
one allele (25, 28, 63).   In the presence of p53 mutations, the functional absence of p53 
can be compensated for by p53 homologue proteins such as p73 and p63.  The p53 
protein has an integral role in cell cycle arrest and apoptosis.  The p53 protein is 
commonly activated following a variety of cell stresses, and via upstream kinases, the 
p53 protein is phosphorylated and activated (25).  The cell cycle is inhibited following 
activation of targets such as p21
WAF1/CIP1
, 14-3-3ζ (maintains G2 cell cycle arrest) and 
GADD45 (25).  Apoptosis is triggered following activation of various apoptotic targets 
such as BAX, APAF1, PUMA, p53AIP1, PIDD and Noxa (25).  Alternatively, activation 
of p53 can result in activation of genes involved in DNA repair (such as p53R2) and 
inhibit metastasis and angiogenesis (25).  Figure 2.3 demonstrates a simplified model of 
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p53 and a p53 homologue, p73, in cell signaling resulting in apoptosis and/or cell cycle 
arrest. 
 
Review of the p73 Tumor Suppressor Gene and Breast Cancer 
 In 1997, two p53 homologues were identified- p73 and p63.  The p73 protein, 
located on the human chromosome 1p36.3, shares 63% of the DNA binding region of 
p53, 38% identity with the tetramerization domain, and 29% identity with the 
transactivation domain (64).  The significant homology between p73 and p53 suggests 
that the p73 protein can function to regulate cell growth and apoptosis in the absence of 
p53.  As previously mentioned, it is estimated that 50% of cancers harbor mutations of 
the p53 tumor suppressor gene (25); however,  p73 is rarely mutated in carcinoma cells 
(64).  In breast cancer, loss of heterozygosity of the p73 gene region has only been 
described at a rate of 13% (65).  Mutations in p73 are uncommon in breast cancer with 
overexpression being the most common abnormality which correlates with an advanced 
tumor stage and a poor prognosis (25, 66).  However, a subset of advanced stage breast 
cancers (lymph node metastasis, vascular invasion, and high-grade malignancy) have 
been found to overexpress the p73 protein (25, 65).  
 The p73 gene encodes a complex number of isoforms produced by alternative 
splicing of the C-terminus.  At least 6 different isoforms have been identified (α, β, γ, δ, 
ε, and δ) that share an N-terminal transactivation domain, DNA-binding domain and the 
oligomerization domain (65).  Although the isoforms differ in their C-terminal ends, each 
of the transcriptionally active isoforms of p73 functions to activate transcription of target 
genes.  The p73α and p73β isoforms are primarily associated with apoptosis and cellular 
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senescence and are the isoforms of particular interest in our research.  The p73α isoform 
is longer than the p73β isoform by 137 residues on the C-terminus of the protein (67).   
The p73β isoform also slightly differs from p73α in the last 5 residues of the C-terminus 
(67).  Some studies suggest the p73β isoform is a more potent transcriptional inducer of 
target genes and more effective at inducing apoptosis (68, 69), but p73α is also credited 
as an effective activator of transcription and apoptosis (70).  In this proposed research, 
our primers determine the expression of transcriptionally active p73, including isoforms 
p73α and p73β (71).  In addition to the transcriptionally active isoforms of p73, 
transcriptionally inactive truncated isoforms of the p73 protein (∆Np73) can be produced 
via a different transcriptional start site (intron 3) (72).  Importantly, these inactive 
isoforms can exhibit a dominant negative effect toward p73 and wild-type p53 (72).  
Negative feedback regulation of p73 by ∆Np73 has been reported which appears to 
control cell survival and apoptosis (72).  Despite the association of p73 and ∆Np73, our 
research only focused on detection of the transcriptionally active isoforms of p73.  The 
primers utilized in our studies to quantitate expression of p73 are specific for the 
transcriptionally active isoforms, including p73α and p73β, to detect the impact of our 
proposed E2F-1 Tat fusion protein treatment on cancer cells.   
 Activation of the p73 tumor suppressor pathway has been observed in adenoviral 
and retroviral studies transfecting the E2F-1 gene into carcinoma cells (73, 74).  Seelen et 
al. identified E2F-1 binding sites of the p73 promoter and suggested that regulation of 
p73 expression by E2F-1 occurs primarily at sites -155 and -132 of the proximal p73 
promoter (75).  Upregulation of p53-responsive genes has also been observed in cells 
upon activation of p73 (34, 76).  Specifically, stimulation of the p73 tumor suppressor 
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gene has induced p21
WAF1/CIP1
 expression leading to cell growth arrest and apoptosis (76, 
77).  In 2003, Marabese et al. reported p73 activation (~2.5-fold increases) following 
treatment of cells with DNA damaging agents such as doxorubicin (71).  Their study also 
indicated an important role for E2F-1 in binding the p73 promoter and activation of 
transcription which triggered downstream pathways that induced apoptosis (71).  The cell 
signaling pathways involving p73 are comparable to the pathways activated by p53, and 
the downstream target genes of p53 can be activated by p73.  The similarities in 
transcriptional activators, modifiers and targets of p73 and p53 are outlined in Figures 2.3 
and 2.4.  Importantly, Figure 2.4 illustrates the important role of p73 expression in 
apoptosis.  Overexpression of p73 results in activation of pro-apoptotic genes such as 
BAX (BCL2-associated X protein), PUMA (p53 upregulated modulator of apoptosis) and 
Noxa (Latin for “damage”) (78).  Activation of Noxa results in the release of cytochrome 
c to the cytosol thus triggering apoptosis (78).  Upregulation of PUMA provokes 
translocation of BAX to the mitochondria which also results in release of cytochrome c.  
Ultimately, activation of effector caspases resulting from mitochondrial dysfunction 
forces the cells down a pathway of destruction.  The apoptotic pathway is a primary 
target for therapies inducing p73 overexpression.   
 
Review of the p21
WAF1/CIP1 
Gene and Breast Cancer 
 The p21
WAF1/CIP1
 gene is located on chromosome 6p21.2 and belongs to the family 
of Cip/Kip cyclin dependent kinase (cdks) inhibitors.  It functions to prevent 
phosphorylation of cdk substrates and thus impedes cell cycle progression (25). 
Specifically, activation of p21
WAF1/CIP1
 results in cell cycle arrest in G1 or G2 following 
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DNA damage (79).  The p21
WAF1/CIP1 
gene is a primary transcriptional target of the p53 
tumor suppressor protein.  The p21
WAF1/CIP1
 gene is not a common target for mutational 
inactivation in breast cancer; in fact, mutations in p21
 WAF1/CIP1
 are extremely rare in most 
cancers (80).  However, in the absence of p53, its innate role in controlling the cell cycle 
may be compromised.  Downregulation of p21
WAF1/CIP1
 is a common occurrence 
following inhibition or mutation of p53.  Multiple other factors also repress expression of 
p21
WAF1/CIP1
 including the c-Myc proto-oncogene, the human papillomavirus, hepatitis C 
virus, E-box binding protein p47ING1a (a member of the inhibitor-of-growth family) and 
the CCAAT displacement protein/cut homeodomain protein (CDP/cut) (81).  
Interestingly, an isoform of the CDP/cut protein, p75, is often expressed at high levels in 
primary breast tumors and breast cancer cell lines versus low levels of expression in 
normal breast tissue (81).  This suggests that p75 repression of p21
WAF1/CIP1
 may 
contribute to tumorigenesis via inhibition of cell cycle arrest (81).  In tumors with p53 
mutations, a p53-independent pathway has the potential to activate expression of 
p21
WAF1/CIP1
.  The p73 protein is a known upstream regulator of the p21
WAF1/CIP1
 gene 
(82).  In 2005, Schmelz et al. reported induction of p21
WAF1/CIP1
 expression in myeloid 
leukemia cells following induction of p73 with 5-Aza-2‟-deoxycytidine (5-Aza-CdR) 
(82).  Schmelz et al. also determined that exogenous induction of p73 isoforms p73α and 
p73β upregulated p21
WAF1/CIP1
 expression resulting in chemosensitization of epithelial 
cells to 5-Aza-CdR (82).  Thus, induction of p21
WAF1/CIP1 
by p73 overexpression resulting 
from our proposed E2F-1 Tat fusion protein therapy may also serve to chemosensitize 
breast carcinoma cells to standard chemotherapeutic agents. 
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Review of BRCA1 Tumor Suppressor Gene and Breast Cancer  
 Mutations in Breast Cancer Susceptibility genes 1 and 2 (BRCA1 and BRCA2) 
occur in only 5-10% of all breast cancers.  Overexpression of wildtype BRCA1 in 
ovarian and breast cancer cell lines has been found to reduce cellular proliferation (28).  
Our research is particularly interested in BRCA1 mutations since one of the primary 
ductal carcinoma cells lines investigated by our research harbors a homozygous 5832C 
BRCA1 mutation.  The BRCA1 gene is located on chromosome 17q21.31 and mutational 
inactivation is generally the result of missense, truncation and silent mutations (27).  The 
BRCA1 protein normally functions to regulate p53 and p21
WAF1/CIP1
 levels in cells.  
Recent studies support the role of BRCA1 in the transcriptional regulation of 
p21
WAF1/CIP1
, GADD45, Cyclin B1, DBB2, XPC, and multiple other targets (83).  BRCA1 
binds to DNA without any sequence specificity which may be an important part of its 
role in DNA repair and transcription.  BRCA1 has a direct role in cell cycle checkpoints 
and inhibits cell cycle progression into S-phase.  In studies that overexpressed the 
BRCA1 protein,  p21
WAF1/CIP1 
was activated in a p53-independent manner (83).  In cell 
lines lacking p21
WAF1/CIP1
, overexpression of BRCA1 did not lead to G1 arrest, thus 
supporting the concept that the arrest of the cell cycle in G1 phase is dependent on the 
expression of p21
WAF1/CIP1 
(83).  These findings support a role for the BRCA1 protein in 
regulating the p21
WAF1/CIP1
 promoter suggesting that the BRCA1 protein is required for 
p21
WAF1/CIP1
 activation.   This research will investigate possible differences in 
p21
WAF1/CIP1
 expression in wildtype BRCA1 versus mutant BRCA1 expressing cell lines 





PROTEIN TRANSDUCTION REVIEW 
 
Discovery of HIV-1 Tat Protein: 
 This research uses an alternative method of introducing the E2F-1 transcription 
factor into breast carcinoma cells by employing Tat-mediated protein transduction.  In 
1988, HIV-1 Tat-mediated protein transduction was independently reported by Green 
(84) and Frankel (85) after experimental data indicated the 86 amino acid transactivator 
protein, Tat (transactivator of transcription), could be internalized by cells with 
subsequent activation of the HIV-1 promoter.  Their work prompted intense 
investigations that explored the implications of Tat-mediated protein transduction as a 
novel therapeutic intervention to treat cancer and other diseases.  In 1994, Fawell et al. 
reported that various cargo molecules complexed to the Tat protein could be internalized 
by tissue culture cells (86).  They chemically cross-linked Tat peptides (amino acid 
residues 1-72 or 37-72) to a variety of cargoes such as β-galactosidase, RNase A and 
horseradish peroxidase (86).  In vitro, their work revealed that Tat chimeras were 
effective on all cell types, and in vivo, the Tat proteins were primarily internalized by 
endothelial cells, Kupffer cells, and/or splenic macrophages because high levels of Tat-β-
galactosidase was detectable in mouse hearts, livers, and spleens (86). 
 In 1998, Nagahara et al. introduced an in-frame Tat bacterial expression vector 
with a hemaglutinin tag referred to as pTatHA (87).  The vector also contains an N-
terminal 6-histidine tag, an 11-amino acid protein transduction domain (residues 47-57) 
flanked by glycine residues to permit free bond rotation and a polylinker serving as a 
multiple cloning site (87).  Nagahara et al. reported transduction of denatured Tat 
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proteins into approximately 100% of primary or transformed cells using a protein 
misfolding purification protocol that employed a bacterial expression system (87).  The 
pTatHA vector has been utilized by numerous groups to produce in-frame genetic fusion 
proteins with the Tat transduction domain to study their subsequent effects both in vitro 
and in vivo.  Recent advances in basic science and pre-clinical/clinical gene therapy 
fields have led to the investigation of cell permeable peptides as tools for gene and 
protein transduction.  The efficient delivery of therapeutic or toxic agents to carcinoma 
cells has been investigated with viral and non-viral gene therapy.   
 
Comparison of Tat Therapy to Viral-based Methodologies 
 Viral delivery of anti-cancer agents has been a key area of investigation targeting 
cellular delivery of therapeutic agents to arrest cell growth or induce apoptosis.  There are 
a number of disadvantages associated with the use of viruses in cancer therapy.  Viral 
vectors only have a limited DNA carrying capacity and the large-scale manufacturing of 
virus can be cost prohibitive.  Additionally, viral gene therapy has encountered problems 
in immunogenicity and the undesirable insertion of genetic material into the host‟s 
genome.  However, recombinant viral vectors are very effective at delivering the genetic 
material across cell membranes to transport the DNA into the cell cytoplasm and to its 
nuclear target (88).  A similar effect can be achieved by employing protein transduction 
domains.  Importantly, several modes of transducing recombinant proteins have been 
investigated as alternative vehicles for anti-cancer agents to affect cellular transcription 
and gene expression.  Protein transduction serves as an alternate modality to introduce 
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therapeutic agents without the common drawbacks associated with viral-based 
methodologies. 
 
Protein Therapy with Protein Transduction Domains (PTD) 
Protein therapy is dependent on the direct delivery of proteins through the plasma 
membrane and into specific cell compartments.  Small cationic peptides, commonly 
referred to as protein transduction domains (PTDs), have the ability to deliver large 
proteins (up to 120 kDa) into mammalian cells in vitro and in vivo (84, 85).  The general 
modes of transducing cellular proteins include protein transduction domains such as the 
homeodomain of Antennapedia, the Herpes simplex virus type 1 (HSV-1) structural 
protein VP22 and the Tat transduction domain of HIV-1.  In addition, transportan and 
polyarginine have also been investigated as cell-permeable peptides (CPP).   
 
Antennapedia Protein Transduction Domain 
The homeodomain of the Antennapedia protein, Antp, has been extensively 
studied and was the first PTD to carry a cargo protein across cell membranes (89).  In 
general, the Antennapedia PTD is efficient at transporting protein less than 100 amino 
acids in length but transduction can be unpredictable and structurally dependent (90).  
High concentrations of Antp43-58 peptide (greater than a few µM) have been found to 
induce cell lysis in vitro, but this toxic effect appears to be cell type specific (91).  The 
DNA-binding region of the Antp transcription factor has been extensively studied and is 
sufficient to transduce cells.  This PTD is referred to as penetratin-1 and is one of the 
most common protein transduction domains researched in combination to Tat (92).  In 
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2006, Letoha et al. reported that treatment with penetratin alone affects both in vitro and 
in vivo inflammatory responses in cells via binding proinflammatory mediators during 
cellular transduction (93).  They also found that treatment with penetratin decreased 
expression of nuclear factor-kappaβ (NF-kappaβ) and tumor necrosis factor (TNF) in 
L929 fibroblasts and RAW 264.7 macrophages (93).  Pouniotis et al. recently determined 
mice challenged with ovalbumin-expressing tumor cells were protected via T-cell 
activation following treatment with penetratin linked to the cytotoxic T lymphocyte 
peptide of ovalbumin (94).   
 
VP22 Protein Transduction Domain 
The VP22 structural protein contains a protein transduction domain of 40 amino 
acids in its C-terminal region and is responsible for the protein‟s novel cell trafficking 
properties (92).  VP22 fusion proteins are secreted from cells, and the proteins target the 
nuclei of adjacent cells in the surrounding area (92).  VP22 fusion proteins have been 
utilized to facilitate cell death with gangcyclovir (95), induce apoptosis in osteosarcoma 
cells when complexed with p53 (96), and induce apoptosis in HeLa cells when fused with 
neuroamidase (97) among other applications extensively reviewed in Dietz et al. (2004) 
(92).  Although commercial kits are now available for the HSV-VP22 protein production 
system (Voyager
TM
 Protein Production Kit, Invitrogen
TM
 Life Technologies, Carlsbad, 
CA), it is not the protein transduction method of choice for a variety of reasons.  The 
VP22 system requires that producer cells first be transfected with the cargo protein‟s 
cDNA.  Consequently, it requires variable amounts of time for the cells to produce and 
secrete the fusion protein (92).  In addition, the protein primarily targets cell nuclei; 
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therefore, it is not the method of choice when the biological activity of the fusion protein 
must be elicited in the cytoplasm.   
 
Transportan Protein Transduction Domain 
Transportan is a  27-amino acid cell permeable peptide produced by fusing the N-
terminal fragment of the neuropeptide galanin with the wasp venom peptide mastoparan 
plus an additional lysine residue between the two peptides (92, 98).  Like other PTDs, 
transportan transduces cells at 4ºC independently of endocytosis inhibitors.  The 
transduction kinetics of transportan are reportedly faster than the Antennapedia-derived 
Antp peptide and Tat mediated transduction; in addition, it can also transduce epithelial 
cells more efficiently than the Antp peptide (92, 99).  Transportan was utilized by 
Kaushik et al. (2002) in anti-HIV therapy to carry a TAR-targeted PNA to decrease 
replication of HIV virions by inhibiting Tat-mediated transactivation of HIV-1 LTR (92, 
100).  In addition, transportan was fused to a phosphotyrosine phosphatase antisense 
PNA to treat impaired glucose-induced insulin release in type 2 diabetes mellitus 
resulting in increased glucose-induced insulin secretion in mutant rat pancreatic islet cells 
in vitro (101).  However, despite the biological potential of the transportan protein, it can 
elicit biological effects in cells independently of its cargo protein.  Transportan has been 
reported to inhibit GTPase activity (102) and elicit an effect on the galanin receptors that 
are widely distributed in the nervous system (103).  Therefore, although transportan 
effectively and rapidly transduces cells, it is not the most desirable cell permeable peptide 
because it has documented biological effects on cells independent of the cargo protein 
being carried into cells. 
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HIV-1 Tat Protein Transduction Domain 
 Groups investigating Tat-mediated protein transduction primarily focus on the 11-
amino acid PTD from HIV-1 (amino acids 47-57) (84, 85).  Tat proteins possess the 
unique ability to enter cells and translocate to the nucleus and nucleolus which is a 
property attributed to the basic region of the Tat protein (104-106).  Dowdy and his 
associates have widely published Tat purification procedures and successfully produced 
multiple Tat fusion proteins such as Tat-p27
Kip1
, Tat-Cdc42 and Tat-p16 (87, 107-111).  
Vocero-Akbani et al. (1999) engineered a transducable caspase-3 protein, Tat-Casp3, 
which entered 100% of target cells and induced apoptosis in HIV-infected cells (107).   
 Tat-conjugated proteins have been heavily investigated in cancer research due to 
their potential applications in cancer therapy.  A Tat-p53 fusion protein was produced and 
induced apoptotic cell death in both p53 positive and negative human tumor cell lines 
(112).  Guelen et al. (2004) produced a Tat-apoptin protein that transduced greater than 
90% of its target cells and resulted in apoptotic activity in Saos-2 and HSC-3 cancer cells 
within 24 hours (113).  Tat-apoptin was efficiently delivered to the nucleus of 
transformed cells and induced tumor cell apoptosis; however, in normal cells, the protein 
remained in the cytoplasmic compartment and did not elicit cell death (113).  In 2006, 
Yan et al. reported transduction of a cell-permeable Survivin antagonist, Tat-Surv-T34A, 
in vivo into melanoma xenografts (114).  Their results demonstrated 40-50% decreases in 
tumor mass and growth in melanoma xenografts (114).  Their work supports systemic 
treatment of xenograft tumors with intraperitoneal injection of Tat fusion proteins to 
induce cell death in tumor cells via Tat-mediated protein transduction.  
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 In addition to delivering therapeutic proteins to cells, the Tat PTD has been 
employed to deliver DNA into mammalian cells.  Hashida et al. (2004) synthesized 
polylysine peptides containing the Tat-PTD, and they reported the DNA was transferred 
into most cancer cell lines as compared to the control.   
 Thus, substantial evidence is present in the literature to support Tat-mediated 
transduction of proteins into a variety of cell types.   
 
Mechanism of Tat-Mediated Protein Transduction 
 The mode of protein transduction employed by Tat fusion proteins has been 
widely debated since the first publications regarding the use of the HIV-1 protein 
transduction domain.  In 1998, Nagahara et al. (87) introduced an in-frame Tat bacterial 
expression vector with a hemagglutinin tag referred to as pTatHA.  The vector contains 
an N-terminal 6-histidine tag which permits purification of the recombinant protein using 
affinity chromatography.  The vector also contains a hemagglutinin tag required to detect 
transduction of recombinant proteins via immunocytochemistry.  This vector was 
obtained from Steven Dowdy of the Howard Hughes Medical Institute in St. Louis, 
Missouri.  The pTatHA vector was used to produce the recombinant proteins utilized in 
our research.   
 The characterization of the transduction properties of Tat fusion proteins has been 
widely investigated.  The route of cellular internalization and intracellular trafficking of 
TFPs is still misunderstood and often appears to be a protein-specific phenomenon.  
Multiple pathways have been suggested to describe the transduction of TFPs including 
cellular membrane destabilization (115), membrane absorption via non-specific 
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endocytosis (116), lipid raft macropinocytosis (117) and caveolar endocytosis (118).  
Eguchi et al. reported that Tat transduction occurred independent of the classical 
endocytotic pathways by observing that the Tat-phage directly penetrated cell membranes 
and transduced into the cytoplasm compartment of cells via destabilizing the caveolar 
membrane (115).  This membrane destabilization did not appear to be cytotoxic at high 
doses of Tat-phage, and the efficiency of transduction was not enhanced by 
endosomotropic agents (115).  In 2003, Vives et al. claimed Tat analogues transduced 
into cells in a nonspecific endocytotic process that occurred actively, appeared energy 
dependent and exhibited rapid internalization of Tat proteins (116).  Wadia et al. 
described a model of Tat transduction in which the PTDs are dependent on lipid rafts and 
Tat proteins preferentially bound cholesterol membrane constituents and triggered 
macropinocytosis (117).  The macropinosomes are described as inherently leaky vesicles 
that do not fuse to lysosomes, but the exact mechanism of macropinosome release of Tat 
proteins remains unknown (117).  Caveolar-mediated endocytosis of Tat fusion proteins 
has been reported to occur in a temperature dependent manner, and the endocytotic 
vesicles originate from lipid rafts (118-120).  Tat proteins appear to co-localize in 
vesicles with markers of caveolar endocytosis, and the transduction of Tat proteins is 
impaired by drugs that disrupt lipid rafts (118-120).  It has also been reported that Tat-
mediated transduction is dependent on Tat binding cell surface heparan sulfate (HS) 
proteoglycans (121).  Tyagi et al. found that cells defective in synthesis of HS 
proteoglycans exhibited impaired internalization of Tat proteins (121).  Tat uptake was 
also decreased by agents degrading HS suggesting that HS proteoglycans are required for 
efficient intracellular delivery of Tat proteins (121).  Additional methods to enhance Tat 
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mediated transduction of proteins have also been published.  Upon cellular uptake of Tat 
proteins, the addition of chloroquine in vitro and in vivo has been suggested to enhance 
the endocytotic delivery of proteins via endosome disruption to promote nuclear targeting 
of Tat fusion proteins (122-124).  Caron et al. reported that lysosomotropic agents such as 
chloroquine enhance the nuclear delivery of Tat fusion proteins up to 23-fold (122).   
 We intend to assess whether or not the addition of chloroquine enhances 
transduction efficiencies of our proposed E2F-1 Tat fusion proteins.   
 
OVERVIEW OF PROPOSED RESEARCH 
 
 As reviewed above, the complex interaction of E2F-1 with the cell cycle can 
result in cell proliferation, cell cycle arrest or apoptosis.  The effects of E2F-1 on cell 
growth and development are key actions directly relevant to cancer therapeutics.  We 
propose producing E2F-1 Tat fusion proteins to impact gene expression in breast 
carcinoma cell lines.  The majority of breast tumors overexpress the catalytic subunit of 
telomerase, hTERT; therefore, telomerase inhibition targeting hTERT is the first 
objective with our proposed E2F-1 Tat fusion protein therapy.  We anticipate that 
introduction of E2F-1 Tat fusion proteins will repress expression of telomerase, thus 
forcing cancer cells into a senescent state or inducing cell death.  In addition, 40-50% of 
carcinomas, including breast cancer, have mutations in the p53 tumor suppressor gene.  
In these cases, the p53 homologue protein, p73, is expected to trigger the same pathways 
as p53.  We postulate that overexpression of E2F-1 will induce expression of p73 and 
result in cell cycle arrest via transactivation of the p21
WAF1/CIP1
 protein.  Significant 
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apoptotic activity is also expected to result following p73 overexpression and subsequent 
activation of BAX, PUMA and Noxa proteins leading to mitochondrial dysfunction and 
activation of effector caspases.   
 As reviewed, numerous studies report inducible apoptosis in tumor cells 
following viral gene therapy overexpressing E2F-1.  We present an alternate form of a 
protein-based cancer therapy via attaching the E2F-1 gene to the Tat transduction domain 
of HIV-1.  This Tat transduction domain has been proven to transduce proteins up to 120 
kDa across cell membranes and the blood brain barrier (108, 110).  Proteins attached to 
the HIV-1 Tat transduction domain have also been found to transduce 100% of target 
cells, and once Tat fusion proteins enter cells, they have the opportunity to elicit their 
biological effect followed by degradation (108, 110).  Importantly, production of E2F-1 
Tat fusion proteins would permit both optimal cellular transduction and a reversible 
overexpression of the E2F-1 protein in cells.  Therefore, the production of biologically 
active E2F-1 Tat fusion proteins is a novel method of introducing the E2F-1 transcription 
factor into tumor cells to investigate its subsequent effects on gene expression.  
Collectively, we anticipate the findings of this research will lead to a greater 
understanding of E2F-1 and the development of an alternative therapy to augment 







Table 1.1- Staging of Breast Cancer 
 
Primary Tumor (T)  
T0 No evidence of primary tumor 
TIS Carcinoma in situ 
T1 Tumor ≤2 cm 
T1a ≤0.5 cm in greatest dimension 
T1b >0.5 but ≤1 cm in greatest dimension 
T1c >1 cm but ≤2 cm in greatest dimension 
T2 Tumor >2 cm but ≤5 cm 
T3 Tumor >5 cm 
T4 Extension to chest wall, inflammation, satellite lesions, ulcerations 
T4a Extension to chest wall 
T4b Edema (including peau d'orange) or ulceration of the skin of the 
breast or satellite skin nodules confined to the same breast 
T4c Both (T4a and T4b) 
T4d Inflammatory carcinoma 
 
Regional Lymph Nodes (N)  
N0 No regional lymph nodes 
N1 Metastasis to movable ipsilateral nodes 
N2 Metastasis to matted or fixed ipsilateral nodes 
N3 Metastasis to ipsilateral internal mammary nodes 
 
Distant Metastasis (M)  
M0 No distant metastasis 
M1 Distant metastasis (includes spread to ipsilateral supraclavicular 
lymph nodes) 
 
Stage Grouping Tumor (T) Lymph Node (N) Metastasis (M) 
Stage 0 TIS N0 M0 
Stage I T1 N0 M0 
Stage IIA T0 N1 M0 
 T1 N1 M0 
 T2 N0 M0 
Stage IIB T2 N1 M0 
 T3 N0 M0 
Stage IIIA T0 N2 M0 
 T1 N2 M0 
 T2 N2 M0 
 T3 N1, N2 M0 
Stage IIIB T4 Any N M0 
 Any T N3 M0 
Stage IV Any T Any N M1 
 
Table 2.1 was  modified from: Kasper DL,  Fauci AS,  Longo DL, Braunwald E, Hauser SL, Jameson JL, eds. Harrison's 
Principles of Internal Medicine, 16th edition. New York, NY: McGraw-Hill, 2005. 
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Table 1.2. Comparison of Breast Cancer Cell Lines 
 




CRL-2331  CRL-2336   HTB-22 
 




































































IIIA, grade 3 
TNM stage 
IIB, grade 3 
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Table 1.3.  Familial Cancer Syndromes Associated with the  























inheritance; early age of 
onset of breast cancer in  
addition to soft-tissue 
sarcomas, leukemia, 
lymphoma, brain cancer, 


























mode of inheritance; 
individuals at risk of 
developing both breast 
and ovarian cancer; 
BRCA2 mutations 
associated with breast 
cancer in men and 

































Breast cancer, thyroid 
carcinoma, endometrial 
cancer 






older patients susceptible 
to developing breast 
cancer, melanoma and 
Hodgkins disease 











Figure 2.1.  Integral role of E2F-1 in control of cell cycle progression, cell cycle arrest 
and apoptosis.  (A) Normally, E2F-1 functions to regulate expression of genes required 
for cell cycle progression such as thymidylate synthetase (TS), ribonucleotide reductase 
(RR) and p107 (35).  E2F-1 is able to target these genes following stimulation via growth 
factors and subsequent activation resulting from phosphorylation of Rb.  (B) In the 
presence of DNA damage, E2F-1 is phosphorylated by ATM/ATR and CHK2 kinases 
which stabilize the E2F-1 proteins.  The high levels of E2F-1 protein resulting from DNA 
damage stimulates transcription of target genes.  Activation of p14
ARF
 functions to inhibit 
a negative regulator of p53, the MDM2 protein.  Following inhibition of MDM2, p53 is 
transactivated resulting in cell cycle arrest and/or apoptosis (35).  E2F-1 also binds the 
promoters of and transactivates expression of ATM, apoptosis protease-activating factor 
1 (APAF1), alternative reading frame (ARF), CHK1 and p73 which also results in cell 


































Figure 2.1 was modified from:  Stevens, C. and La Thangue, N. B. The emerging role of E2F-1 in the DNA damage response and 
checkpoint control. DNA Repair (Amst), 3: 1071-1079, 2004. 
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E2F-1 Signaling Pathways Involved in Cell Cycle  




Figure 2.2.   This figure illustrates the potential effects of telomerase inhibition on 
telomere length of different cell types over a period of time.  In theory, telomerase 
inhibition should only impact cells actively expressing telomerase such as germ cells, 
stem cells and cancer cells.  Following a period of telomerase inhibition, germ cells and 
stem cells would experience transient telomerase inhibition, but their recovery would be 
expected due to ample telomeric DNA.  Cancer cells do not express telomerase in the 
early stages of tumor development; therefore, prior to application of a telomerase 
inhibitor, the telomeric DNA is significantly shortened as cancer cells proliferate (52).  
Telomerase is eventually reactivated which preserves the remaining telomeric DNA.  
However, upon application of a telomerase inhibitor, telomeric DNA is expected to 
shorten to a point where inherent apoptotic or senescent pathways are triggered within 
tumor cells (52).  Overall, during application of a telomerase inhibitor, the primary 
systemic effects would be transient telomerase inhibition in germ cells and stem cells 
while tumor cells would be expected to undergo cell senescence/apoptosis.  
 
Effects of Telomerase Inhibition on Telomere Length over Time 
Therapeutic Telomerase 
Inhibition 
Critically short telomere length 
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Figure 2.2 was modified from Figure 3 of:  Keith, W. N., Bilsland, A., Evans, T. R., and Glasspool, R. M. Telomerase-















Figure 2.3.  A simplified model of p53/p73 pathways and the induction of cell cycle 
arrest and/or apoptosis.  Phosphorylation of the serine residues activates the p53/p73 
protein for DNA binding and transcription of downstream effector genes (25).  The p73 
protein is activated directly in the absence of wildtype p53.  E2F-1 Tat Fusion proteins 
(E2F-1/TatHA and E132/TatHA) have the ability to activate transcription of p53 and p73.  
Following acetylation of p53/p73 by p300, transcription of target genes is initiated 
resulting in transcriptional activation of genes leading to either cell cycle arrest or 
apoptosis (25).  Importantly, p53/p73 transactivates expression of p21
WAF1/CIP1
 which is 
imperative to cell cycle control.  Alternatively, apoptosis can be triggered via activation 




























Ser 9  Ser 15 
   Ser 20 
      Ser 392 
Inhibition of metastasis and angiogenesis 
Stimulates DNA repair 
Figure 2.3 was modified from Figure 1 of:  Gasco, M., Shami, S., and Crook, T. The p53 pathway in breast cancer. Breast Cancer Res,  
4: 70-76, 2002. 
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Figure 2.4.  Mechanism of p53-independent apoptosis.  DNA damage activates ATM or 
ATR which subsequently activates CHK1 or CHK2 resulting in transactivation of native 
E2F-1.  E2F-1 transcribes the p73 gene via binding E2F-1 sites in the proximal p73 
promoter.  The transactivation of p73 results in increased p73 protein levels in cells.  The 
p73 protein activates transcription of the apoptosis-associated proteins Noxa, PUMA and 
BAX.  Increased levels of Noxa results in mitochondrial dysfunction, releasing 
cytochrome c into the cytosol and triggering apoptosis via activation of effector caspases 
(78).  Activation of PUMA and BAX results in translocation of BAX to the mitochondria 
subsequently releasing cytochrome c and activating caspases (78).  A similar induction of 
apoptosis from transactivation of p73 is expected from artificial introduction of E2F-1 
Tat fusion proteins into cells. 
  Noxa        PUMA 












   BAX translocates to 
the mitochondria 
APOPTOSIS 





1. American Cancer Society. Cancer Facts and Figures 2006. Atlanta: American 
Cancer Society, 2006. 
 
2. Padhani, A. R., Ah-See, M. L., and Makris, A. MRI in the detection and 
management of breast cancer. Expert Rev Anticancer Ther, 5: 239-252, 2005. 
3. Society, A. C. Breast Cancer Facts & Figures. 2005-2006. 
 
4. Bartella, L. and Morris, E. A. Advances in breast imaging: magnetic resonance 
imaging. Curr Oncol Rep, 8: 7-13, 2006. 
 
5. Buchanan, C. L., Morris, E. A., Dorn, P. L., Borgen, P. I., and Van Zee, K. J. 
Utility of breast magnetic resonance imaging in patients with occult primary 
breast cancer. Ann Surg Oncol, 12: 1045-1053, 2005. 
 
6. Kasper DL,  Fauci AS,  Longo DL, Braunwald E, Hauser SL, Jameson JL, eds. 
Harrison's Principles of Internal Medicine, 16th edition. New York, NY: 
McGraw-Hill, 2005. 
 
7. Howell, L. P., Gandour-Edwards, R., and O'Sullivan, D. Application of the 
Scarff-Bloom-Richardson tumor grading system to fine-needle aspirates of the 
breast. Am J Clin Pathol, 101: 262-265, 1994. 
 
8. Elston, C. W. and Ellis, I. O. Pathological prognostic factors in breast cancer. I. 
The value of histological grade in breast cancer: experience from a large study 
with long-term follow-up. Histopathology, 19: 403-410, 1991. 
 
9. Kim, M., Katayose, Y., Rojanala, L., Shah, S., Sgagias, M., Jang, L., Jung, Y. J., 
Lee, S. H., Hwang, S. G., and Cowan, K. H. Induction of apoptosis in p16INK4A 
mutant cell lines by adenovirus-mediated overexpression of p16INK4A protein. 
Cell Death Differ, 7: 706-711, 2000. 
 
10. Bacus, S. S., Kiguchi, K., Chin, D., King, C. R., and Huberman, E. Differentiation 
of cultured human breast cancer cells (AU-565 and MCF-7) associated with loss 
of cell surface HER-2/neu antigen. Mol Carcinog, 3: 350-362, 1990. 
 
11. Brinkley, B. R., Beall, P. T., Wible, L. J., Mace, M. L., Turner, D. S., and 
Cailleau, R. M. Variations in cell form and cytoskeleton in human breast 
carcinoma cells in vitro. Cancer Res, 40: 3118-3129, 1980. 
 
12. Cailleau, R., Olive, M., and Cruciger, Q. V. Long-term human breast carcinoma 
cell lines of metastatic origin: preliminary characterization. In Vitro, 14: 911-915, 
1978. 
 54 
13. Fuchs, M., Hutzler, P., Handschuh, G., Hermannstadter, C., Brunner, I., Hofler, 
H., and Luber, B. Dynamics of cell adhesion and motility in living cells is altered 
by a single amino acid change in E-cadherin fused to enhanced green fluorescent 
protein. Cell Motil Cytoskeleton, 59: 50-61, 2004. 
 
14. Gazdar, A. F., Kurvari, V., Virmani, A., Gollahon, L., Sakaguchi, M., 
Westerfield, M., Kodagoda, D., Stasny, V., Cunningham, H. T., Wistuba, II, 
Tomlinson, G., Tonk, V., Ashfaq, R., Leitch, A. M., Minna, J. D., and Shay, J. W. 
Characterization of paired tumor and non-tumor cell lines established from 
patients with breast cancer. Int J Cancer, 78: 766-774, 1998. 
 
15. Siciliano, M. J., Barker, P. E., and Cailleau, R. Mutually exclusive genetic 
signatures of human breast tumor cell lines with a common chromosomal marker. 
Cancer Res, 39: 919-922, 1979. 
 
16. Soule, H. D., Vazguez, J., Long, A., Albert, S., and Brennan, M. A human cell 
line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst, 
51: 1409-1416, 1973. 
 
17. Tomlinson, G. E., Chen, T. T., Stastny, V. A., Virmani, A. K., Spillman, M. A., 
Tonk, V., Blum, J. L., Schneider, N. R., Wistuba, II, Shay, J. W., Minna, J. D., 
and Gazdar, A. F. Characterization of a breast cancer cell line derived from a 
germ-line BRCA1 mutation carrier. Cancer Res, 58: 3237-3242, 1998. 
 
18. Verkooijen, H. M., Chappuis, P. O., Rapiti, E., Vlastos, G., Fioretta, G., Sarp, S., 
Sappino, A. P., Schubert, H., and Bouchardy, C. Impact of familial risk factors on 
management and survival of early-onset breast cancer: a population-based study. 
Br J Cancer, 94: 231-238, 2006. 
 
19. Okobia, M. N. and Bunker, C. H. Epidemiological risk factors for breast cancer--a 
review. Niger J Clin Pract, 8: 35-42, 2005. 
 
20. Marsh, D. and Zori, R. Genetic insights into familial cancers-- update and recent 
discoveries. Cancer Lett, 181: 125-164, 2002. 
 
21. Frank, T. S. Hereditary cancer syndromes. Arch Pathol Lab Med, 125: 85-90, 
2001. 
 
22. Lacroix, M., Toillon, R. A., and Leclercq, G. p53 and breast cancer, an update. 
Endocr Relat Cancer, 13: 293-325, 2006. 
 
23. Lynch, H. T., Shaw, T. G., and Lynch, J. F. Inherited predisposition to cancer: a 
historical overview. Am J Med Genet C Semin Med Genet, 129: 5-22, 2004. 
 
24. Liu, M. C. and Gelmann, E. P. P53 gene mutations: case study of a clinical 
marker for solid tumors. Semin Oncol, 29: 246-257, 2002. 
 55 
25. Gasco, M., Shami, S., and Crook, T. The p53 pathway in breast cancer. Breast 
Cancer Res, 4: 70-76, 2002. 
 
26. Lux, M. P., Fasching, P. A., and Beckmann, M. W. Hereditary breast and ovarian 
cancer: review and future perspectives. J Mol Med, 84: 16-28, 2006. 
 
27. Xu, C. F. and Solomon, E. Mutations of the BRCA1 gene in human cancer. Semin 
Cancer Biol, 7: 33-40, 1996. 
 
28. Oesterreich, S. and Fuqua, S. A. Tumor suppressor genes in breast cancer. Endocr 
Relat Cancer, 6: 405-419, 1999. 
 
29. Won, J., Yim, J., and Kim, T. K. Opposing regulatory roles of E2F in human 
telomerase reverse transcriptase (hTERT) gene expression in human tumor and 
normal somatic cells. Faseb J, 16: 1943-1945, 2002. 
 
30. Girling, R., Partridge, J. F., Bandara, L. R., Burden, N., Totty, N. F., Hsuan, J. J., 
and La Thangue, N. B. A new component of the transcription factor DRTF1/E2F. 
Nature, 362: 83-87, 1993. 
 
31. Kitagawa, M., Higashi, H., Suzuki-Takahashi, I., Segawa, K., Hanks, S. K., Taya, 
Y., Nishimura, S., and Okuyama, A. Phosphorylation of E2F-1 by cyclin A-cdk2. 
Oncogene, 10: 229-236, 1995. 
 
32. Pardee, A. B., Li, C. J., and Reddy, G. P. Regulation in S phase by E2F. Cell 
Cycle, 3: 1091-1094, 2004. 
 
33. Almasan, A., Yin, Y., Kelly, R. E., Lee, E. Y., Bradley, A., Li, W., Bertino, J. R., 
and Wahl, G. M. Deficiency of retinoblastoma protein leads to inappropriate S-
phase entry, activation of E2F-responsive genes, and apoptosis. Proc Natl Acad 
Sci U S A, 92: 5436-5440, 1995. 
 
34. Stanelle, J., Stiewe, T., Theseling, C. C., Peter, M., and Putzer, B. M. Gene 
expression changes in response to E2F1 activation. Nucleic Acids Res, 30: 1859-
1867, 2002. 
 
35. Stevens, C. and La Thangue, N. B. The emerging role of E2F-1 in the DNA 
damage response and checkpoint control. DNA Repair (Amst), 3: 1071-1079, 
2004. 
 
36. Jamshidi-Parsian, A., Dong, Y., Zheng, X., Zhou, H. S., Zacharias, W., and 
McMasters, K. M. Gene expression profiling of E2F-1-induced apoptosis. Gene, 
344: 67-77, 2005. 
 
 56 
37. Ianari, A., Gallo, R., Palma, M., Alesse, E., and Gulino, A. Specific role for 
p300/CREB-binding protein-associated factor activity in E2F1 stabilization in 
response to DNA damage. J Biol Chem, 279: 30830-30835, 2004. 
 
38. Martinez-Balbas, M. A., Bauer, U. M., Nielsen, S. J., Brehm, A., and Kouzarides, 
T. Regulation of E2F1 activity by acetylation. Embo J, 19: 662-671, 2000. 
39. Harley, C. B., Futcher, A. B., and Greider, C. W. Telomeres shorten during 
ageing of human fibroblasts. Nature, 345: 458-460, 1990. 
 
40. Wright, W. E. and Shay, J. W. The two-stage mechanism controlling cellular 
senescence and immortalization. Exp Gerontol, 27: 383-389, 1992. 
 
41. Liu, J. P. Studies of the molecular mechanisms in the regulation of telomerase 
activity. Faseb J, 13: 2091-2104, 1999. 
 
42. Hiyama, E., Gollahon, L., Kataoka, T., Kuroi, K., Yokoyama, T., Gazdar, A. F., 
Hiyama, K., Piatyszek, M. A., and Shay, J. W. Telomerase activity in human 
breast tumors. J Natl Cancer Inst, 88: 116-122, 1996. 
 
43. Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. 
L., Coviello, G. M., Wright, W. E., Weinrich, S. L., and Shay, J. W. Specific 
association of human telomerase activity with immortal cells and cancer. Science, 
266: 2011-2015, 1994. 
 
44. Shay, J. W. and Bacchetti, S. A survey of telomerase activity in human cancer. 
Eur J Cancer, 33: 787-791, 1997. 
 
45. Hiyama, E., Saeki, T., Hiyama, K., Takashima, S., Shay, J. W., Matsuura, Y., and 
Yokoyama, T. Telomerase activity as a marker of breast carcinoma in fine-needle 
aspirated samples. Cancer, 90: 235-238, 2000. 
 
46. Pearson, A. S., Gollahon, L. S., O'Neal, N. C., Saboorian, H., Shay, J. W., and 
Fahey, T. J., 3rd Detection of telomerase activity in breast masses by fine-needle 
aspiration. Ann Surg Oncol, 5: 186-193, 1998. 
 
47. Takakura, M., Kyo, S., Kanaya, T., Hirano, H., Takeda, J., Yutsudo, M., and 
Inoue, M. Cloning of human telomerase catalytic subunit (hTERT) gene promoter 
and identification of proximal core promoter sequences essential for 
transcriptional activation in immortalized and cancer cells. Cancer Res, 59: 551-
557, 1999. 
 
48. Crowe, D. L., Nguyen, D. C., Tsang, K. J., and Kyo, S. E2F-1 represses 
transcription of the human telomerase reverse transcriptase gene. Nucleic Acids 
Res, 29: 2789-2794, 2001. 
 
 57 
49. Phillips, A. C. and Vousden, K. H. E2F-1 induced apoptosis. Apoptosis, 6: 173-
182, 2001. 
 
50. Pierce, A. M., Schneider-Broussard, R., Philhower, J. L., and Johnson, D. G. 
Differential activities of E2F family members: unique functions in regulating 
transcription. Mol Carcinog, 22: 190-198, 1998. 
 
51. Saretzki, G., Ludwig, A., von Zglinicki, T., and Runnebaum, I. B. Ribozyme-
mediated telomerase inhibition induces immediate cell loss but not telomere 
shortening in ovarian cancer cells. Cancer Gene Ther, 8: 827-834, 2001. 
 
52. Keith, W. N., Bilsland, A., Evans, T. R., and Glasspool, R. M. Telomerase-
directed molecular therapeutics. Expert Rev Mol Med, 2002: 1-25, 2002. 
 
53. Dong, Y. B., Yang, H. L., Elliott, M. J., Liu, T. J., Stilwell, A., Atienza, C., Jr., 
and McMasters, K. M. Adenovirus-mediated E2F-1 gene transfer efficiently 
induces apoptosis in melanoma cells. Cancer, 86: 2021-2033, 1999. 
 
54. Dong, Y. B., Yang, H. L., Elliott, M. J., and McMasters, K. M. Adenovirus-
mediated E2F-1 gene transfer sensitizes melanoma cells to apoptosis induced by 
topoisomerase II inhibitors. Cancer Res, 62: 1776-1783, 2002. 
 
55. Henderson, Y. C., Breau, R. L., Liu, T. J., and Clayman, G. L. Telomerase 
activity in head and neck tumors after introduction of wild-type p53, p21, p16, 
and E2F-1 genes by means of recombinant adenovirus. Head Neck, 22: 347-354, 
2000. 
 
56. Hunt, K. K., Deng, J., Liu, T. J., Wilson-Heiner, M., Swisher, S. G., Clayman, G., 
and Hung, M. C. Adenovirus-mediated overexpression of the transcription factor 
E2F-1 induces apoptosis in human breast and ovarian carcinoma cell lines and 
does not require p53. Cancer Res, 57: 4722-4726, 1997. 
 
57. Hsieh, J. K., Fredersdorf, S., Kouzarides, T., Martin, K., and Lu, X. E2F1-induced 
apoptosis requires DNA binding but not transactivation and is inhibited by the 
retinoblastoma protein through direct interaction. Genes Dev, 11: 1840-1852, 
1997. 
 
58. Zhang, X., Mar, V., Zhou, W., Harrington, L., and Robinson, M. O. Telomere 
shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev, 
13: 2388-2399, 1999. 
 
59. Yamasaki, L., Jacks, T., Bronson, R., Goillot, E., Harlow, E., and Dyson, N. J. 
Tumor induction and tissue atrophy in mice lacking E2F-1. Cell, 85: 537-548, 
1996. 
 58 
60. Field, S. J., Tsai, F. Y., Kuo, F., Zubiaga, A. M., Kaelin, W. G., Jr., Livingston, 
D. M., Orkin, S. H., and Greenberg, M. E. E2F-1 functions in mice to promote 
apoptosis and suppress proliferation. Cell, 85: 549-561, 1996. 
 
61. Ho, G. H., Calvano, J. E., Bisogna, M., and Van Zee, K. J. Expression of E2F-1 
and E2F-4 is reduced in primary and metastatic breast carcinomas. Breast Cancer 
Res Treat, 69: 115-122, 2001. 
 
62. Ouchi, T., Monteiro, A. N., August, A., Aaronson, S. A., and Hanafusa, H. 
BRCA1 regulates p53-dependent gene expression. Proc Natl Acad Sci U S A, 95: 
2302-2306, 1998. 
 
63. Balogh, G. A., Mailo, D. A., Corte, M. M., Roncoroni, P., Nardi, H., Vincent, E., 
Martinez, D., Cafasso, M. E., Frizza, A., Ponce, G., Vincent, E., Barutta, E., 
Lizarraga, P., Lizarraga, G., Monti, C., Paolillo, E., Vincent, R., Quatroquio, R., 
Grimi, C., Maturi, H., Aimale, M., Spinsanti, C., Montero, H., Santiago, J., 
Shulman, L., Rivadulla, M., Machiavelli, M., Salum, G., Cuevas, M. A., Picolini, 
J., Gentili, A., Gentili, R., and Mordoh, J. Mutant p53 protein in serum could be 
used as a molecular marker in human breast cancer. Int J Oncol, 28: 995-1002, 
2006. 
 
64. Zaika, A., Irwin, M., Sansome, C., and Moll, U. M. Oncogenes induce and 
activate endogenous p73 protein. J Biol Chem, 276: 11310-11316, 2001. 
 
65. Dominguez, G., Silva, J. M., Silva, J., Garcia, J. M., Sanchez, A., Navarro, A., 
Gallego, I., Provencio, M., Espana, P., and Bonilla, F. Wild type p73 
overexpression and high-grade malignancy in breast cancer. Breast Cancer Res 
Treat, 66: 183-190, 2001. 
 
66. Stiewe, T., Zimmermann, S., Frilling, A., Esche, H., and Putzer, B. M. 
Transactivation-deficient DeltaTA-p73 acts as an oncogene. Cancer Res, 62: 
3598-3602, 2002. 
 
67. Lee, C. W. and La Thangue, N. B. Promoter specificity and stability control of the 
p53-related protein p73. Oncogene, 18: 4171-4181, 1999. 
 
68. Sasaki, Y., Morimoto, I., Ishida, S., Yamashita, T., Imai, K., and Tokino, T. 
Adenovirus-mediated transfer of the p53 family genes, p73 and p51/p63 induces 
cell cycle arrest and apoptosis in colorectal cancer cell lines: potential application 
to gene therapy of colorectal cancer. Gene Ther, 8: 1401-1408, 2001. 
 
69. Zaika, A. I., Kovalev, S., Marchenko, N. D., and Moll, U. M. Overexpression of 




70. Ambrosini, G., Sambol, E. B., Carvajal, D., Vassilev, L. T., Singer, S., and 
Schwartz, G. K. Mouse double minute antagonist Nutlin-3a enhances 
chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating 
E2F1. Oncogene, 2006. 
 
71. Marabese, M., Vikhanskaya, F., Rainelli, C., Sakai, T., and Broggini, M. DNA 
damage induces transcriptional activation of p73 by removing C-EBPalpha 
repression on E2F1. Nucleic Acids Res, 31: 6624-6632, 2003. 
 
72. Ozaki, T. and Nakagawara, A. p73, a sophisticated p53 family member in the 
cancer world. Cancer Sci, 96: 729-737, 2005. 
 
73. Stiewe, T. and Putzer, B. M. Role of the p53-homologue p73 in E2F1-induced 
apoptosis. Nat Genet, 26: 464-469, 2000. 
 
74. Hallstrom, T. C. and Nevins, J. R. Specificity in the activation and control of 
transcription factor E2F-dependent apoptosis. Proc Natl Acad Sci U S A, 100: 
10848-10853, 2003. 
 
75. Seelan, R. S., Irwin, M., van der Stoop, P., Qian, C., Kaelin, W. G., Jr., and Liu, 
W. The human p73 promoter: characterization and identification of functional 
E2F binding sites. Neoplasia, 4: 195-203, 2002. 
 
76. Miro-Mur, F., Meiller, A., Haddada, H., and May, E. p73alpha expression induces 
both accumulation and activation of wt-p53 independent of the p73alpha 
transcriptional activity. Oncogene, 22: 5451-5456, 2003. 
 
77. Peters, U. R., Tschan, M. P., Kreuzer, K. A., Baskaynak, G., Lass, U., Tobler, A., 
Fey, M. F., and Schmidt, C. A. Distinct expression patterns of the p53-homologue 
p73 in malignant and normal hematopoiesis assessed by a novel real-time reverse 
transcription-polymerase chain reaction assay and protein analysis. Cancer Res, 
59: 4233-4236, 1999. 
 
78. Roos, W. P. and Kaina, B. DNA damage-induced cell death by apoptosis. Trends 
Mol Med, 12: 440-450, 2006. 
 
79. Dotto, G. P. p21(WAF1/Cip1): more than a break to the cell cycle? Biochim 
Biophys Acta, 1471: M43-56, 2000. 
 
80. Shiohara, M., Koike, K., Komiyama, A., and Koeffler, H. P. p21WAF1 mutations 
and human malignancies. Leuk Lymphoma, 26: 35-41, 1997. 
 
81. Gartel, A. L. and Radhakrishnan, S. K. Lost in transcription: p21 repression, 
mechanisms, and consequences. Cancer Res, 65: 3980-3985, 2005. 
 
 60 
82. Schmelz, K., Wagner, M., Dorken, B., and Tamm, I. 5-Aza-2'-deoxycytidine 
induces p21WAF expression by demethylation of p73 leading to p53-independent 
apoptosis in myeloid leukemia. Int J Cancer, 114: 683-695, 2005. 
 
83. Somasundaram, K. Breast cancer gene 1 (BRCA1): role in cell cycle regulation 
and DNA repair--perhaps through transcription. J Cell Biochem, 88: 1084-1091, 
2003. 
 
84. Green, M. and Loewenstein, P. M. Autonomous functional domains of chemically 
synthesized human immunodeficiency virus tat trans-activator protein. Cell, 55: 
1179-1188, 1988. 
 
85. Frankel, A. D. and Pabo, C. O. Cellular uptake of the tat protein from human 
immunodeficiency virus. Cell, 55: 1189-1193, 1988. 
 
86. Fawell, S., Seery, J., Daikh, Y., Moore, C., Chen, L. L., Pepinsky, B., and 
Barsoum, J. Tat-mediated delivery of heterologous proteins into cells. Proc Natl 
Acad Sci U S A, 91: 664-668, 1994. 
 
87. Nagahara, H., Vocero-Akbani, A. M., Snyder, E. L., Ho, A., Latham, D. G., 
Lissy, N. A., Becker-Hapak, M., Ezhevsky, S. A., and Dowdy, S. F. Transduction 
of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces 
cell migration. Nat Med, 4: 1449-1452, 1998. 
 
88. Colin, M., Maurice, M., Trugnan, G., Kornprobst, M., Harbottle, R. P., Knight, 
A., Cooper, R. G., Miller, A. D., Capeau, J., Coutelle, C., and Brahimi-Horn, M. 
C. Cell delivery, intracellular trafficking and expression of an integrin-mediated 
gene transfer vector in tracheal epithelial cells. Gene Ther, 7: 139-152, 2000. 
 
89. Perez, F., Joliot, A., Bloch-Gallego, E., Zahraoui, A., Triller, A., and Prochiantz, 
A. Antennapedia homeobox as a signal for the cellular internalization and nuclear 
addressing of a small exogenous peptide. J Cell Sci, 102 ( Pt 4): 717-722, 1992. 
 
90. Joliot, A. and Prochiantz, A. Transduction peptides: from technology to 
physiology. Nat Cell Biol, 6: 189-196, 2004. 
 
91. Drin, G., Cottin, S., Blanc, E., Rees, A. R., and Temsamani, J. Studies on the 
internalization mechanism of cationic cell-penetrating peptides. J Biol Chem, 
278: 31192-31201, 2003. 
 
92. Dietz, G. P. and Bahr, M. Delivery of bioactive molecules into the cell: the Trojan 
horse approach. Mol Cell Neurosci, 27: 85-131, 2004. 
 
93. Letoha, T., Kusz, E., Papai, G., Szabolcs, A., Kaszaki, J., Varga, I., Takacs, T., 
Penke, B., and Duda, E. In vitro and in vivo nuclear factor-kappaB inhibitory 
 61 
effects of the cell-penetrating penetratin peptide. Mol Pharmacol, 69: 2027-2036, 
2006. 
 
94. Pouniotis, D. S., Apostolopoulos, V., and Pietersz, G. A. Penetratin tandemly 
linked to a CTL peptide induces anti-tumour T-cell responses via a cross-
presentation pathway. Immunology, 117: 329-339, 2006. 
 
95. Liu, C. S., Kong, B., Xia, H. H., Ellem, K. A., and Wei, M. Q. VP22 enhanced 
intercellular trafficking of HSV thymidine kinase reduced the level of ganciclovir 
needed to cause suicide cell death. J Gene Med, 3: 145-152, 2001. 
 
96. Phelan, A., Elliott, G., and O'Hare, P. Intercellular delivery of functional p53 by 
the herpesvirus protein VP22. Nat Biotechnol, 16: 440-443, 1998. 
 
97. Morris, S. J., Smith, H., and Sweet, C. Exploitation of the Herpes simplex virus 
translocating protein VP22 to carry influenza virus proteins into cells for studies 
of apoptosis: direct confirmation that neuraminidase induces apoptosis and 
indications that other proteins may have a role. Arch Virol, 147: 961-979, 2002. 
 
98. Pooga, M., Hallbrink, M., Zorko, M., and Langel, U. Cell penetration by 
transportan. Faseb J, 12: 67-77, 1998. 
 
99. Lindgren, M. E., Hallbrink, M. M., Elmquist, A. M., and Langel, U. Passage of 
cell-penetrating peptides across a human epithelial cell layer in vitro. Biochem J, 
377: 69-76, 2004. 
 
100. Kaushik, N., Basu, A., Palumbo, P., Myers, R. L., and Pandey, V. N. Anti-TAR 
polyamide nucleotide analog conjugated with a membrane-permeating peptide 
inhibits human immunodeficiency virus type 1 production. J Virol, 76: 3881-
3891, 2002. 
 
101. Ostenson, C. G., Sandberg-Nordqvist, A. C., Chen, J., Hallbrink, M., Rotin, D., 
Langel, U., and Efendic, S. Overexpression of protein-tyrosine phosphatase PTP 
sigma is linked to impaired glucose-induced insulin secretion in hereditary 
diabetic Goto-Kakizaki rats. Biochem Biophys Res Commun, 291: 945-950, 
2002. 
 
102. Soomets, U., Lindgren, M., Gallet, X., Hallbrink, M., Elmquist, A., Balaspiri, L., 
Zorko, M., Pooga, M., Brasseur, R., and Langel, U. Deletion analogues of 
transportan. Biochim Biophys Acta, 1467: 165-176, 2000. 
 
103. Kask, K., Berthold, M., and Bartfai, T. Galanin receptors: involvement in feeding, 
pain, depression and Alzheimer's disease. Life Sci, 60: 1523-1533, 1997. 
 
104. Marcello, A., Cinelli, R. A., Ferrari, A., Signorelli, A., Tyagi, M., Pellegrini, V., 
Beltram, F., and Giacca, M. Visualization of in vivo direct interaction between 
 62 
HIV-1 TAT and human cyclin T1 in specific subcellular compartments by 
fluorescence resonance energy transfer. J Biol Chem, 276: 39220-39225, 2001. 
 
105. Marcello, A., Lusic, M., Pegoraro, G., Pellegrini, V., Beltram, F., and Giacca, M. 
Nuclear organization and the control of HIV-1 transcription. Gene, 326: 1-11, 
2004. 
 
106. Marcello, A., Zoppe, M., and Giacca, M. Multiple modes of transcriptional 
regulation by the HIV-1 Tat transactivator. IUBMB Life, 51: 175-181, 2001. 
 
107. Vocero-Akbani, A. M., Heyden, N. V., Lissy, N. A., Ratner, L., and Dowdy, S. F. 
Killing HIV-infected cells by transduction with an HIV protease-activated 
caspase-3 protein. Nat Med, 5: 29-33, 1999. 
 
108. Becker-Hapak, M., McAllister, S. S., and Dowdy, S. F. TAT-mediated protein 
transduction into mammalian cells. Methods, 24: 247-256, 2001. 
 
109. Schwarze, S. R. and Dowdy, S. F. In vivo protein transduction: intracellular 
delivery of biologically active proteins, compounds and DNA. Trends Pharmacol 
Sci, 21: 45-48, 2000. 
 
110. Vocero-Akbani, A., Lissy, N. A., and Dowdy, S. F. Transduction of full-length 
Tat fusion proteins directly into mammalian cells: analysis of T cell receptor 
activation-induced cell death. Methods Enzymol, 322: 508-521, 2000. 
 
111. Gius, D. R., Ezhevsky, S. A., Becker-Hapak, M., Nagahara, H., Wei, M. C., and 
Dowdy, S. F. Transduced p16INK4a peptides inhibit hypophosphorylation of the 
retinoblastoma protein and cell cycle progression prior to activation of Cdk2 
complexes in late G1. Cancer Res, 59: 2577-2580, 1999. 
 
112. Ryu, J., Lee, H. J., Kim, K. A., Lee, J. Y., Lee, K. S., Park, J., and Choi, S. Y. 
Intracellular delivery of p53 fused to the basic domain of HIV-1 Tat. Mol Cells, 
17: 353-359, 2004. 
 
113. Guelen, L., Paterson, H., Gaken, J., Meyers, M., Farzaneh, F., and Tavassoli, M. 
TAT-apoptin is efficiently delivered and induces apoptosis in cancer cells. 
Oncogene, 23: 1153-1165, 2004. 
 
114. Yan, H., Thomas, J., Liu, T., Raj, D., London, N., Tandeski, T., Leachman, S. A., 
Lee, R. M., and Grossman, D. Induction of melanoma cell apoptosis and 
inhibition of tumor growth using a cell-permeable Survivin antagonist. Oncogene, 
25: 6968-6974, 2006. 
 
115. Eguchi, A., Akuta, T., Okuyama, H., Senda, T., Yokoi, H., Inokuchi, H., Fujita, 
S., Hayakawa, T., Takeda, K., Hasegawa, M., and Nakanishi, M. Protein 
 63 
transduction domain of HIV-1 Tat protein promotes efficient delivery of DNA 
into mammalian cells. J Biol Chem, 276: 26204-26210, 2001. 
 
116. Vives, E., Richard, J. P., Rispal, C., and Lebleu, B. TAT peptide internalization: 
seeking the mechanism of entry. Curr Protein Pept Sci, 4: 125-132, 2003. 
 
117. Wadia, J. S., Stan, R. V., and Dowdy, S. F. Transducible TAT-HA fusogenic 
peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. 
Nat Med, 10: 310-315, 2004. 
 
118. Fittipaldi, A., Ferrari, A., Zoppe, M., Arcangeli, C., Pellegrini, V., Beltram, F., 
and Giacca, M. Cell membrane lipid rafts mediate caveolar endocytosis of HIV-1 
Tat fusion proteins. J Biol Chem, 278: 34141-34149, 2003. 
 
119. Fittipaldi, A. and Giacca, M. Transcellular protein transduction using the Tat 
protein of HIV-1. Adv Drug Deliv Rev, 57: 597-608, 2005. 
 
120. Ferrari, A., Pellegrini, V., Arcangeli, C., Fittipaldi, A., Giacca, M., and Beltram, 
F. Caveolae-mediated internalization of extracellular HIV-1 tat fusion proteins 
visualized in real time. Mol Ther, 8: 284-294, 2003. 
 
121. Tyagi, M., Rusnati, M., Presta, M., and Giacca, M. Internalization of HIV-1 tat 
requires cell surface heparan sulfate proteoglycans. J Biol Chem, 276: 3254-3261, 
2001. 
 
122. Caron, N. J., Quenneville, S. P., and Tremblay, J. P. Endosome disruption 
enhances the functional nuclear delivery of Tat-fusion proteins. Biochem Biophys 
Res Commun, 319: 12-20, 2004. 
 
123. Zhang, X., Dong, X., Sawyer, G. J., Collins, L., and Fabre, J. W. Regional 
hydrodynamic gene delivery to the rat liver with physiological volumes of DNA 
solution. J Gene Med, 6: 693-703, 2004. 
 
124. Zhang, X., Sawyer, G. J., Dong, X., Qiu, Y., Collins, L., and Fabre, J. W. The in 
vivo use of chloroquine to promote non-viral gene delivery to the liver via the 






PRODUCTION, PURIFICATION AND TRANSDUCTION OF E2F-1/TATHA 




 Purification of Tat fusion proteins is highly dependent on the solubility and 
stability of the proteins under specific physiological parameters necessary for in vitro 
testing of cell lines.  We have developed an effective methodology to generate constructs 
with the HIV-1 Tat transduction domain attached to E2F transcription factors in order to 
test their transduction potential and biological efficacy in carcinoma cell lines.  Wildtype 
E2F-1 and mutant E2F-1 genes (E132; point mutation in DNA-binding domain) were 
cloned into the multiple cloning site (MCS) of the pTatHA expression vector to produce 
E2F-1/TatHA and E132/TatHA constructs.  Proteins were produced in bacterial cell 
cultures and western blotting performed to verify the presence of the hemagglutinin (HA) 
tag.  InVision
TM
 staining was also utilized to identify presence of the 6-histidine tag prior 
to large scale production and purification of proteins.  Using affinity chromatography and 
strong denaturants, the proteins were effectively isolated, partially refolded and purified 
via FPLC.   Following dialysis into appropriate cell culture media, proteins were tested at 
 65 
various concentrations to determine optimal transduction potentials of proteins.  The 
addition of the lysosomotropic agent chloroquine was also tested to determine if 
transduction potentials and subsequent biological effects of Tat fusion proteins (TFPs) 
were enhanced in cell lines.  We developed a successful technique to produce and purify 
recombinant E2F-1 Tat fusion proteins with greater than 95% transduction potentials.  
Additionally, the E2F-1 TFPs elicited their biological effect on breast cancer cell lines 
both with and without the addition of chloroquine.  Overall, we developed a successful 
methodology to produce biologically active E2F-1 and E132 TFPs to impact gene 




 Protein therapeutics is a developing field oriented towards manipulating gene 
expression to impact cellular biology.  However, effective protein therapy is highly 
dependent on several factors.  Proteins must be able to effectively transduce through 
cellular membranes and target specific cell compartments.  Appropriate folding of 
proteins must occur to preserve their biological activity, and proteins must have adequate 
half-lives to achieve their desired responses in cells.  To produce proteins meeting the 
above criteria, multiple variables must be overcome during the production and 
purification process to preserve the proteins’ capacity for transduction and biological 
efficacy.   
 Protein therapy is dependent on the direct delivery of proteins through the plasma 
membrane and into specific cell compartments.  Small cationic peptides, commonly 
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referred to as protein transduction domains (PTDs), have the ability to deliver large 
proteins (up to 120 kDa) into mammalian cells both in vitro and in vivo (1, 2).  One such 
cationic peptide is the 11-amino acid Tat-transduction domain derived from HIV-1 
(amino acids 47-57) (1, 2).  Tat proteins possess the unique ability to enter cells and 
translocate to the nucleus and nucleolus which is a property attributed to the basic region 
of the Tat protein (3-5).  Dowdy and his associates have widely published Tat 
purification procedures and successfully produced multiple Tat fusion proteins such as 
Tat-Casp3, Tat-p27
Kip1
, Tat-Cdc42 and Tat-p16 (6-11).  Traditionally, Tat fusion proteins 
are produced as either soluble or insoluble proteins in bacterial expression systems, and 
the optimal biological activity of proteins is achieved via series of buffer exchanges, 
desalting and/or dialysis.  However, the generation of biologically active proteins with 
PTDs is heavily dependent on the ability of proteins to fold correctly from an insoluble 
state during isolation and purification.  Therefore, some groups are investigating 
mammalian expression systems to bypass the obstacles encountered with bacterial 
expression systems in order to generate biologically active TFPs for both in vitro and in 
vivo cell testing (12). 
 The characterization of the transduction properties of Tat fusion proteins has been 
widely investigated.  The route of cellular internalization and intracellular trafficking of 
TFPs is still misunderstood and often appears to be a protein-specific phenomenon.  
Multiple pathways have been suggested to describe the transduction of Tat fusion 
proteins ranging from cellular membrane destabilization (13), membrane absorption via 
non-specific endocytosis (14), lipid raft macropinocytosis (15) and caveolar endocytosis 
(16).  It has also been reported that Tat-mediated transduction is dependent on Tat 
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binding cell surface heparan sulfate proteoglycans for extracellular Tat internalization 
(17). Upon cellular uptake of Tat proteins, the addition of chloroquine in vitro and in vivo 
has been suggested to enhance the endocytotic delivery of proteins via endosome 
disruption to promote nuclear targeting of Tat fusion proteins (18-20).   
 In this study, we constructed E2F-1/TatHA and E132/TatHA expression vectors, 
produced them in a bacterial expression system and purified the recombinant proteins 
using affinity chromatography with FPLC.  We also attempted to enhance transduction 
capabilities of proteins with the addition of chloroquine in anticipation of achieving a 
greater impact on target gene expression.  Our lab modified existing purification 
protocols to produce an effective methodology produced biologically active E2F-
1/TatHA and E132/TatHA proteins that successfully transduced breast cancer cells. 
 
MATERIALS AND METHODS 
 
Vector DNA 
 The vectors pCMV E2F-1 and pCMV E132 were obtained from Dr. Karen 
Vousden (Beatson Cancer Institute, UK) and the pTatHA vector was a kind gift from Dr. 
Steven Dowdy (University of Washington, St. Louis, MO).  Vectors were received as 
plasmid DNA spotted on Whatman paper.  DNA was extracted from paper via hydration 
in 50 µl Tris
TM
-EDTA (TE) buffer overnight, and a 1 µl volume transformed into E. coli 
Top10F’ cells (Invitrogen Life Technologies, Carlsbad, CA) using the transformation 
protocol described below.  Large quantities of plasmid DNA were extracted from 
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bacterial DNA using a Qiagen Midiprep protocol (QIAGEN Inc., Valencia, CA) to yield 
sufficient DNA for cloning experiments.   
 
E2F-1/TatHA Construct 
Restriction Enzyme Digestion and Purification 
 The E2F-1 gene was directly cloned into the pTatHA vector via NcoI and EcoRI 
restriction enzyme sites. Both pCMV E2F-1 and pTatHA were digested with NcoI and 
EcoRI restriction enzymes overnight at 37ºC and samples run on 1% agarose gels 
containing ethidium bromide (0.5 µg/ml).  Digested bands of DNA were visualized using 
low-intensity ultraviolet light, and DNA fragments (pTatHA= 3 kb, E2F-1=1.36 kb) 
excised with clean razor blades and placed in purification tubes.   
 
Purification of DNA Fragments from Agarose Gel Using Siliconized Glass Wool 
 Purification tubes consisted of 0.6 ml microcentrifuge tubes that contained 
siliconized glass wool compacted in bottom one-third of tube in addition to a 22-gauge 
sized hole in tube base.  Purification tubes were placed in 1.8 ml microcentrifuge tubes to 
collected liquefied agarose gel.  Purification tubes containing excised DNA fragments 
were centrifuged at 10,000 g for 10 minutes at 4ºC.  Liquefied fractions in 1.8 ml tubes 
were retained and volume adjusted with dH2O to 200 µl.  One volume of 
phenol:chloroform:isoamyl alcohol (25:24:1) (~100 µl) was added to sample and tube 
vortexed for 20 seconds.  Tubes were then centrifuged at 14,000 rpm for 5 minutes at 
4ºC.  Aqueous layers were carefully removed from phenol:chloroform and transferred to 
clean 1.8 ml microcentrifuge tubes.  One-half volume (~100 µl) of 7.5 mM ammonium 
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acetate was added to assist with DNA precipitation.  Samples were vortexed lightly and 
two volumes (~600 µl) of 100% ETOH added and samples incubated at -80ºC for 15-30 
minutes to precipitate DNA.  Samples were centrifuged at 14,000 rpm for 5 minutes at 
4ºC and ETOH decanted without disrupting the DNA pellet.  Next, 0.5 ml 70% ETOH 
added to tubes, tubes were inverted twice and samples again centrifuged as described 
above.  Supernatants were removed by decanting, DNA pellets dried, and samples 
resuspended in 20 µl TE buffer (pH 8.0) for subsequent ligation of insert DNA into 
vector.  Samples were quantified prior to ligation reactions. 
 
Ligation of E2F-1 into MCS of pTatHA 
 Purified digested pCMV E2F-1 DNA was ligated into digested pTatHA using T4 
DNA Ligase (Invitrogen Life Technologies, Carlsbad, CA) following the protocol 
provided by the manufacturer.  In brief, 0.1 U T4 DNA Ligase was added to 5X Ligase 
Buffer, 0.1 µg pCMV E2F-1 DNA, 0.03 µg pTatHA DNA, and sufficient PCR H2O to 
yield a 1X final Ligase Reaction Buffer concentration.  Samples were incubated 
overnight at 16ºC, reactions diluted 5-fold with dH2O and a 1 µl volume of the ligation 
reactions transformed into E. coli Top10F’ competent cells (Invitrogen Life 
Technologies, Carlsbad, CA)  following the protocol listed below.   
 
Transformation Protocol for Top10F’ Cells 
 Competent cells were thawed on ice and 3 µl of DMSO added to aliquots of cells.  
50 µl samples of Top10F’ cells were added to 1 µl volumes of diluted ligation reaction in 
1.8 ml microcentrifuge tubes.  Tubes were placed on ice for 30 minutes and gently mixed 
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2-3 times during this incubation period.  Tubes were then heat shocked in a 42ºC water 
bath for one minute and immediately placed on ice for one minute.  A 400 µl volume of 
2YT broth was added to transformation reaction, tube placed in shaking water bath at 
37ºC for 30 minutes, and a 30 µl volume of cell mixture spread on agar plates 
supplemented with 50 µg/ml ampicillin.  Plates were incubated overnight at 37ºC, and the 
following day, single colonies from the transformation plate were screened for the E2F-
1/TatHA construct via isolating plasmid DNA using traditional alkaline extraction (21).  
Plasmid DNA from select colonies were then DNA sequenced (Applied Biosystems, 
Model 373A Automated Sequencer, Oklahoma State University DNA/Protein Resource 
Facility, Stillwater, OK) to verify correct in-frame fusion of E2F-1 into pTatHA’s 
multiple cloning site (MCS).  The oligonucleotide primers used to sequence TatHA 
constructs are as follows: pTatHA forward primer 5’-CCCGCGAAATTAATACGAC-3’ 
and pTatHA reverse primer 5’-GTCCCATTCGCCATTCAGG-3’ (Sigma Genosys, 




5’ Site-Directed Mutagenesis of E132 via PCR 
 The E132 vector contained an artificial EcoRI site in the DNA binding domain 
and could not be directly inserted into pTatHA’s MCS.  Therefore, the E132 gene 
modified using 5’ site-directed mutagenesis via PCR from plasmid pCMV-E132 using 
sense primer:  5’-gcgcgcaaccATGGCCTTGGCCGGG-3’and antisense primer: 5’-
gcgcagcatgcGGATCCAGCCCTGTC-3’ (Sigma Genosys, Woodlands, TX) to generate 
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artificial NcoI and SphI sites (underlined in primer sequences).  The PCR reaction used 2 
Units Vent Taq polymerase (New England Biolabs, Beverly, MA), 1X Thermapol buffer 
(New England Biolabs, Beverly, MA), 500 nM of sense and antisense primers and 5% 
DMSO.  The PCR product was amplified under the following conditions in a Perkin 
Elmer 9600 Thermocycler: initial denaturation: 94ºC- 3  minutes, 55ºC- 1 minute, 72ºC- 
1 minute; 23 cycles: denaturation: 94ºC- 1 minute, annealing: 55ºC- 1 minute, extension: 
72ºC- 1 minute, and final extension of 72ºC for 7 minutes.  PCR products were then 
analyzed on 1% agarose gels and stained with ethidium bromide (0.5 µg/ml) to confirm 
generation of 1.36 kb amplified product (see Figure 3.3).  
 
Restriction Enzyme Digestion and Klenow-Kinase-Ligase (KKL) Protocol 
 The pTatHA DNA was digested with restriction enzymes NcoI and SphI and 
purified using the protocol “Purification of DNA Fragments from Agarose Gel Using 
Siliconized Glass Wool” as described above.  The E132 PCR product was digested with 
NcoI-SphI and subcloned into the NcoI-SphI sites of pTatHA to yield E132/TatHA using 
a modified Klenow-Kinase-Ligase (KKL) protocol (22).  To summarize the KKL 
protocol, first, phenol:chloroform extracted PCR product was precipitated with ethanol 
and subsequently dissolved in distilled water (22).  Next, 2 µl of 10X ligase buffer (300 
mM Tris-HCl, pH 7.8, 100 mM MgCl2, 100 mM DTT, and 5 mM ATP) was added to the 
reaction in addition to the following reagents to yield a 25 µl final volume: 0.2 mM 
dNTPs, 5 U Klenow, 4 U T4 Polynucleotide Kinase, 2 U DNA Ligase (22).  The reaction 
was incubated at 25ºC for 2 hours followed by heat inactivation at 70ºC for 10 minutes 
(22).  The reaction was then diluted with distilled H2O and restriction enzyme buffer 
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added to yield a 1X concentration.  40 U of restriction enzymes was then added to the 
reaction tubes followed by incubated of samples for 2 hours at 37ºC (22).  Digested PCR 
product was then heat inactivated at 70ºC for 10 minutes followed by ligation to pTatHA 
vector via T4 DNA Ligase following protocol described above.  Ligated constructs 
containing E132/TatHA were transformed into E. coli Top10F’ competent cells 
(Invitrogen Life Technologies, Carlsbad, CA), screened with restriction enzyme 
digestions, and correct gene insertion verified by DNA sequencing of plasmid DNA as 
described above.  Illustration of the E132/TatHA plasmid construction is represented by 
Figure 3.4.  
 
Recombinant Protein Production 
Western Blotting and InVision
TM
 Staining 
 E2F-1/TatHA and E132/TatHA plasmids were transformed into BLR(DE3)pLysS 
competent cells (Novagen, Madison, WI) and recombinant proteins produced via 
inoculating 2 ml 2YT broth with single transformed colonies.  After incubation in a 
shaking water bath (225 rpm) for 12-14 hours, 3 ml of fresh 2YT broth, 0.5 µg/ml 
ampicillin and 0.4 mM isopropyl-beta-D-thiogalactopyranoside (IPTG) were added to 
cultures.  Cultures were incubated an additional 6 hours to produce recombinant proteins 
via IPTG stimulation.  Cultures were centrifuged at 6000 x g for 10 minutes and cell 
pellets resuspended in 100 µl of 20 mM Tris buffer (pH 8.0) followed by quantitation 
using a BCA
TM
 Protein Assay Kit (Pierce Biotechnology, Inc., Rockford, IL) with BSA 
standards.  2X Laemmli Sample Buffer (21) was added to 50 µg of total cellular protein 
and samples were boiled for 3-5 minutes and immediately placed on ice.  Samples were 
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then loaded onto 12% SDS-PAGE gels and ran on a Mini-PROTEAN
®
 3 (Bio-Rad 
Laboratories, Hercules, CA) protein electrophoresis unit using the Laemmli buffer 
system.  Prestained 1 kb protein ladders (Fermentas Life Technologies, Hanover, MD) 
were also run on each gel to determine protein size.   
 Duplicate gels were run simultaneously- one gel for western blotting and a second 
gel for Coomassie blue staining.  Gel designated for western blotting was transferred to 
nylon membranes using a Trans-Blot SD Semi-Dry Electrophoretic Transfer Cell (Bio-
Rad Laboratories, Hercules, CA) according to manufacturer’s instructions using 1X TBS-
T transfer buffer.   
 Recombinant protein production was verified using primary mouse monoclonal 
HA antibodies (1:1,000 dilution) (CRP, Inc., Denver, PA) and secondary HRP-labeled 
goat anti-mouse antibodies (1:25,000 dilution) (KPL, Inc., Gaithersburg, MD).  
Membranes were blocked with TBS-T/5% milk solution for 1 hour, incubated with 
primary HA antibody for 1 hour, washed 3 times for 10 minutes each, and incubated with 
secondary HRP antibody for 1 hour.  Following additional washings (3 x 10 minutes), 
western blots were developed with SuperSignal West Pico Chemiluminescent Substrate 
(Pierce Biotechnology, Inc., Rockford, IL) according to manufacturer’s instructions. 
Blots were exposed to X-ray film and developed with KODAK Developer (30 sec) and 
KODAK Fixer (30 sec).  Immunoblots were also visualized using a KODAK Image 
Station 2000R (KODAK, Rochester, NY) according to manufacturer’s instructions (see 
Figure 3.6).  
 Additional SDS-PAGE gels were also run to utilize an InVision
TM
 His-Tag In-Gel 
Stain (Invitrogen Life Technologies, Carlsbad, CA) to verify the presence of 6-histidine 
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tag for purification purposes using HisTrap
TM
 columns.  The following protocol was 
slightly modified from the manufacturer’s protocol.  First, Tris-Glycine SDS-PAGE gels 
containing the recombinant protein and the positive control, BenchMark
TM
 His-Tagged 
Protein Standard (Invitrogen Life Technologies, Carlsbad, CA), were fixed for 1 hour in a 
fixing solution containing the following: 50% ethanol, 20% acetic acid and 30% distilled 
water (v/v).   Gels were then washed with distilled water (2 x 10 minutes) and incubated 
with 25 ml of the InVision
TM
 His-Tag In-Gel Stain.  Following incubation, gels were 
washed with 200 ml of 20 mM sodium phosphate wash buffer (pH 7.8) (3 x 10 minutes).  
The gel was then visualized using an UV transilluminator (302 nm) to verify presence of 
6-histidine tag and an image captured with a CCD camera (see Figure 3.7). 
  
Large-Scale Recombinant Protein Production 
 Recombinant E2F-1/TatHA and E132/TatHA proteins were purified under 
denaturing conditions with affinity chromatography using a modified procedure from 
Amersham Pharmacia (23).  Single colonies from protein expressing cultures inoculated 
200 ml of 2YT broth supplemented with ampicillin (50 µg/ml) and were incubated at 
37ºC while shaking at 225 rpm for 16-18 hours.  An additional 300 ml of broth was 
added along with freshly prepared ampicillin and IPTG (400 µM), and cultures incubated 
an additional 6 hours.  Cultures were centrifuged for 10 minutes at 6000 x g, and the 
bacterial pellets frozen at -20ºC.  Cell pellets were thawed for 20 minutes at 37ºC, and 25 
ml of Buffer 1 (20 mM Tris-HCl, pH 8.0) was added to resuspend the cells with vigorous 
pipetting.  Cells were sonicated on ice (3 x 15 seconds) and centrifuged (10 min x 6000 
g).  Cell pellets containing the inclusion bodies were then resuspended in 25 ml Buffer 2 
 75 
(2 M urea, 20 mM Tris-HCl, 0.5 M NaCl, 2% Triton
TM
 X-100, pH 8.0).  Samples were 
again sonicated on ice and centrifuged as described above.  Pellets were resuspended in 
25 ml Buffer 2 to wash the inclusion bodies and recentrifuged.  A final wash of 25 ml of 
Buffer 1 was then performed, and following centrifugation, pellets were either used 
immediately or frozen at -20ºC for a maximum of two weeks prior to use.   
 
Preparation of Inclusion Bodies for FPLC 
 Cell pellets were resuspended in 5-10 ml Buffer A1 (6 M guanidine-HCl, 0.5 M 
NaCl, 20 mM Tris-HCl, 20 mM imidazole, 5 mM β-mercaptoethanol, pH 8.0) by stirring 
at room temperature for 60 minutes to solubilize recombinant proteins.  Samples were 
centrifuged at 20,000 x g for 15 minutes to pellet residual cell debris.  Protein supernatant 
containing denatured, soluble proteins was removed from residual cell debris.  
Supernatant was further clarified by passage through a 0.45 µM filter (Millipore, 
Bellerica, IL) to remove any remaining particles.   
 
Isolation of Recombinant Proteins using Affinity Chromatography 
 Using an AKTA
TM
 FPLC, nickel-charged HisTrap columns (Amersham 
Pharmacia, Piscataway, NJ) were equilibrated with 5 ml Buffer A1 and the proteins 
loaded at a flow rate of 0.5 ml/minute.  Columns were washed with an additional 10 ml 
of Buffer A1 followed by a wash of 10 ml of Buffer A2 (6 M urea, 0.5 M NaCl, 20 mM 
Tris-HCl, 20 mM imidazole, 5 mM β-mercaptoethanol, pH 8.0).  A linear gradient from 6 
M to 0 M urea was then performed to remove the denaturant and start refolding the 
proteins on the HisTrap
TM
 column by gradually replacing Buffer A2 with Buffer B1 (0.5 
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M NaCl, 20 mM Tris-HCl, 20 mM imidazole, 5 mM β-mercaptoethanol, pH 8.0).  A total 
volume of 40 ml of Buffer B1 was used to perform the gradient wash.  The purified, 
refolded proteins were then eluted with Buffer B2 (0.5 M NaCl, 20 mM Tris-HCl, 500 
mM imidazole, 5 mM β-mercaptoethanol, pH 8.0) using a gradient of 0 mM to 500 mM 
imidazole in the buffer.  Fractions containing the purified protein were analyzed by SDS-
PAGE gel electrophoresis and quantified with the BCA
TM
 Protein Assay Kit (Pierce 
Biotechnology, Inc., Rockford, IL). 
 
Dialysis of Recombinant Proteins into Cell Culture Media 
 E2F-1/TatHA and E132/TatHA recombinant proteins were diluted with Buffer B2 
to a concentration of 0.5 mg/ml to avoid protein precipitation cascades and injected into 
12 ml Slide-A-Lyzer
®
 Dialysis Cassettes (Pierce Biotechnology, Inc., Rockford, IL) 
using 21-gauge, 1-inch beveled hypodermic needles.  Proteins were dialyzed in 1X PBS 
for 2 hours at room temperature.  The cassettes were placed in fresh 1X PBS for an 
additional 2 hours at room temperature and then dialyzed overnight in appropriate cell 
culture media for in vitro experiments.  Following dialysis, proteins were removed from 
cassettes and placed in sterile 50 ml conical centrifuge tubes and centrifuged at 9400 x g 
for 15 minutes to remove any protein precipitate.  Protein supernatant was removed and 
the final concentrations of recombinant proteins determined using the Coomassie Plus
TM
 
Bradford Assay (Pierce Biotechnology, Inc., Rockford, IL) and SDS-PAGE gels using 
BSA protein standards.  Contamination of proteins was minimized by passage through 
0.2 µM filters (Millipore, Bellerica, IL) prior to testing proteins on carcinoma cell lines, 
and purified protein was supplemented with 10% heat-inactivated FBS (Hyclone, Logan, 
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UT) and 50 IU/ml penicillin/ 0.05 mg/ml Streptomycin.  Proteins were tested at various 
concentrations to determine optimal transduction at different time points using 
immunocytochemistry to monitor cellular uptake of E2F-1/TatHA and E132/TatHA.  
 
Synthesis of TatHA Control Protein 
 The TatHA control protein was artificially synthesized (amino acid sequence: 
YPYDVPDYAYGRKKRRQRRR) (24) on a Ranin Symphony/Multiplex Peptide 
Synthesizer (Center for Integrated BioSystems, Logan, UT).  The TatHA peptide was 
reconstituted using Cellgro
TM 
RNase/DNase/Protease free dH20 for cell culture 
(Mediatech Inc., Herndon, VA) and stored at -70ºC at a working concentration of 1 
mg/ml (25).    
 
Primary Carcinoma Cell Culture 
 Primary infiltrating ductal breast carcinoma cell lines HCC1937 (ATCC number: 
CRL-2336) and HCC1599 (ATCC number: CRL-2331) were obtained from the 
American Type Culture Collection (Manassas, VA).  The cells were grown in RPMI-
1640 medium supplemented with 10% FBS, 50 IU/ml penicillin/ 0.05 mg/ml 
Streptomycin, 10 mM HEPES, and 1 mM sodium pyruvate.  Cells were grown in a 37ºC 
humidified incubator with 5% CO2 (Figure 3.13).  Additional breast carcinoma cell lines 
were also utilized in our research: MDA-MB-231 (ATCC number: HTB-26), MDA-MB-
435S (ATCC number: HTB-129), and MCF-7 cells (ATCC number: HTB-22).  MDA-
MB-231 and MDA-MB-435S cell lines were both grown in a 1:1 ratio of DMEM:Ham’s 
F12 media supplemented with 10% FBS and 5 IU/ml penicillin/0.05mg/ml Streptomycin.  
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MCF-7 cells were grown in MEME cell culture media supplemented with 10% FBS, 50 
IU/ml penicillin/ 0.05 mg/ml Streptomycin, 10 mM HEPES, and 1 mM sodium pyruvate.  
Cell lines were grown in 25 cc
2
 and 75 cc
2
 tissue culture flasks and passaged every 2-4 
days when 70-80% confluent.  Cells were detached from flasks using 0.25% trypsin, 
0.03% EDTA solution according to standard cell culture protocols (26).   
 
Immunocytochemistry  
 HCC1937 and HCC1599 cells were exposed to 2 µM E2F-1/TatHA, 
E132/TATHA, and TatHA fusion peptides for various time points: 1, 6, 12 and 24 hours.  
Cells were washed 3 times with 1X PBS, fixed for 30 minutes in 3.7% formaldehyde and 
permeabilized with 0.5% Triton X-100 in 1X PBS for 30 minutes.  Cells were blocked 
for 30 minutes with 1% FBS and 0.1% Tween-20 in 1X PBS.  Cells were incubated for 
60 minutes with primary mouse HA antibodies (1:1000 dilution in 1X PBS), washed 3 
times for 10 minutes each, and incubated for 60 minutes with a secondary FITC-labeled 
goat anti-mouse antibody (1:250 dilution in 1X PBS) (KPL, Inc., Gaithersburg, MD). For 
transduction experiments with counterstained cell nuclei, cells were washed, and 
incubated for 15 minutes with 1 µM TO-PRO-3 iodide (Molecular Probes, Eugene, OR).  
Cells from immunocytochemistry experiments were mounted on slides using the 
Prolong
®
 Antifade Kit (Molecular Probes, Eugene, OR) and images captured with Bio-





Cell Culture Experiments with Recombinant Proteins 
 HCC1937 and HCC1599 cells were seeded at a density of 2 x 10
5
 cells/well in 
CellStar
®
 6-well tissue culture plates.  HCC1937 (adherent) cells were allowed 24 hours 
to adhere to plates before recombinant proteins were added.  HCC1599 (suspension) cells 
were seeded directly into wells with TFPs.  After specified treatment time of 6, 12, 24, 48 
or 72 hours, RNA was isolated and analyzed via RT-qPCR to determine effects on gene 
transcription.  In preliminary studies, 200 µM chloroquine was added to cell culture 
media with the TFPs to assess effects on transcription and gene expression. Chloroquine 
(Sigma-Aldrich, Inc., St. Louis, MO) stock solution (50 mg/ml) was prepared fresh, 




 We were able to successfully produce Tat fusion peptides utilizing both wildtype 
and mutant E2F-1 expression vectors to investigate their transcriptional effects on target 
genes.  The vector pCMV E2F-1 contains the wildtype form of the human transcription 
factor E2F-1, and the pCMV E132 vector contains human E2F-1 with a mutation in its 
DNA-binding domain that produces an artificial EcoRI restriction enzyme site. The 
pTatHA vector utilized for our cloning experiments contains an N’-terminal 6-histidine 
tag, 11-amino acid Tat-transduction domain, a hemagglutinin (HA) tag and a polylinker 
referred to as the multiple cloning site (MCS) (10).  Additionally, the Tat transduction 
domain is followed by multiple glycine residues for free bond rotation which promotes 
proper protein folding (10).  In gene expression studies described in subsequent chapters, 
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E132/TatHA was designed to serve as a control protein along with an artificially 
produced TatHA alone control peptide.   
 The production of E2F-1/TatHA and E132/TatHA recombinant proteins is a 
multi-step process to ultimately produce biologically active TFPs with the ability to 
transduce all cell types.  As diagramed in Figure 3.1, the E2F-1 gene from vector pCMV 
E2F-1 was directly cloned into the MCS of pTatHA via restriction enzyme digestion 
followed by ligation.  Prior to DNA sequencing, restriction enzyme digestions with NcoI 
and EcoRI were performed re-excise the E2F-1 gene from the pTatHA vector to verify 
success of cloning experiments (see Figure 3.2), and DNA sequencing confirmed the in-
frame insertion of wildtype E2F-1 into the MCS of pTatHA.  The insertion of E132 into 
the MCS of pTatHA required additional effort due to the lack of two compatible 
restriction enzyme sites for cloning in order to leave the EcoRI DNA-binding domain 
mutation intact.  To overcome this obstacle, 5’ site-directed mutagenesis via PCR was 
used to generate an artificial SphI site on the 3’ end of the E132 gene.  The PCR reaction 
successfully generated the appropriately size fragment of DNA containing the E132 gene 
and the new 3’ SphI site (see Figure 3.3).  The pTatHA vector was then digested with 
NcoI and SphI to prepare the MCS for insertion of E132.  Attempts to directly clone 
restriction enzyme digested, amplified E132 DNA into restriction enzyme digested 
pTatHA were unsuccessful.  After using the Klenow-Kinase-Ligase protocol (22) 
described under Materials and Methods, the E132 gene was finally cloned into the MCS 
of pTatHA as outlined in Figure 3.4.  Next, a series of restriction enzyme digestions were 
performed on E132/TatHA to verify presence of specific restriction enzyme sites and the 
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internal EcoRI mutation as demonstrated in Figure 3.5.  DNA sequencing was also 
utilized to confirm the in-frame insertion of E132 into the MCS of pTatHA. 
 Following successful construction of E2F-1/TatHA and E132/TatHA expression 
vectors, plasmid DNA was transformed into BLR(DE3)pLysS competent cells. We also 
transformed BL21(DE3)LysS bacterial cells with our expression vectors, but the 
BLR(DE3)pLysS yielded greater levels of recombinant proteins.  Additionally, our 
protocol used 2YT broth due to optimal protein production versus LB broth as suggested 
by Becker-Hapak et al. (8).  Following optimization of small scale protein production as 
described under Materials and Methods, we verified the presence of both the HA tag and 
6-histidine tag.  The HA tag was confirmed via western blotting with primary monoclonal 
HA antibodies and secondary HRP-labeled antibodies.  Figure 3.6 demonstrates 
confirmation of the HA tag in both E2F-1/TatHA and E132/TatHA expressing cultures.  
The 6-histidine tag was confirmed using the InVision
TM
 His-Tag In-Gel Stain for SDS-
PAGE gels.  Presence of the 6-histidine tag was evident in both E2F-1/TatHA and 
E132/TatHA cultures and isolated proteins as demonstrated in Figure 3.7.  The presence 
of both tags within our proteins was essential for protein isolation, purification (6-
histidine tag was required to bind HisTrap
TM
 columns) and to verify the transduction of 
our TFPs into carcinoma cell lines (via primary HA antibodies and secondary FITC-
labeled antibodies).   
 Large scale protein production occurred either immediately before protein 
isolation via FPLC (for fresh pellets) or several weeks prior to isolation (pellets frozen at 
-20ºC).  Large cell pellets were produced from the 500 ml cultures, and after initial trials, 
it was determined that E2F-1/TatHA and E132/TatHA proteins were produced as 
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insoluble inclusion bodies in the bacterial expression vectors.  Complete sonication of our 
samples was an extremely important key to clean isolation of inclusion bodies, and 
multiple sonication steps were required throughout the purification process.  Cell lytic 
agents and detergents were also tested to isolate the inclusion bodies, but sonication 
proved to be the most cost effective, optimal method to yield large quantities of inclusion 
bodies with minimal cell debris.   
 The FPLC procedure used by our lab employs one of the strongest denaturants, 6 
M guanidine-HCl, in lieu of the 8 M urea denaturant reported by other labs.  Initially, we 
utilized 8 M urea, but we determined that the proteins did not adequately bind the nickel-
charged HisTrap
TM
 columns used during the isolation process.  Likewise, when we 
attempted to solubilize the inclusion bodies with 8 M urea, the combination was usually 
too viscous to filter or run through the HisTrap
TM
 columns.  The Buffer A1 solution 
containing 6 M guanidine-HCl effectively solubilized the inclusion bodies from both 
fresh and frozen pellets.  Likewise, we were also able to filter the proteins to remove cell 
debris and prevent clogging of the HisTrap
TM
 columns.  Therefore, including 6 M 
guanidine-HCl in the purification protocol was a crucial step to denature the E2F-
1/TatHA and E132/TatHA proteins to promote column binding.   
 FPLC was employed to isolated proteins for several reasons.  We performed 
several buffer exchanges throughout the purification process, used large volumes of 
buffers for gradient washes and required a slow flow rate to promote His-tag proteins 
binding the column.  Figure 3.8 outlines the FPLC purification protocol to isolate and 
purify the E2F-1/TatHA and E132/TatHA proteins.  The gradual exchange of buffers and 
slow flow rate permitted the partial refolding of proteins on the column prior to their 
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elution.  Optimal protein loading of the HisTrap
TM
 columns occurred with a flow rate of 
0.5 ml/min.  The FPLC chromatograms in Figures 3.9 and 3.10 illustrate the isolation and 
refolding procedure for E2F-1/TatHA and E132/TatHA respectively.  Proteins were 
solubilized in the buffer with 6 M guanidine-HCl, and following loading and washing of 
the proteins on the column, the buffer was changed to an 8 M urea-containing buffer to 
remove the guanidine and partially renature the proteins.  Likewise, optimal biological 
activity of proteins was achieved with the transition from 6 M guanidine to 6 M urea 
followed by the removal of urea by washing with Buffer B1.  A salt concentration of 0.5 
M NaCl was used in all the buffers in addition to fresh β-mercaptoethanol to stabilize 
proteins.  Figures 3.9 and 3.10 demonstrate the concentration of proteins (via UV 
absorbance at A280) as they loaded onto the columns, were washed by buffers, and finally, 
eluted by a linear gradient of increasing concentrations of imidazole.  The high 
absorbance peak during the loading phase illustrates that other contaminant proteins were 
unable to bind the nickel-charged column, thus they were washed out as the His-tagged 
proteins bound.  The second large peak on the chromatograms demonstrates the elution of 
His-tagged E2F-1/TatHA and E132/TatHA proteins.  On average, the elution peak 
represented 10-12 mg of recombinant protein eluted in a 1-3 ml volume of Buffer B2.  
Figures 3.11 and 3.12 represent the E2F-1/TatHA (Figure 3.11) and E132/TatHA (Figure 
3.12) proteins throughout the production and purification process.  Figures 3.11.A and 
3.12.A are SDS-PAGE gels demonstrating the 60 kDa TFPs from the culture stage 
through FPLC isolation, and finally, following dialysis into cell culture media.  Figures 
3.11.B and 3.12.B show a more detailed view of the FPLC chromatogram elution peaks 
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and fractions.  The SDS-PAGE gels demonstrate a sample of the purified protein from 
Fractions X and Y in lanes 4 and 5 of each gel respectively.   
 Following recombinant protein isolation via FPLC, the proteins were in a partially 
refolded state (23) and ready for dilution and dialysis.  Proteins were diluted to a 
concentration of 0.5 mg/ml with elution buffer (Buffer A2) prior to dialysis to avoid 
protein precipitation cascades.  Following dialysis and sterile filterization, proteins were 
added to several breast cancer cell lines to assess protein transduction.  Figure 3.13 
represents brightfield microscopy images of HCC1937 and HCC1599 cells to illustrate 
growth properties and morphology.  The HCC1937 cells are adherent while the 
HCC1599 cells grow in suspension, thus, only immunocytochemistry images of 
HCC1937 are shown.  The additional breast cancer cell lines studied in preliminary 
experiments, including MCF-7, MDA-MB-231 and MDA-MB-435S cells, all grow as 
adherent cells; therefore, immunocytochemistry experiments were easily performed.   
 Figures 3.14 and 3.15 demonstrate the transduction of E2F-1/TatHaA and 
E132/TatHA TFPs into the HCC1937 and MCF-7 cell lines.  There were substantial 
cytoplasmic, perinuclear and nucleolar accumulations of the proteins.  The recombinant 
TFPs appeared to successfully transduce all cell types, including the other 
abovementioned breast cancer cell lines.  We added chloroquine to our cell culture media 
in several experiments in hopes of achieving even greater protein transduction and 
nuclear localization of the TFPs.  However, chloroquine did not increase the transduction 
of TFPs as detected via fluorescent microscopy.  Likewise, preliminary gene expression 
studies did not show increased activation or repression of target genes with the addition 
of chloroquine in concentrations ranging from 50 µM to 500 µM (data not shown).  
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Overall, it appeared the E2F-1/TatHA and E132/TatHA proteins were able to 
successfully transduce cell lines with and without the addition of chloroquine to cell 
culture media with no apparent enhancement of transcriptional activation or repression of 




 E2F-1/TatHA and E132/TatHA proteins were produced by our lab and confirmed to 
be biologically active in studies investigating their effects on gene expression.  We 
modified our purification procedures accordingly to optimize their biological activity by 
avoiding protein precipitation cascade triggers.  At any point in our protein experiments, 
if the E2F-1/TATHA and E132/TatHA proteins began to precipitate, they were discarded 
and fresh proteins produced and purified.  Protein precipitation was observed as the 
formation of a cloudy white precipitate following protein dilution, dialysis or 
centrifugation.  If proteins clogged the 0.2 µM filters used for filter sterilization, the 
proteins had initiated a protein precipitation cascade in most cases.  Preliminary studies 
using proteins susceptible to precipitation, or proteins still in solution following removed 
of precipitate via centrifugation, commonly resulted in decreased protein transduction.  
Proteins with altered transduction capabilities unable to effectively transduce cells 
appeared as extracellular accumulations and clumps of proteins via 
immunocytochemistry.  Additionally, a neglible effect on gene transcription was 
observed if these proteins were applied to cells (data not shown).  Since biological 
activity of the proteins appeared to be affected by precipitation, we did not use any 
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proteins that experienced an initiation of a precipitation cascade or proteins suggestive of 
precipitation (i.e. clogged filters) in any of our formal experiments.   
 Prior to dialysis, proteins were always diluted to a 0.5 mg/ml concentration with 
elution buffer because concentrations greater than 0.5 mg/ml typically resulted in rapid 
protein precipitation.  Only freshly dialyzed proteins were used in our experiments; 
however, proteins could be stored for a maximum of 5 days at 4ºC without evidence of 
precipitation in order to complete a series of experiments using the same batch of 
proteins.  We did attempt to cryopreserve E2F-1/TatHA and E132/TatHA to preserve 
their biological activity by adding a 10-20% (v/v) final concentration of glycerol to the 
diluted proteins prior to flash-freezing and storage at -80ºC (8, 10).  Unfortunately, the 
E2F-1/TatHA and E132/TatHA proteins were moderately susceptible to precipitation 
during the thawing process.  Although precipitation was minimized with the addition of 
20% glycerol, proteins would easily precipitate if we utilized dialysis to remove the high 
concentration of glycerol.  We also performed a “glycerol shock study” to assess the 
toxic effects of glycerol on the breast cancer cell lines.  Various glycerol concentrations 
[1%, 5%, 10%, 15% and 20% (v/v)] were added to HCC1937, HCC1599 and MCF-7 
cells in their respective cell culture media and incubated for 24 hours with microscopic 
assessment for cell stress every 6 hours.  Cells were sensitive to glycerol concentrations 
from 5-20% following 6 hours of incubation.  At the 24 hour time point, cells were 
extremely stressed in the 20% glycerol concentration, and the majority of cells had 
detached (HCC1937 and MCF-7) and lysed (data not shown).  Compelling evidence of 
cell detachment was also present in cells exposed to 5% glycerol at the 24 hour time 
point.  In general, the breast cancer cell lines utilized in our studies were extremely 
 87 
sensitive to glycerol concentrations greater than 1% following an incubation of 24 hours.   
Therefore, we omitted glycerol from our formal experiments and opted to only use 
freshly dialyzed proteins for in vitro testing.   
 The E2F-1/TatHA and E132/TatHA proteins produced in our lab possess the 
capability to transduce all cell types.  The exact mechanism of E2F-1 TFP transduction 
has not been definitively determined but appeared to parallel the pattern of transduction 
observed in the study by Yang et al. (2002) where significant nuclear and nucleolar 
accumulation of proteins was observed (27).  Likewise, it is plausible that internalization 
of the E2F-1/TatHA and E132/TatHA fusion proteins occurs in the rapid, lipid raft-
dependent and receptor independent form of endocytosis not associated with caveolar- 
and clathrin-mediated endocytosis described by Wadia et al. (2004) (15, 18, 28).  In all 
breast cancer cell lines tested, significant cytoplasmic, perinuclear and nucleolar 
accumulation of proteins were evident after all measured time points (1, 6, 12 and 24 
hours).  Due to the rapid, substantial perinuclear accumulation of the proteins, their half-
lives also seemed to be greatly extended versus the native forms of the proteins. The 
wildtype E2F-1 protein and the mutant E2F-1 protein, E132, reportedly have biological 
half-lives of approximately 70 minutes (28).  Caron et al. (2004) reported that perinuclear 
accumulation of proteins was suggestive of sequestration of the recombinant proteins 
within the Golgi apparatus and endoplasmic reticulum (ER) resulting in a sustained 
release of TFPs to the nuclear target and thus appearing to extend the protein half-lives 
(18).  The extended half-lives of the E2F-1/TatHA and E132/TatHA recombinant 
proteins observed in our studies suggests that the transduction and probable Golgi and ER 
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accumulation in cells results in sustained biological activity of the proteins following 24 
hours of treatment.     
 We attempted to enhance the transduction and biological effect of the E2F-1/TatHA 
and E132/TatHA proteins by adding various amounts of the lysosomotropic agent 
chloroquine to the cell culture media.  No differences in transduction via 
immunocytochemistry were evident in chloroquine versus non-chloroquine treated cells.  
Similarly, no increased effect on gene expression was observed in chloroquine treated 
cells versus non-chloroquine treated cells after results were compared in larger 
preliminary test groups.  Other research groups investigating the addition of chloroquine 
to enhance endosomal disruption have observed cytotoxicity with cell exposure to 
chloroquine concentrations greater or equal to 100 µM (15).  The addition of chloroquine 
to our cell culture media also appeared to have a mildly toxic effect on our breast cancer 
cell lines.  Following a minimum of 12 hours exposure to 200 µM chloroquine, adherent 
cell lines HCC1937 and MCF-7 began to detach in control groups exposed to cell culture 
media with chloroquine.  A similar detachment and membrane blebbing was also 
observed in cells treated with TFPs in addition to chloroquine.  Due to the possible 
toxicity of the chloroquine on our cell lines and negligible effects on gene transcription, 
chloroquine was not used in our formal experiments to assess the transcriptional effects 
of the TFPs in our breast carcinoma cell lines. 
 Our lab was successful at optimizing protocols to produce and purify soluble, 
biologically active E2F-1/TatHA and E132/TatHA recombinant proteins with the ability 
to transduce greater than 95% of target cells.  However, there were specific limitations to 
the testing parameters of our Tat fusion proteins.  First, the maximum testable 
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concentration of TFPs was 2 µM due to the susceptibility of the proteins to precipitate at 
higher concentrations.  Second, we were unable to use cryopreserved TFPs on our cell 
lines because the cells were sensitive to the high concentration of glycerol.  Our 
experiments with cells were also limited to less than a week per batch of purified proteins 
since protein storage was restricted to a maximum of 5 days to preserve biological 
activity.  The instability of our proteins and their diminished biological activity in the 
presence of protein precipitation often delayed cell testing until the dilution and dialysis 
portion of our procedure was optimized.  Therefore, future studies will be performed 
using mammalian expression systems to produce the E2F-1/TatHA and E132/TatHA 
proteins. We speculate that mammalian expression vectors may promote production of 
larger quantities of biologically active proteins possibly without the same protein 












(A) Restriction enzyme 
digestion of pCMV E2F-1 
with NcoI and EcoRI 
overnight at 37ºC. 
(C) Ligation of E2F-1  
gene into digested MCS  
of pTatHA. 
(B) Restriction enzyme 
digestion of pTatHA with 
NcoI and EcoRI overnight at 
37ºC. 
Plasmid Map Illustrating Construction of E2F-1/TatHA Vector 
Figure 3.1.  Plasmid map illustrating construction of E2F-1/TatHA vector.  (A) 
Restriction enzyme digestion to excise E2F-1 gene from pCMV E2F-1.   (B) 
Restriction enzyme digestion of pTatHA to prepare MCS for insertion of E2F-1 gene.  
(C) Ligation of purified digested E2F-1 DNA into digested pTatHA via NcoI and 








Restriction Enzyme Digestion of E2F-1/TatHA DNA 
 





  500 bp 
  250 bp 
Figure 3.2.  Agarose gel (1%) stained with ethidium bromide containing 
samples of E2F-1/TatHA DNA digested with restriction enzymes (RE) to verify 
presence of specific RE sites prior to DNA sequencing.  Lane 1, DNA molecular 
weight marker with size indicated on left hand side of gel.  Lane 2, E2F-1/TatHA 
digested with NcoI and EcoRI restriction enzymes to excise E2F-1 gene (1360 
bp) from TatHA vector (3000 bp).   
 
 ◄ TatHA (3000 bp) 







5’ Site-Directed Mutagenesis of pCMV E132 via PCR Amplification 
 
         1                         2 
 ◄E132 (1360 bp) 
1500 bp 
1000 bp 
Figure 3.3.   Agarose gel (1%) stained with ethidium bromide to confirm correct 
size of PCR product generated by 5’ site-directed mutagenesis of the E132 gene.  
Lane 1, DNA molecular weight marker with specific basepair (bp) sizes illustrated 
on the left.  Lane 2, E132 PCR product with the artificial restriction enzyme sites 
NcoI and SphI.  E132 gene PCR product (1360 bp) indicated by arrow on right 
side.  See Materials and Methods for detailed PCR protocol and primer sequences. 
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(B) Restriction enzyme 
digestion of pTatHA with 
NcoI and SphI overnight at 
37ºC. 
(C) Ligation of E132 
gene into digested MCS  
of pTatHA via KKL 
protocol. 
(A) 5’ Site-directed mutagenesis and 
restriction enzyme digestion of E132 to 
generate artificial NcoI and SphI sites 
for subcloning into pTatHA. 
Figure 3.4.  Plasmid map illustrating construction of E132/TatHA vector.  (A) 5’ Site-
directed mutagenesis of E132 to generate NcoI and SphI restriction enzyme sites 
followed by restriction enzyme digestion with NcoI and SphI.  (B) Restriction enzyme 
digestion of pTatHA to prepare MCS for insertion of E132 gene.  (C) Ligation of 
purified digested E132 DNA into digested pTatHA via NcoI and SphI restriction 
enzyme sites using KKL and T4 DNA Ligase protocols. 
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Restriction Enzyme Digestion of E132/TatHA DNA 
 
Figure 3.5.  Agarose gel (1%) stained with ethidium bromide containing 
samples of E132/TatHA DNA digested with restriction enzymes (RE) to verify 
presence of specific RE sites prior to DNA sequencing.  Lane 1, DNA molecular 
weight marker with size indicated on left hand side of gel.  Lane 2, E132/TatHA 
digested with NcoI and SphI restriction enzymes to excise E132 gene (1360 bp) 
from TatHA vector (3000 bp).  Lane 3, E132/TatHA digested with NcoI and 
EcoRI to cut E132 mutation site in DNA-binding domain to yield appropriately 













Western Blot Verifying Production of E2F-1/TatHA  
and E132/TatHA Recombinant Proteins 
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                 1                             2 
Figure 3.6.  Western Blot analysis of lysates from bacterial cultures producing 
recombinant Tat fusion proteins.  Protein (50 µg) was subjected to SDS-PAGE 
analysis and immunoblotting performed using primary mouse monoclonal HA 
antibodies (1:1000 dilution) and secondary HRP-labeled goat anti-mouse 







 His-Tag Stained SDS-PAGE Gels to Verify Expression of 6-
Histidine Tag in E2F-1/TatHA and E132/TatHA Proteins 
 
  80 kDa 
  30 kDa 
      1                 2                3               4 
     ◄ E2F-1/TatHA            
          (60kDa) 
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  30 kDa 
 
       5                 6                7               8 
   ◄ E132/TatHA                 
        (60kDa) 
 
Figure 3.7.  SDS-PAGE gels containing cell lysates from E2F-1/TatHA and 
E132/TatHA expressing cultures, isolated inclusion bodies, and purified 
recombinant proteins.  Gels were stained with InVision
TM
 His-tag In-gel Stain to 
rapidly detect His-tagged fusion proteins.  Lane 1, BenchMark
TM
 His-tagged 
Standard protein marker.  Lane 2, sample of bacterial culture producing E2F-
1/TatHA.  Lane 3, sample of isolated inclusion bodies from E2F-1/TatHA culture.  
Lane 4, FPLC purified E2F-1/TatHA proteins.  Lane 5, BenchMark
TM
 His-tagged 
Standard protein marker.  Lane 6, sample of bacterial culture producing 
E132/TatHA.  Lane 7, sample of isolated inclusion bodies from E132/TatHA 
culture.  Lane 8, FPLC purified E132/TatHA proteins. 
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Wash column with Buffer A1 
Buffer Exchange  
Replace Buffer A1 by washing column  
with Buffer A2 
Linear Gradient 
Replace Buffer A2 with Buffer B1 
Linear Gradient 
Elute proteins with increasing concentrations of 
Buffer B2 
Final wash of column with Buffer B1 
FPLC Purification Protocol for E2F-1/TatHA and E132/TatHA  
Equilibrate HisTrapTM column with Buffer A1 
Protein Loading 
Load HisTrapTM column with proteins 




  Buffer A1: 6 M guanidine-HCl, 0.5 M NaCl, 20 mM Tris-HCl, 20 mM imidazole, 5 mM β-mercaptoethanol 
  Buffer A2: 6 M urea, 0.5 M NaCl, 20 mM Tris-HCl, 20 mM imidazole, 5 mM β-mercaptoethanol 
  Buffer B1: 0.5 M NaCl, 20 mM Tris-HCl, 20 mM imidazole, 5 mM β-mercaptoethanol 
  Buffer B2: 0.5 M NaCl, 20 mM Tris-HCl, 500 mM imidazole, 5 mM β-mercaptoethanol 
Figure 3.8.  Flowchart illustrating FPLC purification protocol for E2F-1/TatHA and 
E132/TatHA recombinant proteins.  A series of linear gradients and buffer exchanges 
were performed during the purification process to replace strong denaturants, slowly 
refold the proteins while they were bound to the column and thoroughly wash the 
proteins.  Flow rates and volumes of buffers utilized are indicated to the right of the 
flowchart.  Eluted proteins were analyzed via SDS-PAGE gels and further diluted and 
dialyzed to be used in cell culture experiments.   
Flow rate:  1 ml/min 
Volume:  10 ml  
Flow rate: 0.5 ml/min 
Volume:  5 - 25 ml 
Flow rate:  1 ml/min 
Volume:  10 ml 
Flow rate:  1 ml/min 
Volume:  10 ml 
Flow rate:  1 ml/min 
Volume:  30 ml 
Flow rate:  1 ml/min 
Volume:  10 ml 
Flow rate: 0.5 ml/min 
Volume:  10 - 20 ml 
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     = UV absorbance              
     = Linear gradients to exchange buffers 
     = Fractions of proteins collected  
FPLC Chromatogram Representing Protein Purification of           
E2F-1/TatHA  
Figure 3.9.  This figure represents the FPLC chromatogram for purification of E2F-
1/TatHA recombinant proteins.  On this graph, the ordinate represents UV absorbance 
at A280 to determine peak protein concentration.  The abscissa represents the volume in 
ml of buffer flowing through HisTrap columns to load, wash and elute the E2F-
1/TatHA proteins.  (A) Buffer A1 wash to equilibrate HisTrap
TM
 column, load the 
recombinant protein and wash with an additional 10 ml of buffer.  (B) Buffer A2 to 
replace Buffer A1, wash bound proteins and partially renature recombinant proteins. 
(C) A 30 ml linear gradient ranging from 6 M down to 0 M urea to exchange Buffer 
A2 with Buffer B1 to gradually refold and renature proteins bound to HisTrap
TM
 
column.  (D) A linear gradient ranging from 20 mM up to 500 mM imidazole 
performed to elute recombinant proteins by exchanging Buffer B1 with Buffer B2.  
Fractions of collected, purified proteins were subsequently analyzed on SDS-PAGE 
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Figure 3.10.  FPLC chromatogram illustrating the purification of E132/TatHA 
recombinant proteins.  On this graph, the ordinate represents UV absorbance at A280 to 
determine peak protein concentration.  The abscissa represents the volume in ml of 
buffer flowing through HisTrap
TM
 columns to load, wash and elute the E132/TatHA 
proteins.  (A) Buffer A1 equilibration, loading and washing of proteins. (B) Buffer A2 
wash. (C) Linear gradient to exchange Buffer A2 with Buffer B1. (D) Linear gradient 
to exchange Buffer B1 with Buffer B2.  Fractions of collected, purified proteins were 
subsequently analyzed on SDS-PAGE gels.  Refer to Materials and Methods for 
specific details.   
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Figure 3.11.  FPLC purification of E2F-1/TatHA recombinant proteins and analysis 
with SDS-PAGE gel electrophoresis.  (A) SDS-PAGE gel of E2F-1/TatHA 
recombinant protein produced in culture and isolated via FPLC.  Lane 1, protein 
molecular weight marker.  Lane 2, sample of bacterial culture producing E2F-
1/TatHA proteins (60 kDa).  Lane 3, purified E2F-1/TatHA protein represented by 
FPLC fraction X (see Figure B) on chromatogram.  Lane 4, purified E2F-1/TatHA 
protein represented by FPLC fraction Y (see Figure B).  Lane 5, sample of E2F-
1/TatHA diluted and dialyzed into cell culture media.  (B) FPLC chromatogram 
illustrating eluted fractions of purified E2F-1/TatHA proteins.  Ordinate is 
absorbance with peak protein concentration determined by absorbance at A280, and 
abscissa represents eluted fractions of purified protein in Buffer B2.  Fraction #14 is 
designated by X and Fraction #15 is represented by Y. 
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Figure 3.12.  FPLC purification of E132/TatHA recombinant proteins and analysis 
with SDS-PAGE gel electrophoresis. (A) SDS-PAGE gel of E132/TatHA recombinant 
protein produced in culture and isolated via FPLC.  Lane 1, protein molecular weight 
marker.  Lane 2, sample of bacterial culture producing E132/TatHA proteins (60.0 
kDa.  Lane 3, purified E132/TatHA protein represented by FPLC fraction X (see 
Figure B) on chromatogram.  Lane 4, purified E132/TatHA protein represented by 
FPLC fraction Y (see Figure B).  Lane 5, sample of E132/TatHA diluted and dialyzed 
into cell culture media.  (B) FPLC chromatogram illustrating eluted fractions of 
purified E132/TatHA proteins.  Ordinate is absorbance with peak protein 
concentration determined by absorbance at A280, and abscissa represents eluted 
fractions of purified protein in Buffer B2.  Fraction #14 is designated by X and 
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Figure 3.13.  Brightfield microscopic images of breast cancer cell lines 
HCC1937 and HCC1599.  The HCC1937 cell line grows as large, adherent 
epithelial cells.  HCC1937 was isolated from a primary ductal carcinoma 
classified as a TNM Stage IIB, grade 3.  HCC1937 is homozygous for BRCA1 
5382C mutation, homozygous deletion of the PTEN gene and cells are negative 
for the expression of the following genes:  Her2/neu,  estrogen receptor, 
progesterone receptor and for expression of p53 (29, 30).  The HCC1599 cell 
line grows as multicellular aggregates in suspension.  HCC1599 was established 
from an invasive ductal carcinoma classified as TNM stage IIIA, grade 3.  The 
HCC1599 cells are negative for the expression of p53, estrogen receptor, 
progesterone receptor, and Her2/neu (29, 30). 
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Figure 3.14.  Transduction of E2F-1/TatHA and E132/TatHA proteins into 
HCC1937 cells.  Immunocytochemistry was performed with primary HA antibodies 
and secondary FITC-labeled antibodies as described under Materials and Methods. 
(A) Cells treated with 2 µM E2F-1/TatHA.  (B) Cells treated with 2 µM 
E132/TatHA. (C) Cells untreated with Tat fusion peptides.  Legend: n, nucleus of 
cell; arrow, perinuclear accumulation of proteins; arrowhead, nucleolar localization 
of TFPs.  Images were captured using the 40X objective on the Bio-Rad MRC 1024 
Laser Scanning Confocal Microscope with oil immersion and either 1X or 4X zoom. 
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Figure 3.15.  Transduction of E2F-1/TatHA and E132/TatHA proteins into MCF-7 
cells.  Immunocytochemistry was performed with primary HA-antibodies and 
secondary FITC-labeled antibodies as described under Materials and Methods.  (A) 
Cells treated with 2 µM E2F-1/TatHA.  (B) Cells treated with 2 µM E132/TatHA. 
(C) Cells untreated with Tat fusion peptides.  Legend: n, nucleus of cell; arrow, 
perinuclear accumulation of proteins; arrowhead, nucleolar localization of TFPs.  
Images were captured using the 40X objective on the Bio-Rad MRC 1024 Laser 
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TRANSDUCTION OF E2F-1 TAT FUSION PROTEINS REPRESSES 





 The objective of this study was to investigate repression of telomerase activity in 
primary ductal breast cancer cells through transcriptional regulation of the catalytic 
subunit hTERT.  We hypothesized that inhibition of telomerase expression could be 
achieved via Tat mediated protein transduction of the repressor protein E2F-1.  Protein 
purification techniques were refined to yield biologically active Tat fusion proteins 
(TFPs) capable of transducing the breast cancer cell lines HCC1937 and HCC1599.  Cell 
lines were treated with wildtype E2F-1 (E2F-1/TatHA), mutant E2F-1 (E132/TatHA) and 
a control Tat peptide (TatHA) for 24 hours.  Real-time RT-qPCR results revealed 
significant repression of the catalytic subunit of telomerase (hTERT) in both HCC1937 
and HCC1599 cells.  In HCC1937 cells, hTERT was repressed 3.5-fold by E2F-1/TatHA 
in comparison to E132/TatHA (p<0.0012) and the TatHA peptide controls (p<0.0024).  
In HCC1599 cells, hTERT was also repressed with E2F-1/TatHA treatment by 4.0-fold 
 109 
when compared to the E132/TatHA control (p<0.0001).  A slightly lower hTERT 
repression of 3.3-fold was observed with E2F-1/TatHA in the HCC1599 cells when 
compared to the TatHA control (p<0.0001).  These results suggest that transduction of 
E2F-1/TatHA fusion proteins in vitro is an effective repressor of hTERT expression in 




 Telomerase activity is detectable in 80-90% of malignancies and is absent in most 
normal somatic cells (1).  Breast cancer has been identified as an important target for 
developing telomerase inhibitors.  Importantly, fine-needle aspirations of malignant 
breast tumors revealed that 81% were positive for telomerase (2), and Hiyama et al. 
(2000) also reported that 95% of advanced stage breast cancers express telomerase (3).  
Due to the majority of tumor cells expressing telomerase, this protein is being evaluated 
as a tumor marker for breast cancer and other solid malignancies (4).  
 Telomerase, a ribonucleoprotein, synthesizes tandem repeats of the DNA 
sequence TTAGGG at the terminal ends of chromosomes permitting continuous genomic 
replication and cell division.  Telomerase includes an RNA component (hTR) that serves 
as the template for telomeric DNA and a protein catalytic subunit (hTERT) with reverse 
transcriptase activity (5).  The activity of telomerase is regulated by the transcription of 
hTERT, and the cloning and characterization of the hTERT-promoter has permitted 
examination of elements controlling transcriptional activation and repression of hTERT 
(6).   
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 To impact expression of hTERT in breast cancer cells, our research will utilize the 
E2F-1 transcription factor.  The E2F family of transcription factors mediates cell cycle 
progression, and they are released upon phosphorylation of Retinoblastoma (Rb) family 
proteins (7-9).  While most of these factors are associated with inducing gene expression, 
E2F-1 has been identified as a transcriptional repressor of the hTERT gene, specifically 
binding to two separate sites (-174 bp and -98 bp) of the proximal hTERT promoter (7).  
In addition, a study that examined the apoptotic function of E2F-1 found that cell death 
generated by ectopic expression of E2F-1 was independent of the p53 regulatory pathway 
(8). Therefore, even in cells with intact p53 suppressor gene function, overexpression of 
E2F-1 should inhibit transcription of the hTERT gene and potentially induce apoptosis.  
Previous studies utilizing adenoviral-mediated transfection of E2F-1 genes induced 
apoptosis of melanoma cells (10), and an additional study revealed that E2F-1 suppressed 
cell growth while decreasing telomerase activity in the Tu-167 SCCHN cell line (11).  
Adenoviral-mediated overexpression of E2F-1 also induced apoptosis in human breast 
and ovarian carcinoma cell lines independently of p53 (12).  We anticipate that 
telomerase repression via E2F-1 protein therapy could induce apoptotic activity and/or 
cell senescence in cancer cells more effectively than the viral-based studies described 
above.  
 Tat-mediated protein transduction was utilized in our research to effectively target 
cancer cells.  Transduction occurs in a receptor- and transporter-independent fashion, 
targets the lipid bilayer, and also crosses the blood-brain barrier (13).  Tat has been 
reported to transduce 100% of mammalian cells, and studies also suggest the 
transcriptional effects of Tat-mediated protein transduction are reversible and have no 
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detrimental effects because clearance of transduced proteins is dependent on the half-life 
of the protein (13-15).  Becker-Hapak et al. (14) also reported that Tat-mediated 
transduction is concentration dependent, reaches maximum intracellular concentration in 
less than 5 minutes, and nearly equal intracellular concentrations of the fusion proteins 
have been detected between all transduced cells. 
 Our research investigated primary infiltrating ductal carcinoma cells, both with 
and without a BRCA1 gene mutation.  In 2001, published results by Ho et al. (16) 
determined that E2F-1 and E2F-4 were decreased in primary breast carcinomas, and 70% 
of the tumors revealed decreased expression of E2F-1.  Additionally, the metastatic nodal 
tissue examined indicated that 100% of the tissue samples had significantly low levels of 
E2F-1 as compared to normal breast tissue.  Ho et al. also suggested that E2Fs act as 
tumor suppressors in breast cancer and their down-regulation may be important in the 
development of metastases (16).  It is important to determine the repressive effects of 
E2F-1 on hTERT transcription in tumor cells with and without the normal BRCA1 
protein to determine any variance between BRCA1 status and inhibition of telomerase.  
Recently, Wang et al. (17) determined that the BRCA1 promoter was transactivated in a 
dose-dependent manner by E2F-1 and served as a target for E2F-dependent 
transcriptional regulation.  Other studies have also demonstrated that BRCA1 is a potent 
inducer of apoptosis by binding directly to p53 and stimulating transcriptional activation 
of pro-apoptotic genes such as Bax (18, 19).  Therefore, telomerase inhibition in the 
primary infiltrating ductal carcinoma cell line with a BRCA1 gene mutation, HCC1937, 
will be compared to a breast cancer cell line without detectible BRCA1 gene mutations, 
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HCC1599.  Aside from variance in BRCA1 status, both HCC1937 and HCC1599 cell 
lines carry similar mutations in p53, Her2/neu and ER/PR receptors (20).   
 Here we report the first results of the repressive effects of E2F-1 on telomerase 
activity using Tat-mediated transduction.  These studies validated our proposed 
hypothesis that telomerase activity can be repressed in infiltrating ductal carcinoma cells 
via transcriptional regulation of hTERT utilizing protein transduction techniques with 
E2F-1 Tat fusion proteins.   
 
MATERIALS AND METHODS 
 
Vector DNA 
 The vectors pCMV E2F-1 and pCMV E132 were obtained from Dr. Karen 
Vousden (Beatson Cancer Institute, UK) and the pTatHA vector was a kind gift from Dr. 
Steven Dowdy (University of Washington, St. Louis, MO).   
 
E2F-1/TatHA and E132/TatHA Constructs 
 The wildtype E2F-1 gene was directly cloned into the pTatHA vector via NcoI 
and EcoRI restriction enzyme sites.  The E132 vector (mutant E2F-1) contained an 
artificial EcoRI site in the DNA binding domain and could not be directly inserted into 
pTatHA’s multiple cloning site (MCS).  Therefore, the E132 gene was modified using 5’ 
site-directed mutagenesis via PCR from plasmid pCMV-E132 using sense primer:  5’-
gcgcgcaaccATGGCCTTGGCCGGG-3’and antisense primer: 5’-
gcgcagcatgcGGATCCAGCCCTGTC-3’ to generate artificial NcoI and SphI sites 
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(underlined in primer sequences).  The PCR reaction used 2 Units Vent Taq polymerase 
(New England Biolabs, Beverly, MA), 1X Thermapol buffer (New England Biolabs, 
Beverly, MA), 500 nM of sense and antisense primers and 5% DMSO.  The PCR product 
was amplified under the following conditions: initial cycle 94ºC- 3  minutes, 55ºC- 1 
minute, 72ºC- 1 minute followed by 23 cycles of 94ºC- 1 minute, annealing, 55ºC- 1 
minute, 72ºC- 1 minute and a final extension of 72ºC for 7 minutes.  The pTatHA DNA 
was digested with restriction enzymes NcoI and SphI and purified using 
phenol/chloroform extraction.  The E132 PCR product was digested with NcoI-SphI and 
subcloned into the NcoI-SphI sites of pTatHA to yield E132/TatHA using a Klenow-
Kinase-Ligase (KKL) protocol (21).     
 
Recombinant Protein Production 
 E2F-1/TatHA and E132/TatHA plasmids were transformed into BLR(DE3)pLysS 
competent cells (Novagen, Madison, WI) and recombinant proteins produced via 
inoculating 2 ml 2YT broth with single transformed colonies.  After incubation in 
shaking water bath (225 rpm) for 12-14 hours, 3 ml of fresh 2YT broth, 0.5 µg/ml 
ampicillin, and 0.4 mM isopropyl-beta-D-thiogalactopyranoside (IPTG) were added to 
cultures.  Cultures incubated an additional 6 hours to produce recombinant proteins via 
IPTG stimulation.  Cultures were centrifuged at 6000 x g for 10 minutes and cell pellets 
resuspended in 100 µl of 20 mM Tris buffer (pH 8.0) followed by quantitation using a 
BCA
TM
 Protein Assay Kit (Pierce Biotechnologies, Inc., Rockford, IL) with BSA 
standards.  2X Laemmli Sample Buffer was added to 50 µg of total cellular protein and 
samples were boiled for 3-5 minutes and immediately placed on ice (22).  Samples were 
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then loaded onto 12% SDS-PAGE gels and run on a Mini-PROTEAN
®
 3 (Bio-Rad 
Laboratories, Hercules, CA) protein electrophoresis unit using the Laemmli buffer 
system.  Prestained 1 kb protein ladders (Fermentas Life Technologies, Hanover, MD) 
were also run on each gel to determine protein size (refer to Figure 4.1).   
 
Western Blotting 
 For Western blotting experiments, duplicate gels were run simultaneously- one 
gel for western blotting and a second gel for Coomassie blue staining.  The gel designated 
for western blotting was transferred to nylon membranes using a Trans-Blot SD Semi-
Dry Electrophoretic Transfer Cell (Bio-Rad Laboratories, Hercules, CA) according to 
manufacturer’s instructions using 1X TBS-T transfer buffer.  Recombinant protein 
production was verified using primary mouse monoclonal anti-HA antibodies (1:1,000 
dilution) (CRP, Inc., Denver, PA) and secondary HRP-labeled goat anti-mouse antibodies 
(1:25,000 dilution) (KPL, Inc., Gaithersburg, MD).  Membranes were blocked with TBS-
T/5% milk solution for 1 hour, incubated with primary anti-HA antibody for 1 hour, 
washed 3 times for 10 minutes each, and incubated with secondary HRP antibody for 1 
hour.  Following additional washings (3 x 10 minutes), western blots were developed 
with SuperSignal West Pico Chemiluminescent Substrate (Pierce Biotechnology, Inc., 
Rockford, IL) according to manufacturer’s instructions.  Blots were exposed to X-ray 





Large-Scale Recombinant Protein Production 
 Recombinant E2F-1/TatHA and E132/TatHA proteins were purified under 
denaturing conditions with affinity chromatography using a modified procedure from 
Amersham Pharmacia (23).  Single colonies from protein expressing cultures inoculated 
200 ml of 2YT broth supplemented with ampicillin (50 µg/ml) and were incubated at 
37ºC while shaking at 225 rpm for 16-18 hours.  An additional 300 ml of broth was 
added along with fresh ampicillin and IPTG (400 µM), and cultures incubated an 
additional 6 hours.  Cultures were centrifuged for 10 minutes at 6000 x g, and the pellets 
frozen at -20ºC.  Cell pellets were thawed for 20 minutes at 37ºC, and 25 ml of Buffer 1 
(20 mM Tris
TM
-HCl, pH 8.0) added to resuspend the cells with vigorous pipetting.  Cells 
were sonicated on ice (3 x 15 sec) and centrifuged (10 min x 6000 g).  Cell pellets 
containing the inclusion bodies were then resuspended in 25 ml Buffer 2 (2 M urea, 20 
mM Tris-HCl, 0.5 M NaCl, 2% Triton
TM
 X-100, pH 8.0).  Samples were again sonicated 
on ice and centrifuged as described above.  Pellets were resuspended in 25 ml Buffer 2 to 
wash the inclusion bodies and recentrifuged.  A final wash of 25 ml of Buffer 1 was then 
performed, and following centrifugation, pellets were either used immediately or frozen 
at -20ºC for a maximum of two weeks prior to use. 
   
Preparation of Inclusion Bodies for FPLC 
 Cell pellets were resuspended in 5-10 ml Buffer A1 (6 M guanidine-HCl, 0.5 M 
NaCl, 20 mM Tris-HCl, 20 mM imidazole, 5 mM -mercaptoethanol, pH 8.0) by stirring 
at room temperature for 60 minutes to solubilize recombinant proteins.  Samples were 
centrifuged at 20,000 x g for 15 minutes to pellet residual cell debris.  Protein supernatant 
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containing denatured, soluble proteins was removed from residual cell debris.  
Supernatant was further clarified by passage through a 0.45 µM filter (Millipore, 
Bellerica, IL) to further remove any particles.   
 





 charged columns (Amersham Pharmacia, Piscataway, NJ) were 
equilibrated with 5 ml Buffer A1 and the proteins loaded at a flow rate of 0.5 ml/minute.  
Columns were washed with an additional 10 ml of Buffer A1 followed by a wash of 10 
ml of Buffer A2 (6 M urea, 0.5 M NaCl, 20 mM Tris-HCl, 20 mM imidazole, 5 mM -
mercaptoethanol, pH 8.0).  A linear gradient from 6 M to 0 M urea was then performed to 
remove the denaturant and start refolding the proteins on the HisTrap
TM
 column by 
gradually replacing Buffer A2 with Buffer B1 (0.5 M NaCl, 20 mM Tris-HCl, 20 mM 
imidazole, 5 mM -mercaptoethanol, pH 8.0).  A total volume of 40 ml of Buffer B1 was 
used to perform the gradient wash.  The purified, refolded proteins were then eluted with 
Buffer B2 (0.5 M NaCl, 20 mM Tris-HCl, 500 mM imidazole, 5 mM -mercaptoethanol, 
pH 8.0) using a gradient of 0 mM to 500 mM imidazole in the buffer.  Fractions 
containing the purified protein were analyzed by SDS-PAGE gel electrophoresis and 
quantified with the BCA
TM
 Protein Assay Kit (Pierce Biotechnology, Inc., Rockford, IL).   
 
Dialysis of Recombinant Proteins into Cell Culture Media 
 E2F-1/TatHA and E132/TatHA recombinant proteins were diluted with Buffer B2 
to a concentration of 0.5 mg/ml to avoid protein precipitation cascades and injected into 
12 ml Slide-A-Lyzer
®
 Dialysis Cassettes (Pierce Biotechnology, Inc., Rockford, IL) 
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using 21-gauge, 1-inch beveled hypodermic needles.  Proteins were dialyzed in 1X PBS 
for 2 hours at room temperature.  The cassettes were placed in fresh 1X PBS for an 
additional 2 hours at room temperature and then dialyzed overnight in appropriate cell 
culture media for designed cell line experiments.  Following dialysis, proteins were 
removed from cassettes and placed in sterile 50 ml conical centrifuge tubes and 
centrifuged at 9400 x g for 15 minutes to remove any protein precipitate.  Protein 
supernatant was removed and the final concentrations of recombinant proteins 
determined using the Coomassie Plus
TM
 Bradford Assay (Pierce Biotechnology, Inc., 
Rockford, IL) and SDS-PAGE gels using BSA protein standards.  Contamination of 
proteins was minimized by passage through 0.2 µM filters (Millipore, Bellerica, IL). 
Purified protein was supplemented with 10% heat-inactivated FBS (Hyclone, Logan, UT) 
and 50 IU/ml penicillin/0.05 mg/ml streptomycin.  Prior to testing on carcinoma cell 
lines, various µM concentrations were tested to determine optimal transduction at 
different time points using immunocytochemistry to monitor cellular uptake of E2F-
1/TatHA and E132/TatHA.  
 
Synthesis of TatHA Control Protein 
 The TatHA control protein was artificially synthesized (amino acid sequence: 
YPYDVPDYAYGRKKRRQRRR) (24) on a Ranin Symphony/Multiplex Peptide 
Synthesizer (Center for Integrated BioSystems, Logan, UT).  The TatHA peptide was 
reconstituted using Cellgro
TM 
RNase free/DNase/Protease free dH20 for cell culture 
(Mediatech Inc., Herndon, VA) and stored at -70ºC at a working concentration of 1 
mg/ml (25).    
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Primary Carcinoma Cell Culture 
 Primary infiltrating ductal breast carcinoma cell lines HCC1937 (ATCC number: 
CRL-2336) and HCC1599 (ATCC number: CRL-2331) were obtained from the 
American Type Culture Collection (Manassas, VA).  The cells were grown in RPMI-
1640 medium supplemented with 10% FBS, 50 IU/ml penicillin/ 0.05 mg/ml 
streptomycin, 10 mM HEPES, and 1 mM sodium pyruvate.  Cells were grown in a 37ºC 
humidified incubator with 5% CO2.  Cell lines were grown in 25 cc
2
 and 75 cc
2
 tissue 
culture flasks and passaged every 2-4 days when 70-80% confluent.  Cells were detached 
from flasks using 0.25% trypsin, 0.03% EDTA solution according to standard cell culture 
protocols (26).   
 
Immunocytochemisty 
 HCC1937 and HCC1599 cells were exposed to 2 µM E2F-1/TatHA, 
E132/TATHA, and TatHA fusion peptides for various time points: 1, 6, 12 and 24 hours.  
Cells were washed 3 times with 1X PBS, fixed for 30 minutes in 3.7% formaldehyde and 
permeabilized with 0.5% Triton X-100 in 1X PBS for 30 minutes.  Cells were blocked 
for 30 minutes with 1% FBS and 0.1% Tween-20 in 1X PBS.  Cells were incubated for 
60 minutes with primary mouse HA antibodies (1:1000 dilution in 1X PBS), washed 3 
times for 10 minutes each, and incubated for 60 minutes with a secondary FITC-labeled 
goat anti-mouse antibody (1:250 dilution in 1X PBS) (KPL, Inc., Gaithersburg, MD).  
Cells were then washed, and incubated for 15 minutes with 1 µM TO-PRO-3 iodide 
(Molecular Probes, Eugene, OR) to counterstain the cell nuclei.  Cells were then mounted 
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on slides using Prolong
®
 Antifade (Molecular Probes, Eugene, OR) and images captured 
with Bio-Rad MRC 1024 Laser Scanning Confocal Microscope (see Figure 4.2).  
 
Cell Culture Experiments with Recombinant Proteins 
 HCC1937 and HCC1599 cells were seeded at a density of 2 x 10
5
 cells/well in 
CellStar
®
 6-well tissue culture plates.  HCC1937 (adherent) cells were allowed 24 hours 
to adhere to plates before recombinant proteins were added.  HCC1599 (suspension) cells 
were seeded directly into wells with TFPs.  After 24 hours of co-incubation, RNA was 
isolated and analyzed via RT-qPCR as described below.   
 
RNA Isolation, Reverse Transcription and Quantitative PCR  
 Total RNA was isolated from cells using the Mini RNA Isolation IITM kit (Zymo 
Research, Orange, CA) using the following protocol.  After treatment with TFPs, 
adherent cell lines were washed at least three times with 1X PBS and detached from 




 (Hyclone, Logan, UT).  Cells were added 
to 1.8 ml microcentrifuge tubes and pelleted by centrifugation at 14,000 rpm for 1 
minute.  Supernatant was decanted and excess fluid removed via micropipetting.  A 600 
µl volume of ZR RNA Buffer was added to cells, tubes vortexed 30 seconds, and sample 
transferred to a Zymo-Spin III column placed in a 2 ml collection tube.  Zymo-Spin III 
column was centrifuged at 14,000 rpm for 1 minute.  A 350 µl volume of RNA Wash 
Buffer was added to the Zymo-Spin III column and centrifuged as described above to 
wash column.  A second wash was performed with 350 µl RNA Wash Buffer to further 
clean RNA.  The spin column was then transferred to a sterile 1.8-ml microcentrifuge 
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tube.  A 50 µl volume of RNase-free water was added directly to the membrane of the 
Zymo-Spin III Column and column centrifuged for 15 seconds to elute RNA.  The eluted 
RNA was quantified using a Nanodrop
®
 ND-1000 Spectrophotometer (Nanodrop 
Technologies, Wilmington, DE).     
 A two-step reverse transcriptase-quantitative polymerase chain reaction (RT-
qPCR) was performed for all the experiments described in this study.  A 200 ng quantity 
of RNA was treated with DNase (1 U/µg) (Fisher Scientific, Pittsburgh, PA) in a 10 µl 
digestion reaction volume including a final 1X concentration of RQ1 RNase-Free DNase 
Reaction Buffer (40 mM Tris-HCl, 10 mM MgSO4, 1 mM CaCl2, pH 8.0) (Fisher 
Scientific, Pittsburgh, PA).  Samples were incubated at 37ºC for 30 minutes followed by 
the addition of 1 µl of RQ1 DNase Stop Solution (20 mM EGTA, pH 8.0) (Fisher 
Scientific, Pittsburgh, PA) and samples incubated at 65ºC for 10 minutes to inactivate the 
DNase.  The 11 µl volume of DNase-digested RNA was used for the RT-PCR reaction.   
 
Production of cDNA from Total RNA 
 The 11 µl volume containing the RNA was combined with 2 µl random 
hexadeoxynucleotides (0.5 µg/ul) (Fisher Scientific, Pittsburgh, PA) and a 4 µl volume of 
dNTP mix (10 mM per dNTP) (New England Biolabs, Beverly, MA). Tubes were heated 
for 5 minutes at 70ºC to anneal primers to RNA, samples then placed on ice, and the 
following components added to the reaction tube to yield a 20 µl volume: 2 µl 10X RT 
Buffer (50 mM Tris-HCl, 75 mM KCl, 3 mM MgCl2, 10 mM DTT, pH 8.3) (New 
England Biolabs, Beverly, MA), 10 U of RNase Inhibitor (Fisher Scientific, Pittsburgh, 
PA), and 25 U M-MuLV Reverse Transcriptase (New England Biolabs, Beverly, MA).  
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Reaction tubes were incubated at 42ºC for 1 hour to generate cDNA, and the RT enzyme 
heat inactivated at 95ºC for 5 minutes.  A 0.5 µl volume containing 2.5 U of RNase H 
(New England Biolabs, Beverly, MA) was added to tubes and samples incubated at 37ºC 
for 20 minutes to degrade RNA.  RNase H was then heat inactivated at 95ºC for 5 
minutes.  Each cDNA pool was diluted to 50 µl and stored at -20ºC until analyzed via 
real-time qPCR reaction. 
 
Real-time Quantitative PCR  
 Real-time qPCR was performed using the MyiQTM Single Color Real-Time PCR 
Detection System (Bio-Rad, Hercules, CA).  A 2 µl sample of each cDNA pool served as 




 Green Supermix (Bio-Rad, Hercules, 
CA) and 300 nM of each primer: hTERT sense & antisense primers (5’-
GGAGCAAGTTGCAAAGCATTG-3’ & 5’-CCCACGACGTAGTCCATGTT-3’) (27), 
B-actin sense & antisense primers (5’-CACTCTTCCAGCCTTCCTTCC-3’& 5’-
CTGTGTTGGCGTACAGGTCT-3’) (28).  All qPCR reactions were performed in at 
least triplicate for each sample using 96-well plates.  The following cycling program was 
used for all primer sets.  Initial denaturation step at 95ºC for 3 minutes followed by 45 
cycles at 94ºC- 30 sec., 59.5 ºC- 30 sec., 72ºC- 30 sec., and an 80ºC- 15 sec. data 
acquisition step.  A melt curve was performed for every reaction plate.  Fold changes in 
gene expression were determined using the 2
-∆∆CT method (29).  The CT data were 
imported into Microsoft Excel.  CT values for hTERT and B-actin were averaged for each 
sample, and ∆CT calculated (∆CT=CT, avg. hTERT – CT, avg. B-actin).  ∆∆CT was calculated in 
the following manner: ∆∆CT = Avg. ∆CT, hTERT from E2F-1 or E132 TFP treatment - ∆CT, hTERT from 
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 Statistical significance of mean fold changes in gene expression was determined 
by Student’s paired t-test using Microsoft Excel and Analyze-it
TM
 (Analyze-it Software, 




 We were able to successfully produce E2F-1/Tat fusion peptides utilizing both 
wildtype and mutant E2F-1 expression vectors to investigate their transcriptional effects 
on hTERT.  Techniques were modified to produce both E2F-1/TatHA and E132/TatHA 
recombinant proteins (see Figure 4.1) and recombinant protein production was verified 
via western blotting.  Protein transduction was determined in each cell line via 
immunocytochemistry, and the results supported effective transduction of E2F-1/TatHA, 
E132/TatHA and TatHA into all cell types.  The TFPs were detected throughout the cell 
cytoplasm with perinuclear localization and detectable nuclear accumulation (Figure 4.2).  
The series of immunocytochemistry experiments ranging from 1 hour to 24 hours 
incubation with TFPs all revealed successful transduction of recombinant proteins into 
greater than 95% of carcinoma cells.   
 Our experiments were only performed with freshly dialyzed proteins to avoid 
protein precipitation and to ensure biological activity of proteins.  The proteins were 
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added to cells for 24 hours to assess differences in hTERT expression between the 
wildtype E2F1/TatHA protein, mutant E2F-1 (E132/TatHA) and the TatHA control 
protein.  Following RNA isolation and real-time RT-qPCR, results revealed significant 
repression of hTERT in both HCC1937 and HCC1599 breast cancer cells.  In HCC1937 
cells, hTERT was repressed 3.5-fold by E2F-1/TatHA in comparison to the TatHA 
control peptide (p< 0.0024) (Figure 4.3).  The cells treated with E132/TatHA did not 
reveal effective repression of hTERT in comparison to TatHA (p<0.6484).  When 
comparing the wildtype E2F-1/TatHA protein to its mutated counterpart, E132/TatHA, 
statistically significant 3.5-fold repression of hTERT gene expression occurred in 
HCC1937 cells with E2F-1/TatHA protein treatment versus the E132/TatHA control 
protein (p< 0.0012) (Figure 4.4).  Overall, there was no discernable effect on hTERT 
expression between the control E132/TatHA and control TatHA alone fusion proteins.  In 
HCC1937 cells, E2F-1/TatHA greatly repressed hTERT in comparison to both 
E132/TatHA and TatHA control proteins.   
 In HCC1599 cells, a significant 3.3-fold repression of hTERT gene expression 
was observed with E2F-1/TatHA protein treatment versus the TatHA control protein 
(p<0.0001) following 24 hours of treatment (Figure 4.3).  Interestingly, a 4.0-fold 
repression of hTERT expression was observed with E2F-1/TatHA protein treatment of 
HCC1599 cells versus the E132/TatHA control protein (p< 0.0001) (Figure 4.4).  A 
slightly increased expression of hTERT (1.15-fold increase) was observed in TatHA 
treated HCC1599 cells versus the E132/TatHA protein, but this difference was only 
marginally statistically significant (p<0.0102) (Figure 4.3).  Further testing will be 
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performed to assess differences between E132/TatHA and TatHA control proteins in 
larger in vitro test groups.  
 Minimal differences in hTERT expression were detected in HCC1937 and 
HCC1599 cells based on the BRCA1 status.  As previously mentioned, the HCC1937 cell 
line has a homozygous BRCA1 mutation (5382C) in addition to mutations in p53, 
Her2/neu and ER/PR receptors.  In contrast, the HCC1599 cell line expresses the 
wildtype BRCA1 tumor suppressor gene but also contains mutations in p53, Her2/neu 
and ER/PR receptors.  A slightly higher repression of hTERT was observed in HCC1599 
cells (4.0-fold) versus HCC1937 (3.5-fold) when E2F-1/TatHA was compared to the 
E132/TatHA control, but this slight difference in hTERT repression is most likely not 




 The results from this study suggest that E2F-1/TatHA is a moderately effective 
repressor of hTERT.  In comparison to E132/TatHA and TatHA controls, hTERT was 
repressed by 3.3 to 4.0-fold in HCC1937 and HCC1599 breast carcinoma cells.  The 
efficient transduction of the E2F-1/TatHA peptides into breast cancer cells combined 
with their transcriptional effects on hTERT expression suggests an alternate route to 
inhibit telomerase expression in breast cancer cells.  The extent of hTERT repression in 
our study is comparable to the results observed by Crowe et al.’s study (2001) which 
suggests that our alternative route of introducing the E2F-1 transcription factor into 
cancer cells does not result in greater repression of hTERT than liposome-mediated 
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transfection of E2F-1(7).  However, the introduction of biologically active E2F-1/TatHA 
proteins has potential benefits.  Treatment with our wildtype and mutant TFPs results in 
reversible repression of hTERT which could serve as a modality to augment the effects of 
other chemotherapeutic or apoptotic agents.  This particular study did not examine the 
direct effects on apoptosis, but continued treatment with E2F-1/TatHA proteins could 
serve to effectively repress hTERT leading to long-term telomerase repression.   
 To interpret the results of our hTERT repression studies, it is important to review 
the expected effects of E2F-1/TatHA treatment of cells versus E132/TatHA and control 
peptide TatHA.  Crowe et al. determined the normal E2F-1 expression vector binds to 
two sites of the hTERT promoter and represses its transcription by approximately 4-fold 
in their study (7).  The negative control, mutant E2F-1, referred to as E132/TatHA in our 
research, has a point mutation in the DNA-binding domain and cannot bind to the E2F-1 
binding sites on the hTERT promoter and exhibited no repressive effects on hTERT (7).  
We expected to observe similar results in our study, and since Tat-mediated protein 
transduction is an effective method of delivering biologically active proteins into cells, 
we hoped to achieve greater than 4.0-fold repression of hTERT in our study.  However, 
as demonstrated by our data following 24 hours of treatment with E2F-1/TatHA, only a 
maximum of 4-fold hTERT repression was observed in HCC1599 cells.   
 The characterization of E2F-1 as a transcriptional repressor is a controversial role 
for this factor because it has traditionally been denoted as a transactivator of various 
genes.  Hsieh et al. (30) reported that transcriptional repression rather than the 
transactivation function of E2F-1 is involved in the induction of apoptosis.  Zhang et al. 
(19) provided the first direct evidence that telomerase is required for maintaining the 
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vitality of both human tumor and immortal cells.  Zhang et al. also reported that cell 
death in immortal cells was telomere-length dependent, and upon inhibiting telomerase in 
cells with short telomeres, the resulting damage to the chromosomes triggered apoptotic 
cell death (19).   Interestingly, Yamasaki et al., (31) determined that E2F-1 null mutant 
mice developed a variety of malignant tumors, and Field et al. (32) indicated that E2F-1 
functions in mice to promote apoptosis and suppress cell proliferation.  Tumor formation 
in the absence of E2F-1 was also suggested by Crowe et al. (7).  Their study utilized E2F-
1 expression vectors and liposomal transfection into SCC25 cells resulting in 
transcriptional repression of hTERT via consensus binding in the hTERT- promoter at 
putative E2F-1 sites (7).  Importantly, Crowe et al. reported that transfection of the E2F-1 
constructs reduced endogenous hTERT mRNA levels by 4-fold, and the reduced hTERT 
mRNA levels were accompanied by decreasing telomerase activity (7).  The study by 
Crowe et al. was one of the first to correlate the novel transcriptional repressive effects of 
E2F-1 on the hTERT gene promoter while monitoring subsequent telomerase activity (7).  
However, the repressive effects of E2F-1 on hTERT must be further examined in future 
studies.  The liposome-mediated transfection of E2F-1 via the Lipofectamine
TM
 kit 
(Invitrogen Life Technologies, Carlsbad, CA) as described in Crowe et al. does not 
guarantee transfection of 100% of the cancer cells (7), nor do any of the adenoviral-
mediated studies previously mentioned (10-12).  Therefore, to determine if E2F-1 can 
completely repress hTERT transcription, the E2F-1 protein must be effectively 
transduced into 100% of the cancer cells.  Our research suggested greater than 95% 
transduction rates with E2F-1 TFPs, but maximum hTERT repression was only 4-fold 
with our alternative mode of transduction which is comparable to the results published by 
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Crowe et al (7).  Complete repression of hTERT was not observed in our study using 
TFPs suggesting that a combination of transcriptional repressors may be required using 
Tat-mediated transduction to completely inhibit expression of hTERT. 
 The breast cancer cells lines utilized in our study represent non-metastatic 
primary ductal carcinoma cell lines.  HCC1937 cells were derived from a TNM stage IIB, 
grade 3 breast tumor, and the HCC1599 cell line was started from a TNM stage IIIA, 
grade 3 primary ductal carcinoma (20).  Our research suggests that E2F-1/TatHA is an 
effective repressor of hTERT in primary ductal carcinoma cells that are actively 
expressing telomerase.  Although we have not fully investigated metastatic breast 
carcinoma cell lines, preliminary studies (results not shown) with MDA-MB-231 and 
MDA-MB-435S cells, both of which are derived from pleural effusions from metastatic 
breast cancer (TNM stage IV) (17), did not reveal statistically significant repression of 
hTERT.  Therefore, the E2F-1/TatHA proteins investigated in this study would be 
potential adjuvants to therapy in nonmetastatic, primary breast tumors.   
 Collectively, these studies were undertaken to develop an effective technique to 
achieve complete transduction of cancer cells with fusion peptides.  The hypothesized 
repression of telomerase activity in infiltrating ductal carcinoma cells via E2F-1 repressor 
proteins is supported by significant hTERT repression in both HCC1937 and HCC1599 
cells.  However, the ability to achieve complete repression of hTERT via the E2F-1 
transcription factor still remains elusive.  Future experiments will further investigate the 
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SDS-PAGE Gels of Recombinant E2F-1/TatHA and  
E132/TatHA Proteins 
Figure 4.1.  SDS-PAGE gels of recombinant E2F-1/TatHA and E132/TatHA 
proteins.  (A) SDS-PAGE gel of E2F-1/TatHA purified protein.  Lane 1, Protein 
molecular weight marker.  Lane 2, E2F-1/TatHA expressing culture.  Lane 3, FPLC 
purified E2F-1/TatHA protein (60 kDa).  (B) SDS-PAGE gel of E132/TatHA 
purified protein.  Lane 4, Protein molecular weight marker.  Lane 5, E132/TatHA 



























  TO-PRO-3                            FITC                          COMBINED 
Immunocytochemistry Images of HCC1937 Cells 
Figure 4.2.  Immunocytochemistry images of HCC1937 cells transduced with 
Tat fusion proteins for 24 hours. (A) Cells treated with 2 µM E2F-1/TatHA.  (B) 
Cells treated with 2 µM E132/TatHA. (C) Cells treated with 2 µM TatHA 
control peptide.  Images were captured using the 40X objective on the Bio-Rad 




Fold Repression of hTERT Gene Expression in Breast  
Cancer Cell Lines- TatHA Control 
 
 
Figure 4.3.  Fold changes in hTERT gene expression compared to TatHA control in 
breast cancer cell lines.  HCC1937 and HCC1599 cells were treated for 24 hours with 2 
µM Tat fusion proteins.  RNA was isolated and RT-qPCR performed as described under 
Materials and Methods.  The asterisks (*) indicate statistically significant fold changes in 
gene expression.  A significant 3.5-fold repression of hTERT gene expression was 
observed in HCC1937 cells treated with E2F-1/TatHA proteins in comparison to 
treatment with TatHA control proteins (p<0.0024).  Repression of hTERT in HCC1937 
cells treated with E132/TatHA proteins versus the TatHA control proteins was not 
statistically significant (p<0.6484).  A 3.3-fold repression of hTERT was observed in 
HCC1599 cells treated with E2F-1/TatHA proteins versus the TatHA control protein 
(p<0.0001).  hTERT gene expression was slightly increased (1.15-fold increase) in 
HCC1599 cells treated with E132/TatHA proteins versus the TatHA control proteins 
(p<0.0102).  The results are means +/- SEM of three separate experiments (HCC1937, 












































Fold Repression of hTERT Gene Expression in Breast  
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Figure 4.4.  Fold changes in hTERT gene expression compared to E132/TatHA control 
in breast cancer cell lines.  HCC1937 and HCC1599 cells were treated for 24 hours with 
2 µM Tat fusion proteins.  RNA was isolated and RT-qPCR performed as described 
under Materials and Methods.  The asterisks (*) indicate statistically significant fold 
changes in gene expression.  In HCC1599 cells, hTERT gene expression was repressed 
4.0-fold by treatment with E2F-1/TatHA proteins in comparison to the E132/TatHA 
control proteins (p<0.0001).  In HCC1937 cells, hTERT gene expression was repressed 
3.5-fold by treatment with E2F-1/TatHA proteins versus the E132/TatHA control 
proteins (p<0.0012).  The results are means +/- SEM of three separate experiments 
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TRANSDUCTION OF E2F-1 TAT FUSION PROTEINS ACTIVATES THE p73 
AND p21
WAF1/CIP1
 TUMOR SUPPRESSOR PATHWAYS IN p53-MUTATED 




 Mutations in the p53 tumor suppressor gene are present in 40-50% of breast 
carcinomas (1, 2).  In cancer cells harboring a p53 mutation, overexpression of a p53 
homologue (the p73 tumor suppressor) induces apoptosis (3, 4).  Upregulation of p73 and 
subsequent cell death have been achieved via transfection of the E2F-1 transcription 
factor gene (5, 6).  Here we report an alternative, reversible methodology to induce p73 
expression in breast carcinoma cells utilizing protein transduction with E2F-1 Tat fusion 
proteins (TFPs) to target and kill breast cancer cells.  We produced recombinant E2F-
1/TatHA fusion proteins which transduced greater than 95% of treated cells.  Biological 
activity of the E2F-1 TFP was determined by monitoring induction of p73 expression 
using real-time RT-qPCR, and apoptosis was assessed by microscopic examination and 
via TUNEL assay.  Two p53 deficient breast cancer cell lines, HCC1937 and HCC1599, 
were exposed to 2 µM E2F-1 TFP or control TatHA protein for 24 hours.  Greater than 2-
fold induction of p73 was observed in E2F-1 TFP treated cells as compared to TatHA 
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treated controls.  A significant increase in the p53-responsive gene, p21
WAF1/CIP1
, was also 
observed in cell lines via real-time qPCR.  Following E2F-1 TFP treatment for 24 hours, 
apoptotic activity was evident in the breast cancer cells.  In conclusion, the E2F-1/TatHA 
protein effectively transduced HCC1599 and HCC1937 cells, activated transcription of 
p73 and induced apoptosis.  This study supports the hypothesis that transduced E2F-
1/TatHA fusion protein activates the p73 and p21
WAF1/CIP1
 tumor suppressor pathways in 




 The majority of neoplastic cells exhibit aberrations in cell cycle control which can 
lead to increased cell-cycle progression.  Common mutations that lead to diminished cell-
cycle control include alterations in the p53 tumor suppressor gene.  Approximately 50% 
of cancers, including breast cancer, harbor mutations of the p53 tumor suppressor gene 
(1); however, a p53-homologue, p73, is rarely mutated in carcinoma cells (7).  The 
transcriptionally active form of p73 (commonly referred to as TA-p73) was investigated 
by our research group.  Various isoforms of the transcriptionally active p73 tumor 
suppressor exist and have the ability to activate p53-responsive genes.  Isoforms such as 
p73α and p73β contain N-terminal transactivation domains responsible for activation of 
various p53 target genes associated with apoptosis and cell cycle control (8, 9).    
 An important regulator of p73 expression, the E2F-1 transcription factor, has been 
found to activate p73 expression in select studies.  Activation of the p73 tumor 
suppressor pathway has been observed in adenoviral and retroviral studies transfecting 
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the E2F-1 gene into carcinoma cells (5, 6).  Additionally, upregulation of p53-responsive 
genes has been observed in cells upon activation of p73 (10, 11).  Specifically, 
stimulation of the p73 tumor suppressor gene has induced p21
WAF1/CIP1
 expression leading 
to cell growth arrest and apoptosis (11, 12).   
 Our research used an alternative method of introducing the E2F-1 transcription 
factor into breast carcinoma cells by employing Tat-mediated protein transduction.  
Proteins attached to the HIV-1 Tat transduction domain have been found to transduce 
100% of target cells (13-17).  Once Tat fusion proteins enter cells, they have the 
opportunity to elicit their biological effect followed by degradation, resulting in the 
reversible therapeutic application of the E2F-1 transcription factor.  Our production of 
E2F-1/TatHA fusion peptides has permitted an alternative route of assessing p73 
activation and apoptosis in p53-mutated primary ductal breast cancer cells.  Upon 
verification that E2F-1 TFPs transduced HCC1937 and HCC1599 cells, we determined 
fold changes in gene expression of p73 via real-time RT-qPCR.   
 Two different E2F-1 TFPs were utilized in this study: E2F-1/TatHA (wildtype 
E2F-1) and E132/TatHA (E2F-1 with a DNA binding domain mutation) (see Figure 5.1).  
Previous studies revealed that only one of the six domains within the E2F-1 protein is 
critical to bind the promoter of p73 and activate transcription (5).  Hallstrom and Nevins 
(2003) reported that the “marked-box domain” was crucial to increasing expression of 
p73 (5); therefore, we determined if the E132/TatHA protein (intact marked-box domain; 
mutant DNA binding domain) elicited the same apoptotic effect as wildtype E2F-
1/TatHA.  In addition, we determined if treatment with E2F-1/TatHA and E132/TatHA 
proteins resulted in activation of the p73-target gene p21
WAF1/CIP1
 in comparison to a 
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control TatHA protein.  We also monitored carcinoma cell lines for increases in 
p21
WAF1/CIP1 
expression in response to TFP treatment to assess if p53-responsive genes 
were upregulated via overexpression of p73.  
 The p21
WAF1/CIP1 
gene functions as an inhibitor of cyclin-dependent kinases and is 
directly induced by the p53 tumor suppressor protein and its homologues.  The 
p21
WAF1/CIP1
 gene is an uncommon target for mutational inactivation in breast cancer 
(18); however, in the absence of p53, its innate role in controlling the cell cycle may be 
compromised.  Additionally, the level of p21
WAF1/CIP1
 gene expression in cells is 
reportedly affected by the BRCA1 tumor suppressor protein (19).  Overexpression of 
BRCA1 in ovarian and breast cancer cell lines has been found to reduce cellular 
proliferation (20).  BRCA1 may also function to regulate the p21
WAF1/CIP1
 promoter and 
serve as an essential factor required for adequate p21
WAF1/CIP1
 activation.  BRCA1 has a 
direct role in cell cycle checkpoints and inhibits cell cycle progression into S-phase 
which was observed in studies that overexpressed the BRCA1 protein revealing 
subsequent activation of p21
WAF1/CIP1
 in a p53-independent manner (19).  Additionally, in 
cell lines lacking p21
WAF1/CIP1
, overexpression of BRCA1 did not lead to G1 arrest, thus 
supporting the concept that the arrest of the cell cycle in G1 phase is dependent on the 
expression of p21
WAF1/CIP1
 (19).  The induction of p21
WAF1/CIP1
 via p73 overexpression 
will be monitored by real-time RT-qPCR in our experiments to distinguish possible 
differences in BRCA1 status on p21
WAF1/CIP1
 expression and subsequent apoptotic 
activity. 
 Our research examines the repressive effects of E2F-1/TatHA, E132/TatHA and 
TatHA treatment on p53-mutated primary infiltrating ductal carcinoma cell lines 
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HCC1937 and HCC1599.  The HCC1937 cell line contains a homozygous BRCA1 
mutation (5382C) while the HCC1599 cell line expresses the wildtype BRCA1 gene (21, 
22).  We propose that decreased expression of BRCA1 in the HCC1937 cell line may 
impact the ability of p73 overexpression to activate p21
WAF1/CIP1
.  Overall, we expect to 
observe increased fold induction of p73 in all cell lines tested with possible variations in 
p21
WAF1/CIP1
 expression based on BRCA1 status of tumor cells.  Additionally, several 
other metastatic breast cancer cell lines were studied on a preliminary basis to determine 
if E2F-1/TatHA and E132/TatHA TFP treatments impact advanced stage breast cancers.   
 
MATERIALS AND METHODS 
 
Vector DNA 
 The vectors pCMV E2F-1 and pCMV E132 were obtained from Dr. Karen 
Vousden (Beatson Cancer Institute, UK) and the pTatHA vector was a kind gift from Dr. 
Steven Dowdy (University of Washington, St. Louis, MO).   
 
E2F-1/TatHA and E132/TatHA Constructs 
 The E2F-1 gene was directly cloned into the pTatHA vector via NcoI and EcoRI 
restriction enzyme sites.  Purified digested pCMV E2F-1 DNA was ligated into digested 
pTatHA using T4 DNA Ligase (Invitrogen Life Technologies, Carlsbad, CA) following 
the manufacturer’s protocol. The E132 vector contained an artificial EcoRI site in the 
DNA binding domain and could not be directly inserted into pTatHA’s multiple cloning 
site (MCS).  Therefore, the E132 gene was modified using 5’ site-directed mutagenesis 
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via PCR from plasmid pCMV-E132 using sense primer:  5’-
gcgcgcaaccATGGCCTTGGCCGGG-3’and antisense primer: 5’-
gcgcagcatgcGGATCCAGCCCTGTC-3’ (Sigma Genosys, Woodlands, TX) to generate 
artificial NcoI and SphI sites (underlined in primer sequences).  The PCR reaction 
included 2 Units Vent Taq polymerase (New England Biolabs, Beverly, MA), 1X 
Thermapol buffer (New England Biolabs, Beverly, MA), 500 nM of sense and antisense 
primers and 5% DMSO.  The PCR product was amplified under the following conditions 
in a Perkin Elmer 9600 Thermocycler: initial denaturation: 94ºC- 3  minutes, 55ºC- 1 
minute, 72ºC- 1 minute; 23 cycles: denaturation: 94ºC- 1 minute, annealing: 55ºC- 1 
minute, extension: 72ºC- 1 minute, and final extension of 72ºC for 7 minutes.  PCR 
products were analyzed on 1% agarose gels and stained with ethidium bromide (0.5 
µg/ml) to confirm generation of 1.36 kb amplified product. The pTatHA DNA was 
digested with restriction enzymes NcoI and SphI and purified.  E132 PCR product was 
digested with NcoI-SphI and subcloned into the NcoI-SphI sites of pTatHA to yield 
E132/TatHA using a Klenow-Kinase-Ligase (KKL) protocol (23).  Ligated constructs 
containing E132/TatHA were transformed into E. coli Top10F’ competent cells 
(Invitrogen Life Technologies, Carlsbad, CA) and correct gene insertion verified by DNA 
sequencing of plasmid DNA.    
 
Small-Scale Recombinant Protein Production  
 E2F-1/TatHA and E132/TatHA plasmids were transformed into BLR(DE3)pLysS 
competent cells (Novagen, Madison, WI) and recombinant proteins produced via 
inoculating 2 ml 2YT broth with single transformed colonies.  After incubation in 
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shaking water bath (225 rpm) for 12-14 hours, 3 ml of fresh 2YT broth, 0.5 µg/ml 
ampicillin, and 0.4 mM isopropyl-beta-D-thiogalactopyranoside (IPTG) were added to 
cultures.  Bacterial cultures were incubated an additional 6 hours to produce recombinant 
proteins.  Cultures were centrifuged at 6000 x g for 10 minutes and cell pellets 
resuspended in 100 µl of 20 mM Tris buffer (pH 8.0) followed by quantitation using a 
BCA
TM
 Protein Assay Kit (Pierce Biotechnologies, Inc., Rockford, IL) with BSA 
standards.  2X Laemmli Sample Buffer (24) was added to 50 µg of total cellular protein 
and samples were boiled for 3-5 minutes and immediately placed on ice.  Samples were 
then loaded onto 12% SDS-PAGE gels and electrophoresis performed using a Mini-
PROTEAN
®
 3 (Bio-Rad Laboratories, Hercules, CA) protein electrophoresis unit with 
the Laemmli buffer system.  Prestained 1 kb protein ladders (Fermentas Life 
Technologies, Hanover, MD) were also ran on each gel to determine protein size.   
 
Western Blotting 
 Duplicate gels were electrophoresed simultaneously- one gel for western blotting 
and a second gel for Coomassie blue staining.  Gel designated for western blotting was 
transferred to nylon membranes using a Trans-Blot SD Semi-Dry Electrophoretic 
Transfer Cell (Bio-Rad Laboratories, Hercules, CA) according to manufacturer’s 
instructions using 1X TBS-T transfer buffer. Recombinant protein production was 
verified using primary mouse monoclonal anti-HA antibodies (1:1,000 dilution) (CRP 
Inc., Denver, PA) and secondary HRP-labeled goat anti-mouse antibodies (1:25,000 
dilution) (KPL Inc., Gaithersburg, MD).  Membranes were blocked with TBS-T/5% milk 
solution for 1 hour, incubated with primary anti-HA antibody for 1 hour, washed 3 times 
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for 10 minutes each, and incubated with secondary HRP antibody for 1 hour.  Following 
additional washings (3 x 10 minutes), western blots were developed with SuperSignal 
West Pico Chemiluminescent Substrate (Pierce Biotechnology, Inc., Rockford, IL) 
according to manufacturer’s instructions.   Blots were exposed to X-ray film and 
developed with KODAK Developer (30 sec) and KODAK Fixer (30 sec).  Immunoblots 
were also visualized using a KODAK Image Station 2000R (KODAK, Rochester, NY) 
according to manufacturer’s instructions.  
 
Large-Scale Recombinant Protein Production 
 Recombinant E2F-1/TatHA and E132/TatHA proteins were purified under 
denaturing conditions with affinity chromatography using a modified procedure from 
Amersham Pharmacia (25).  Single colonies from protein expressing cultures inoculated 
200 ml of 2YT broth supplemented with ampicillin (50 µg/ml) and were incubated at 
37ºC while shaking at 225 rpm for 16-18 hours.  An additional 300 ml of broth was 
added along with fresh ampicillin and IPTG (400 µM), and cultures incubated an 
additional 6 hours.  Cultures were centrifuged for 10 minutes at 6000 x g, and the 
bacterial pellets frozen at -20ºC.  Cell pellets were thawed for 20 minutes at 37ºC, and 25 
ml of Buffer 1 (20 mM Tris
TM
-HCl, pH 8.0) added to resuspend the cells with vigorous 
pipetting.  Cells were sonicated on ice (3 x 15 sec) and centrifuged (10 min x 6000 g).  
Cell pellets containing the inclusion bodies were then resuspended in 25 ml Buffer 2 (2 
M urea, 20 mM Tris-HCl, 0.5 M NaCl, 2% Triton
TM
 X-100, pH 8.0).  Samples were 
again sonicated on ice and centrifuged as described above.  Pellets were resuspended in 
25 ml Buffer 2 to wash the inclusion bodies and recentrifuged.  A final wash of 25 ml of 
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Buffer 1 was then performed, and following centrifugation, pellets were either used 
immediately or frozen at -20ºC for a maximum of two weeks prior to use.   
 
Preparation of Inclusion Bodies for FPLC 
 Cell pellets were resuspended in 5-10 ml Buffer A1 (6 M guanidine-HCl, 0.5 M 
NaCl, 20 mM Tris-HCl, 20 mM imidazole, 5 mM -mercaptoethanol, pH 8.0) by stirring 
at room temperature for 60 minutes to solubilize recombinant proteins.  Samples were 
centrifuged at 20,000 x g for 15 minutes to pellet residual cell debris.  Protein supernatant 
containing denatured, soluble proteins was removed from debris and further clarified by 
passage through a 0.45 µM filter (Millipore, Bellerica, IL) to remove impurities.   
 
Isolation of Recombinant Proteins Using Affinity Chromatography 








 columns (Amersham 
Pharmacia, Piscataway, NJ) were equilibrated with 5 ml Buffer A1 and the proteins 
loaded at a flow rate of 0.5 ml/minute.  Columns were washed with an additional 10 ml 
of Buffer A1 followed by a wash of 10 ml of Buffer A2 (6 M urea, 0.5 M NaCl, 20 mM 
Tris-HCl, 20 mM imidazole, 5 mM -mercaptoethanol, pH 8.0).  A linear gradient from 6 
M to 0 M urea was then performed to remove the denaturant and start refolding the 
proteins on the HisTrap
TM
 column by gradually replacing Buffer A2 with Buffer B1 (0.5 
M NaCl, 20 mM Tris-HCl, 20 mM imidazole, 5 mM -mercaptoethanol, pH 8.0).  A total 
volume of 40 ml of Buffer B1 was used to perform the gradient wash.  The purified, 
refolded proteins were then eluted with Buffer B2 (0.5 M NaCl, 20 mM Tris-HCl, 500 
mM imidazole, 5 mM -mercaptoethanol, pH 8.0) using a gradient of 0 mM to 500 mM 
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imidazole in the buffer.  Fractions containing the purified protein were analyzed by SDS-
PAGE gel electrophoresis and quantified with the BCA
TM
 Protein Assay Kit (Pierce 
Biotechnologies).   
 
Dialysis of Recombinant Proteins into Cell Culture Media 
 E2F-1/TatHA and E132/TatHA recombinant proteins were diluted with FPLC 
elution buffer B2 to 0.5 mg/ml to avoid protein precipitation cascades.  Proteins were 
injected into 12 ml Slide-A-Lyzer
®
 Dialysis Cassettes (Pierce Biotechnology, Rockford, 
IL) for dialysis into PBS followed by overnight dialysis into cell culture media per 
manufacturer’s protocol.  Proteins were freshly dialyzed for each set of experiments and 
never frozen.  Following dialysis, proteins were centrifuged, sterile filtered with 0.2 µM 
filters (Millipore, Bellerica, MA) and the final concentrations of recombinant proteins 
determined using the Coomassie Plus
TM
 Bradford Assay (Pierce Biotechnology, 
Rockford, IL) and SDS-PAGE gels using BSA protein standards.  Recombinant proteins 
in media were supplemented with 10% heat-inactivated FBS (Hyclone, Logan, UT) and 
50 IU/ml penicillin/ 0.05 mg/ml streptomycin.  
 
Synthesis of TatHA Control Protein 
 The TatHA control protein was artificially synthesized (amino acid sequence: 
YPYDVPDYAYGRKKRRQRRR) (26) on a Ranin Symphony/Multiplex Peptide 
Synthesizer (Center for Integrated BioSystems, Logan, UT).  The TatHA peptide was 
reconstituted using Cellgro
TM 
RNase/DNase/Protease free dH20 for cell culture 
 145 
(Mediatech Inc., Herndon, VA) and stored at -70ºC at a working concentration of 1 
mg/ml (27).    
 
Primary Carcinoma Cell Culture  
 Primary infiltrating ductal breast carcinoma cell lines HCC1937 (ATCC number: 
CRL-2336) and HCC1599 (ATCC number: CRL-2331) were obtained from the 
American Type Culture Collection (Manassas, VA).  The cells were grown in RPMI-
1640 medium supplemented with 10% FBS, 50 IU/ml penicillin/ 0.05 mg/ml 
streptomycin, 10 mM HEPES and 1 mM sodium pyruvate.  Cells were grown in a 37ºC 
humidified incubator with 5% CO2.  Additional breast carcinoma cell lines were also 
utilized in our research: MDA-MB-231 (ATCC number: HTB-26), MDA-MB-435S 
(ATCC number: HTB-129) and MCF-7 cells (ATCC number: HTB-22).  MDA-MB-231 
and MDA-MB-435S cell lines were both grown in a 1:1 ratio of DMEM:Ham’s F12 
media supplemented with 10% FBS and 5 IU/ml penicillin/ 0.05mg/ml streptomycin.  
MCF-7 cells were grown in MEME cell culture media supplemented with 10% FBS, 50 
IU/ml penicillin/ 0.05 mg/ml streptomycin, 10 mM HEPES and 1 mM sodium pyruvate.  
Cell lines were grown in 25 cc
2
 and 75 cc
2
 tissue culture flasks and passaged every 2-4 
days when 70-80% confluent.  Cells were detached from flasks using 0.25% trypsin, 
0.03% EDTA solution according to standard cell culture protocols (28).   
 
Immunocytochemisty and TUNEL Assay 
 Proteins were tested at various µM concentrations to determine optimal 
transduction at different time points using immunocytochemistry to monitor cellular 
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uptake of E2F-1/TatHA, E132/TatHA and TatHA proteins.  For final experiments, 
HCC1937 and HCC1599 cells were exposed to 2 µM E2F-1/TatHA, E132/TATHA and 
TatHA fusion peptides for the following time points: 1, 6, 12 and 24 hours.  Cells were 
washed 3 times with 1X PBS, fixed for 30 minutes in 3.7% formaldehyde and 
permeabilized with 0.5% Triton X-100 in 1X PBS for 30 minutes.  Cells were blocked 
for 30 minutes with 1% FBS and 0.1% Tween-20 in 1X PBS.  Cells were incubated for 
60 minutes with primary mouse HA antibodies (1:1000 dilution in 1X PBS), washed 3 
times for 10 minutes each, and incubated for 60 minutes with a secondary FITC-labeled 
goat anti-mouse antibody (1:250 dilution in 1X PBS) (KPL, Inc., Gaithersburg, MD).  
For immunocytochemistry experiments, cells were washed, and incubated for 15 minutes 
with 1 µM TO-PRO-3 iodide (Molecular Probes, Eugene, OR) to counterstain the cell 
nuclei.  To perform the TUNEL assay, we used a TMR red In Situ Cell Death Detection 
Kit (Roche Applied Science, Indianapolis, IN).  Cells were fixed, permeabilized, and 
incubated with antibodies as described above to label recombinant proteins. Following 
the kit’s instructions, samples were then incubated with TUNEL reagents to label 
terminal DNA strand breaks.  Cells from immunocytochemistry and TUNEL experiments 
were mounted on slides using the Prolong
®
 Antifade Kit (Molecular Probes, Eugene, OR) 
and images captured with Bio-Rad MRC 1024 Laser Scanning Confocal Microscope 
using the 40X objective. 
 
Cell Culture Experiments with Recombinant Proteins 
 HCC1937 and HCC1599 cells were seeded at a density of 2 x 10
5
 cells/well in 
CellStar
®
 6-well tissue culture plates.  HCC1937 (adherent) cells were allowed 24 hours 
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to adhere to plates before recombinant proteins were added.  HCC1599 (suspension) cells 
were seeded directly into wells with TFPs.  For preliminary studies, MDA-MB-231, 
MDA-MB-435S and MCF-7 cells were allowed to adhere to plates for 24 hours prior to 
experiments with TFPs.  Following the specific treatment times of 6, 12 or 24 hours, 
RNA was isolated and analyzed via RT-qPCR as described below.   
 
RNA Isolation, Reverse Transcription, and qPCR 
 Total RNA was isolated from cells using the Mini RNA Isolation II
TM
 kit (Zymo 
Research, Orange, CA).  After treatment with TFPs, adherent cell lines were washed at 





 (Hyclone, Logan, UT).  RNA isolation was performed according to the 
manufacturer’s protocol.  The eluted RNA was quantified using a Nanodrop
®
 ND-1000 
Spectrophotometer (Nanodrop Technologies, Wilmington, DE) and stored at -80ºC. We 
used two-step reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR) 
for all the experiments described in this study.  A 200 ng quantity of RNA was treated 
with DNase (1 U/µg) (Fisher Scientific, Pittsburgh, PA) in a 10 µl digestion reaction 
volume including a final 1X concentration of RQ1 RNase-Free DNase Reaction Buffer 
(40 mM Tris-HCl, 10 mM MgSO4, 1 mM CaCl2, pH 8.0) (Fisher Scientific, Pittsburgh, 
PA).  Samples were incubated at 37ºC for 30 minutes, 1 µl of RQ1 DNase Stop Solution 
(20 mM EGTA, pH 8.0) (Fisher Scientific, Pittsburgh, PA) was added to the reactions 
and samples incubated at 65ºC for 10 minutes to inactivate the DNase.  The 11 µl volume 
of DNase-digested RNA was used for the RT-PCR reaction.   
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Production of cDNA from Total RNA via RT-PCR 
 The 11 µl volume containing the RNA was combined with 2 µl random 
hexadeoxynucleotides (0.5 µg/ul) (Fisher Scientific, Pittsburgh, PA) and a 4 µl volume of 
dNTP mix (10 mM per dNTP) (New England Biolabs, Beverly, MA). Tubes were heated 
for 5 minutes at 70ºC to anneal primers to RNA, samples then placed on ice, and the 
following components added to the reaction tube to yield a 20 µl volume: 2 µl 10X RT 
Buffer (50 mM Tris-HCl, 75 mM KCl, 3 mM MgCl2, 10 mM DTT, pH 8.3) (New 
England Biolabs, Beverly, MA), 10 U of RNase Inhibitor (Fisher Scientific, Pittsburgh, 
PA), and 25 U M-MuLV Reverse Transcriptase (New England Biolabs, Beverly, MA).  
Reaction tubes were incubated at 42ºC for 1 hour to generate cDNA, and the RT enzyme 
heat inactivated at 95ºC for 5 minutes.  A 0.5 µl volume containing 2.5 U of RNase H 
(New England Biolabs, Beverly, MA) was added to tubes and samples incubated at 37ºC 
for 20 minutes to degrade RNA.  RNase H was then heat inactivated at 95ºC for 5 
minutes.  Each cDNA pool was diluted to 50 µl and stored at -20ºC until analyzed via 
real-time qPCR reaction. 
 
Real-time qPCR Using SYBR
®
 Green 
 Real-time qPCR was performed using the MyiQ
TM
 Single Color Real-Time PCR 
Detection System (Bio-Rad Laboratories, Hercules, CA).  A 2 µl sample of each cDNA 




 Green Supermix (Bio-
Rad Laboratories) and 300 nM of each primer.  Primers were obtained from Fisher 
Scientific (Pittsburgh, PA) and sequences are as follows: p73 sense primer 5’-
GGATTCCAGCATGGACGTCTT-3’ (29), p73 antisense primer 5’-
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GCGCGGCTGCTCATCT-3’ (29), p21 sense primer 5’-
GATTAGCAGCGGAACAAGGA-3’, p21 antisense primer 5’-
CAACTACTCCCAGCCCCATA-3’, -actin sense 5’-CACTCTTCCAGCCTTCCTTCC-
3’ (30) and -actin antisense primer 5’-CTGTGTTGGCGTACAGGTCT-3’ (30).  All 
qPCR reactions were performed in at least triplicate for each sample using a 96-well real-
time plate.  The following cycling program was used for all primer sets.  Initial 
denaturation step at 95ºC for 3 minutes followed by 45 cycles using with following 
parameters: 94ºC- 30 seconds (denaturation), 59.5 ºC- 30 seconds (annealing step), 72ºC- 
30 seconds (extension), and 80ºC- 15 seconds (data acquisition step).  A melt curve was 
performed for every reaction plate.  Fold changes in gene expression were determined 
using the 2
-∆∆CT 
method (31).  Following analysis with real-time quantitative PCR, the CT 
data were imported into Microsoft Excel.  CT values for p73, p21, and -actin were 
averaged for each sample, and ∆CT calculated (∆CT=CT, avg. p73, p21 – CT, avg. -actin).  ∆∆CT 
was calculated in the following manner: ∆∆CT = Avg. ∆CT, p73/p21 from E2F-1 or E132 TFP treatment 






 Statistical significance of mean fold changes in gene expression was determined 
by Student’s paired t-test using Microsoft Excel and Analyze-it
TM
 (Analyze-it Software, 






 Our lab successfully produced and purified biologically active E2F-1 Tat fusion 
proteins with the ability to transduce all breast cancer cell lines that underwent testing 
(transduction rates >95%).  Figure 5.2 represents a western blot verifying the 
hemagglutinin-tag in the 60 kDa recombinant E2F-1/TatHA and E132/TatHA proteins 
from bacterial culture isolates.  Following purification of the recombinant proteins, 
transduction experiments using immunocytochemistry in TFP treated HCC1937 and 
HCC1599 cells revealed significant perinuclear and cytoplasmic accumulation of the 
recombinant proteins with trace to moderate nuclear and nucleolar accumulation of 
proteins (data not shown).  HCC1599, MCF-7, MDA-MB-231 and MDA-MB-435S all 
exhibited effective transduction of the TFPs (data not shown). 
 Importantly, our experiments were only performed with freshly dialyzed 
recombinant E2F-1/TatHA and E132/TatHA proteins to avoid the addition of glycerol 
required for cryopreservation and to minimize protein precipitation.  The E2F-1 Tat 
fusion proteins were highly sensitive to precipitation during purification, dialysis and 
following attempted storage at -20ºC and -80ºC.  E2F-1/TatHA and E132/TatHA 
recombinant proteins were especially vulnerable to pH changes during FPLC and 
temperature changes during dialysis.  If a precipitation cascade was initiated, the proteins 
were not utilized in experiments due to diminished biological activity (data not shown).  
Following the protein purification procedure describe in Materials and Methods, the TFPs 
that maintained biological activity throughout the purification and dialysis process were 
able to impact gene expression in the p53-mutated primary ductal breast cancer cell lines.   
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 The effects of 2 µM E2F-1/TatHA, E132/TatHA and TatHA on p73 gene 
expression were examined in HCC1599 cells at several different time points: 6, 12 and 24 
hours.  Figure 5.3 demonstrates the gradual increase of p73 gene expression following 
both E2F-1/TatHA and E132/TatHA treatments as compared to the TatHA peptide 
control.  After six hours of TFP treatment, p73 expression was increased by 1.3-fold in 
E2F-1/TatHA treated cells (p<0.0001, n=16) and 1.4-fold in E132/TatHA treated cells 
(p<0.0001, n=16) in comparison to the TatHA control peptide.  Treatment with TFPs for 
12 hours resulted in a 2.2-fold increase of p73 gene expression with E2F-1/TatHA treated 
cells (p<0.0001, n=17) and a 2.2-fold increase in E132/TatHA treated cells (p<0.0001, 
n=17) in comparison to the TatHA control peptide.  Following TFP treatment, the 
greatest fold increase in p73 gene expression was observed following 24 hours of TFP 
exposure.  Treatment with E2F-1/TatHA (p<0.0001, n=18) for 24 hours resulted in 2.7-
fold increase in p73 expression and E132/TatHA treatment (p<0.0001, n=18) resulted in 
a similar 2.2-fold increase of p73.  For all three time points, no significant difference in 
gene expression was detected after 6 and 12 hours of treatment with E2F-1/TatHA versus 
E132/TatHA (6 hours: p<0.4212, n=16; 12 hours: p<0.9577, n=17).  However, a small 
statistically significant difference was observed after 24 hours of treatment with E2F-
1/TatHA versus E132/TatHA (p<0.0178, n=17).  
 In HCC1937 cells, treatment with 2 µM TFPs for 24 hours resulted in a 2.0-fold 
increase in p73 gene expression with exposure to both E2F-1/TatHA (p<0.0001, n=17) 
and E132/TatHA (p<0.0001, n=17) (see Figure 5.4).  Again, no significant differences 
were observed between E2F-1/TatHA and E132/TatHA treatment (p<0.8520, n=17).  In 
preliminary experiments with MDA-MB-231, MDA-MB-435S and MCF-7 cells, 
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treatment with TFPs for 24 hours resulted in no significant increases in p73 gene 
expression (results not shown). 
 Following 24 hours of TFP treatment, total RNA from cells was analyzed for 
changes in p21
WAF1/CIP1
 expression associated with alterations in p73 gene expression.  In 
HCC1599 cells, p21
WAF1/CIP1
 gene expression increased by 3.3-fold with E2F-1/TatHA 
treatment (p<0.0001, n=18) and by 3.4-fold with E132/TatHA treatment (p<0.0001, 
n=17) in comparison to the TatHA control peptide (refer to Figure 5.5).  No significant 
difference was observed between E2F-1/TatHA treatment versus E132/TatHA treatment 
(p<0.7829, n=17).  In the HCC1937 cell line, a lesser degree of increased p21
WAF1/CIP1
 
gene expression was observed (Figure 5.5).  Following 24 hours of treatment with TFPs, 
a small 1.4-fold increase in p21
WAF1/CIP1
 was detected in both E2F-1/TatHA (p<0.0046, 
n=16) and E132/TatHA treated cells (p<0.0223, n=16).  An obvious difference in 
p21
WAF1/CIP1
 gene expression was appreciated in the wildtype BRCA1 cell line HCC1599 
versus the BRCA1 mutated cell line HCC1937.  These results support the diminished 
ability of increased levels of p73 to activate p21
WAF1/CIP1
 expression in breast cancers 
with BRCA1 mutations.  
 Both HCC1599 and HCC1937 cells were examined for apoptotic activity 
following 24 hours of treatment with TFPs.  Initially, flow cytometric analysis was 
attempted with TUNEL assays to quantitate apoptotic activity; however, both cells lines 
were not compatible with FACS analysis due to severe cell clumping regardless of 
troubleshooting techniques and cell dissociation agent utilized.  In the adherent cell line, 
HCC1937, cells were examined using fluorescent microscopy to quantitate apoptotic 
activity following TFP treatment (refer to Materials and Methods).  Figure 5.6 illustrates 
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the apoptotic activity observed in HCC1937 cells following treatment with TFPs.  
Approximately 11.7% of cells were TUNEL-positive with E2F-1/TatHA treatment 
(p<0.0001, n=9) and 10.5% of cells TUNEL-positive with E132/TatHA treatment 
(p<0.0001, n=9).  Treatment with the TatHA control peptide only revealed 0.46% of 
TUNEL-positive cells.  Therefore, following treatment with TFPs, significant apoptotic 
activity was detected in both E2F-1/TatHA and E132/TatHA treated breast cancer cells.  
Greater statistically significant apoptotic activity was appreciated with E2F-1/TatHA 
versus E132/TatHA treatment (p<0.0067, n=9) which could be associated with the 
greater expression of p73 in cells treated with E2F-1/TatHA for 24 hours.  
 Figure 5.7 demonstrates apoptotic activity in HCC1937 and HCC1599 cells using 
immunocytochemistry combined with the TUNEL-assay.  Transduction of the different 
TFPs is represented by the fluorescein-labeled proteins that exhibit cytoplasmic, 
perinuclear and nucleolar accumulation in both cell lines.  Texas Red fluorescing nuclei 
representing apoptotic activity were visualized in both cells lines.  Although the apoptotic 
activity in HCC1937 cells could be quantitated, in the HCC1599 cells, fluorescent 
microscopy was only used to qualitatively assess apoptotic activity (see Figure 5.7).  Due 
to irreversible cell clumping, the number of cells undergoing apoptosis could not be 
accurately quantified microscopically.  It is speculated that in comparison to the level of 
apoptosis observed in HCC1937 cells, a comparable number of HCC1599 cells 
underwent apoptosis suggesting about 10% of E2F-1/TatHA and E132/TatHA treated 






 Approximately 80% of breast cancers are primary infiltrating ductal carcinomas; 
therefore, it is important to examine the biological effects of E2F-1/TatHA on this stage 
of tumor development.  Our research investigated an alternate route to modulate cancer 
cell growth in anticipation of augmenting the chemotherapeutic effects of conventional 
therapies in breast tumors that express mutant p53 tumor suppressor genes but maintain 
transcriptionally active p73.  Utilizing p53-mutated primary ductal breast cancer cell 
lines, HCC1937 and HCC1599, we were able to effectively induce expression of p73 
with both E2F-1/TatHA and E132/TatHA protein treatments versus the control peptide.  
Despite the mutation in the DNA-binding domain present in E132/TatHA, the intact 
marked-box domain enabled this protein to elicit its effect on p73.  However, following 
24 hours of treatment, the wildtype E2F-1/TatHA protein increased p73 by 2.7-fold 
versus the 2.2-fold observed from E132/TatHA treatment.  This difference could be 
attributed to altered biological activity of the E132/TatHA proteins due to the DNA-
binding domain mutation affecting protein folding and capacity to bind the p73 promoter.  
Further evaluation of these differences will be assessed in future experiments.  In 
comparison to the study by Marabese et al. (2003), our results that suggest increased p73 
expression resulting from E2F-1/TatHA and E132/TatHA treatment supports their 
reported findings of 2.5-fold induction of p73 in the neuroblastoma cell line SH-SY5Y 
following treatment with doxorubicin (29).  Our results parallel the findings of Marabese 
et al. (29) and support the ability of E2F-1 and E132 Tat fusion peptide treatment to 
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induce changes in gene expression comparable to the effects elicited by chemotherapeutic 
agents.  
 It is widely accepted that p53 has a central role in the induction of apoptosis.  Due 
to the high prevalence of p53 mutations in breast cancer cells, alternative pathways must 
be activated to impact the cell cycle.  This study supports the effective activation of p73 
and induction of p53-responsive genes in p53-mutated cell lines.  In HCC1599 cells, 
E2F-1/TatHA and E132/TatHA treatment increased p21
WAF1/CIP1
 expression by at least 
3.3-fold.  In contrast, the BRCA1 mutated cell line, HCC1937, demonstrated a 
significantly smaller 1.4-fold activation of p21
WAF1/CIP1
.  These results support the 
importance of wildtype BRCA1 tumor suppressor proteins in the activation of p53-target 
genes.  Apoptotic activity was still present in both cell lines suggesting additional 
pathways and target genes may have been induced by TFP treatment.  These results 
suggest that E2F-1/TatHA treatment of breast cancer cells would be potentially more 
beneficial in tumors expressing wildtype BRCA1.  Future evaluation of gene and protein 
expression following TFP treatment using microarray technology may reveal additional 
upregulated and downregulated pathways resulting from E2F-1 TFP treatment to further 
distinguish the association between p21
WAF1/CIP1
 and BRCA1.   
 The E2F-1/TatHA fusion proteins tested in our experiments affected p73 
expression in non-metastatic primary ductal breast cancer cell lines.  The metastatic 
breast cancer cell lines investigated in our preliminary experiments did not reveal 
significant fold increases in p73.  However, both MDA-MB-231, MDA-MB-435S and 
MCF-7 already overexpress p73 (7, 32-34) suggesting that advanced, metastatic breast 
cancer would not be responsive to the E2F-1/TatHA or E132/TatHA treatments.  No 
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morphological changes suggesting apoptosis were observed in the MDA-MB-231 or 
MDA-MB-435S cell lines with TFP treatment (data not shown).  The MCF-7 cells treated 
with the TFPs did not experience any changes in p73 and p21
WAF1/CIP1
 gene expression as 
detected by real-time RT-qPCR.  However, the MCF-7 cells did exhibit morphological 
changes consistent with apoptosis such as cell detachment, cell shrinkage and membrane 
blebbing after 24 hours of treatment with TFPs.  Further evaluation of apoptotic pathways 
using microarray analysis will be pursued to assess the affects of E2F-1 TFP treatment in 
MCF-7 cells.        
 In summation, we were able to successfully produce biologically active E2F-1 Tat 
fusion proteins that elicited a biological effect in primary, p53-mutated breast cancer cell 
lines HCC1937 and HCC1599.  Real-time RT-qPCR revealed significant fold increases 
in both p73 expression and the p53-responsive gene p21
WAF1/CIP1
.  Evidence of apoptosis 
was observed in both cell lines after 24 hours of treatment suggesting that longer 
treatment times with TFPs could significantly augment therapies targeting primary breast 
cancer cells.  Additionally, our research supports an alternative route of impacting gene 
expression in primary breast tumors by using E2F-1 Tat fusion proteins which could 
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Construction of Expression Vectors and Specific Domains within 
E2F-1 Tat Fusion Proteins 
 
Figure 5.1. Construction of expression vectors and specific domains within E2F-1 Tat 
Fusion Proteins. Abbreviations: HIS= 6-Histidine tag used in protein purification, HA= 
Hemagglutinin tag, TAT= HIV-1 Tat transduction domain, E132= mutant variant of 
E2F-1 (mutation in DNA-binding domain), E2F-1= wildtype E2F-1 transcription factor.  
(A) TatHA control peptide, (B) E132/TatHA peptide, (C) E2F-1/TatHA peptide with 
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Figure 5.2. Western Blot analysis of lysates from bacterial cultures producing 
recombinant Tat fusion proteins.  Protein (50 µg) was subjected to SDS-PAGE analysis 
and immunoblotting performed using primary mouse monoclonal HA antibodies 
(1:1000 dilution) and secondary HRP-labeled goat anti-mouse antibodies (1:25000 
dilution).  Lane 1, E2F-1/TatHA.  Lane 2, E132/TatHA. 
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Figure 5.3.  Fold difference in p73 gene expression in HCC1599 cells following 6, 12 
and 24 hours of treatment with TFPs.  HCC1599 cells were seeded at a density of 2 x 10
5
 
in 24-well plates for treatment with 2 M Tat fusion proteins.  Following treatment for 6, 
12 or 24 hours, RNA was isolated and subjected to RT-qPCR as described under 
Materials and Methods.  Fold increases in p73 gene expression for different Tat fusion 
proteins are indicated on the chart.  The asterisks (*) indicate significant fold increases in 
p73.  The results are means +/- SEM of three separate experiments (6 hour treatment, 












Fold Change in p73 Gene Expression in HCC1937 Cells 
 






















































Figure 5.4.  Fold difference in p73 gene expression in HCC1937 cells following 24 hours 
of treatment with TFPs. HCC1937 cells were seeded at a density of 2 x 10
5
 in 24-well 
plates.  Cells were allowed 24 hours to adhere to plates prior to Tat fusion protein 
treatment.  Cells were treated with 2 M Tat fusion proteins for 24 hours, washed, and 
cells detached from plates using HyQTase (Hyclone, Logan, UT).  RNA was isolated and 
RT-qPCR performed as described under Materials and Methods.  The asterisks (*) 
indicate significant fold increases in p73.  The results are means +/- SEM of three 
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WAF1/CIP1























































Figure 5.5.  Fold difference in p21
WAF1/CIP1
 gene expression in HCC1599 and HCC1937 
cells following 24 hours of treatment with TFPs.  HCC1599 and HCC1937 cells were 
seeded at a density of 2 x 10
5
 in 24-well plates.  HCC1937 cells were allowed 24 hours to 
adhere to plates prior to Tat fusion protein treatment, and HCC1599 cells were seeded 
directly into media with TFPs.  Cells were treated with 2 M Tat fusion proteins for 24 
hours. RNA was isolated and RT-qPCR performed as described under Materials and 
Methods. The asterisks (*) indicate significant fold increases in p21
WAF1/CIP1
.  The results 








Apoptotic Activity in HCC1937 Cells Following 24 Hours of Tat  






































Figure 5.6.  Apoptotic activity in HCC1937 cells following treatment with 2 µM TFPs 
for 24 hours.  The percentage of cells undergoing apoptosis is represented by the bar 
graph.  For each treatment, cells that were positive and negative for the TUNEL assay 
were manually counted in three separate fields of view.  The apoptotic activity represents 
the mean number of TUNEL-positive cells from three independent experiments.  The 
asterisks (*) indicate significant increases in apoptotic activity in E2F-1/TatHA treated 
cells (p<0.0001, n=9) and E132/TatHA treated cells (p<0.0001, n=9) in comparison to 









Immunocytochemistry of Apoptotic Activity in HCC1599 and HCC1937 
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Figure 5.7. Immunocytochemistry and apoptotic activity in HCC1599 and 
HCC1937 cells after 24 hours of treatment with TFPs.  (A) E2F-1/TatHA treated 
cells.  (B) E132/TatHA treated cells.  (C) TatHA treated cells.  Breast cancer cells 
were treated with 2 µM Tat fusion proteins for 24 hours.  E2F-1/TatHA and 
E132/TatHA induced apoptosis in both HCC1599 and HCC1937 cells.  Apoptotic 
cells are indicated by the Texas Red fluorescing nuclei.  Transduction of the 
recombinant Tat fusion proteins is indicated by fluorescein-labeled proteins as 
described under Materials and Methods. Images were captured using a 40X 
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GENERAL DISCUSSION AND CONCLUSION 
 
 This research has provided valuable information regarding future applications of 
E2F-1 Tat fusion proteins to augment current chemotherapeutic regimens used to treat 
primary ductal breast carcinomas.  The production and purification of E2F-1 Tat fusion 
proteins has permitted the investigation of a reversible, protein therapy to target specific 
genetic alterations contributing to tumorigenesis.  Specifically, this research targeted p53-
mutated primary infiltrating ductal breast carcinomas.  Approximately 80% of all breast 
tumors are classified as primary infiltrating ductal breast carcinomas, and our goal was to 
impact this stage of tumor development with our novel therapy.  Importantly, this 
research is the first to report the therapeutic application of E2F-1 Tat fusion proteins in 
primary infiltrating ductal breast cancer cell lines.  
 In order to test the therapeutic potential of E2F-1 Tat fusion proteins, the protein 
constructs were first cloned and optimal protein production conditions determined. 
A multi-step purification protocol was optimized to produce large quantities of 
recombinant E2F-1 and E132 Tat fusion proteins.  Utilizing 6 M guanidine-HCl in the 
solubilization buffers permitted complete denaturation of recombinant proteins allowing 
for isolation on nickel-charged HisTrap
TM
 columns.  Conditions were also optimized to 
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prevent protein precipitation cascades during the purification stage of protein production.  
An obvious limitation of protein therapy is the ability to produce sufficient quantities of 
proteins for in vitro and possibly in vivo experimentation.  We modified existing protein 
purification protocols for E2F-1/TatHA and E132/TatHA proteins to yield 10-12 mg of 
recombinant proteins per 500 ml of bacterial culture.  This protocol enabled us to produce 
sufficient protein for multiple series of in vitro experiments.  However, future in vivo 
studies are potentially limited due to the maximum 0.5 mg/ml concentration of E2F-
1/TatHA and E132/TatHA proteins produced using our protocol designed to prevent 
protein precipitation.  In addition, we were unable to use cryopreserved TFPs on our cell 
lines because the cells were extremely sensitive to all concentrations of glycerol tested.  
Our experiments with cells were limited to less than a week per batch of purified proteins 
since protein storage was restricted to a maximum of 5 days to preserve biological 
activity.  Therefore, future investigation into mammalian expression systems to produce 
the E2F-1/TatHA and E132/TatHA proteins will be investigated in hopes of increasing 
the solubility and biological activity of our proteins.  It is anticipated that mammalian 
expression vectors could also permit the production of larger quantities of biologically 
active proteins without the obstacles encountered from our bacterial expression system.    
 Following purification of E2F-1/TatHA and E132/TatHA fusion proteins, we 
prepared various cell lines for in vitro testing and to verify protein transduction.  The 
E2F-1/TatHA and E132/TatHA proteins produced in our lab possess the capability to 
transduce all cell types.  The exact mechanism of E2F-1 TFP transduction has not been 
definitively determined but appeared to parallel the pattern of transduction observed in 
the study by Yang et al. (2002) where significant nuclear and nucleolar accumulation of 
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proteins was observed (1).  Likewise, it is plausible that internalization of the E2F-
1/TatHA and E132/TatHA fusion proteins occurs in the rapid, lipid raft-dependent and 
receptor independent form of endocytosis not associated with caveolar- and clathrin-
mediated endocytosis described by Wadia et al. (2004) (2-4).  In all breast cancer cell 
lines tested, significant cytoplasmic, perinuclear and nucleolar accumulations of proteins 
were evident after all measured time points (1, 6, 12 and 24 hours).  Due to the rapid, 
substantial perinuclear accumulation of the proteins, their half-lives also seemed to be 
greatly extended versus the native forms of the proteins.  The wildtype E2F-1 protein and 
the mutant E2F-1 protein, E132, reportedly have biological half-lives of approximately 
70 minutes (4).  Caron et al. (2004) published that perinuclear accumulation of proteins is 
suggestive of sequestration of the recombinant proteins within the Golgi apparatus and 
endoplasmic reticulum (ER) (2).  This protein sequestration ultimately results in a 
sustained release of TFPs to the nuclear target thus appearing to extend the protein half-
lives (2).  The extended half-lives of the E2F-1/TatHA and E132/TatHA recombinant 
proteins observed in our studies suggests that the transduction and probable Golgi and ER 
accumulation in cells results in sustained biological activity of the proteins following 24 
hours of treatment.       
 Upon verification of efficient protein transduction, we assessed the effects of 
E2F-1/TatHA and E132/TatHA on gene expression in breast carcinoma cell lines.  It is 
important to review the specific genetic alterations in the breast cancer cell lines 
investigated by this research.  First, the HCC1937 and HCC1599 cell lines both contain 
p53 tumor suppressor gene mutations and are negative for expression of ER/PR receptors 
and Her2/neu.  Second, both cell lines are similar in tumor stage development (TNM 
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stage IIB, grade 3 and TNM stage IIIA, grade 3 respectively).  Third, both cell lines are 
positive for the expression of the catalytic subunit of telomerase, hTERT (human 
telomerase reverse transcriptase).  Thus, it was anticipated that E2F-1/TatHA proteins 
would impact both cell lines in a similar manner.  Initially, it was expected that E2F-
1/TatHA would effectively repress the expression of hTERT in both HCC1937 and 
HCC1599 cell lines.  The E132/TatHA protein (mutated DNA-binding domain) was used 
as a control in hTERT experiments in addition to a TatHA alone protein.  Following 
treatment of cell lines with E2F-1/TatHA, E132/TatHA and TatHA proteins for 24 hours, 
our data revealed significant repression of hTERT with E2F-1/TatHA treatment; 
however, complete repression of hTERT was not achieved.  In HCC1937 cells, hTERT 
was repressed 3.5-fold by E2F-1/TatHA in comparison to E132/TatHA and the TatHA 
peptide controls.  In HCC1599 cells, hTERT was also repressed with E2F-1/TatHA 
treatment by 4.0-fold when compared to E132/TatHA control.  A slightly lower hTERT 
repression of 3.3-fold was observed with E2F-1/TatHA in the HCC1599 cells when 
compared to the TatHA control.  Overall, these results suggest that transduction of E2F-
1/TatHA fusion proteins in vitro is a moderately effective repressor of hTERT expression 
in the primary ductal breast cancer cell lines HCC1937 and HCC1599.  The hypothesized 
repression of telomerase activity in infiltrating ductal carcinoma cells via E2F-1 repressor 
proteins is supported by significant hTERT repression in both HCC1937 and HCC1599 
cells.  However, the ability to achieve complete repression of hTERT via the E2F-1 
transcription factor still remains elusive.  Future experiments will further investigate the 
transcriptional repressive effects of E2F-1 and its effects on cell-cycle progression and 
telomerase repression. 
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 Although real-time RT-qPCR did not reveal significant effects of E132/TatHA on 
hTERT expression, the cell lines did exhibit visible signs of stress such as cell membrane 
blebbing and cell detachment in both E2F-1/TatHA and E132/TatHA versus TatHA 
treated cell lines.  This was suggestive of an alternate effect of E132/TatHA on gene 
transcription via the remaining intact protein domains.  Further literature review revealed 
an important role for the E2F-1 transcription factor in activating the p73 tumor 
suppressor pathway, and our initial research focus expanded to investigate this alternate 
pathway to target cell senescence and apoptosis.  Multiple studies using E2F-1 adenoviral 
and retroviral transfection of the E2F-1 gene support the activation of the p73 tumor 
suppressor pathway in carcinoma cells (5, 6).  Additionally, upregulation of p53-
responsive genes has been observed in cells following activation of p73 (7, 8).  
Specifically, stimulation of the p73 tumor suppressor gene has induced p21
WAF1/CIP1
 
expression leading to cell growth arrest and apoptosis in tumor cells (8, 9).   
 Despite the mutation in the DNA-binding domain present in E132/TatHA, the 
intact marked-box domain enabled this protein to elicit its effect on p73.  In our work, we 
monitored expression of the transcriptionally active form of p73, often referred to as 
TAp73, which includes both the alpha and beta isoforms of the p73 tumor suppressor 
protein.  Both TAp73α and TAp73β have been found to induce apoptosis in cell lines and 
activate p53-homologue proteins.  The real-time primer sequences utilized in our research 
were obtained from Marabese et al. in anticipation of achieving comparable elevations in 
transcriptionally active p73 gene expression with our novel E2F-1/TatHA and 
E132/TatHA protein therapy.  In our experiments, following 24 hours of treatment in 
HCC1599 cells, the wildtype E2F-1/TatHA protein increased p73 by 2.7-fold versus the 
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2.2-fold observed following E132/TatHA treatment.  This small difference could be 
attributed to altered biological activity of the E132/TatHA proteins due to the DNA-
binding domain mutation affecting protein folding and capacity to bind the p73 promoter.  
However, in HCC1937 cells, both E2F-1/TatHA and E132/TatHA treatment for 24 hours 
increased p73 by 2-fold.  Interestingly, these results support the biological activity of 
E132/TatHA proteins in alternate cellular pathways other than transcriptional repression 
of hTERT, which could explain some of the morphological changes we observed in both 
E2F-1/TatHA and E132/TatHA treated cell lines.  These findings are also consistent with 
the results published in the study by Marabese et al. (2003).  Our results, ranging from 
2.0- to 2.7-fold increases in p73 expression following E2F-1/TatHA and E132/TatHA 
treatment, reflect Marabese et al.’s reported findings of 2.5-fold induction of p73 in the 
neuroblastoma cell line SH-SY5Y following treatment with doxorubicin (10).  Therefore, 
our results parallel the findings of Marabese et al. (10) and support the ability of E2F-1 
and E132 Tat fusion peptide treatment to induce changes in gene expression comparable 
to the effects elicited by chemotherapeutic agents such as doxorubicin.  The 
chemotherapeutic agent doxorubicin (also referred to as Adriamycin) is a standard 
chemotherapeutic agent used to treat breast cancer.  The similar elevation in p73 
expression between our E2F-1/TatHA treatment and doxorubicin supports the feasible 
role of our protein therapy in breast cancer management in combination to standard 
chemotherapeutic agents.  
 As mentioned above, this research primarily focused on breast cancer cell lines 
with p53 tumor suppressor gene mutations.  Due to the high prevalence of p53 mutations 
in breast carcinomas, alternative pathways must be activated to impact the cell cycle.  
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This study supports the efficient activation of p73 and induction of p53-responsive genes 
in p53-mutated cell lines.  In HCC1599 cells, E2F-1/TatHA and E132/TatHA treatment 
increased p21
WAF1/CIP1
 expression by at least 3.3-fold.  In contrast, the BRCA1 mutated 
cell line, HCC1937, demonstrated a significantly smaller 1.4-fold activation of 
p21
WAF1/CIP1
.  Overall, this research supports the ability of E2F-1/TatHA and 
E132/TatHA proteins to induce expression of p21
WAF1/CIP1
 via p73 overexpression in 
comparison to TatHA controls.  However, an obvious difference in p21
WAF1/CIP1
 gene 
expression was appreciated in the wildtype BRCA1 cell line, HCC1599, versus the 
mutated BRCA1 cell line, HCC1937.  These results reveal the diminished ability of 
increased levels of p73 to activate p21
WAF1/CIP1
 expression in breast carcinomas with 
BRCA1 mutations.  These results also stress the importance of wildtype BRCA1 tumor 
suppressor proteins in the activation of p53-target genes.   Apoptotic activity was still 
present in both cell lines suggesting that additional pathways and target genes may have 
been induced by TFP treatment.  These results suggest that E2F-1 Tat protein treatment 
of breast cancer cells would be more beneficial in tumors expressing wildtype BRCA1.  
Future evaluation of gene and protein expression following TFP treatment using 
microarray technology may reveal additional upregulated and downregulated cellular 
pathways resulting from E2F-1 TFP treatment to further distinguish the association 
between p21
WAF1/CIP1
 and BRCA1.   
 Our data support a significant biological effect of E2F-1/TatHA and E132/TatHA 
proteins on gene expression of hTERT, p73 and p21
WAF1/CIP1
.  In addition to impacting 
gene expression, significant apoptotic activity was detected in HCC1937 and HCC1599 
cells following treatment with E2F-1/TatHA and E132/TatHA proteins for 24 hours.  
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Fluorescent microscopic evaluation of HCC1937 cells revealed that approximately 11.7% 
of cells were TUNEL-positive after exposure to E2F-1/TatHA proteins and 10.5% of 
cells were TUNEL-positive following E132/TatHA treatment.  Cells treated with the 
TatHA control peptide only revealed 0.46% TUNEL-positive cells.  Therefore, following 
exposure to TFPs, significant apoptotic activity was detected in both E2F-1/TatHA and 
E132/TatHA treated breast cancer cells.  The apoptotic activity visualized in HCC1599 
cells was difficult to quantitate due to cell clumping, but we estimated that approximately 
10% of cells were TUNEL-positive following 24 hours of treatment with E2F-1/TatHA 
and E132/TatHA proteins.  The mechanism of apoptosis resulting from E2F-1/TatHA and 
E132/TatHA treatment is assumed to be a downstream effect of the upregulated p73 
protein acting in a similar manner as p53.  As described in Chapter 2, the most likely 
mechanism of apoptosis is p73-mediated transactivation of BAX, PUMA and Noxa 
proteins leading to subsequent mitochondrial dysfunction and activation of effector 
caspases.  Likewise, induction of p21
WAF1/CIP1
 contributed to cell cycle arrest following 
p73 overexpression. 
 The E2F-1/TatHA and E132/TatHA proteins tested in our experiments impacted 
gene transcription and induced apoptosis in non-metastatic primary ductal breast cancer 
cell lines.  The metastatic breast cancer cell lines investigated in our preliminary 
experiments did not reveal significant fold changes in hTERT, p73 or p21
WAF1/CIP1
 
expression.  However, MDA-MB-231, MDA-MB-435S and MCF-7 already overexpress 
p73 (11-14) suggesting that advanced, metastatic breast cancer would not be responsive 
to the E2F-1/TatHA or E132/TatHA treatments.  No morphological changes consistent 
with apoptosis were observed in the MDA-MB-231 or MDA-MB-435S cell lines with 
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TFP treatment (data not shown).  The MCF-7 cells treated with the TFPs did not 
experience any changes in hTERT, p73 and p21
WAF1/CIP1
 gene expression as detected by 
real-time RT-qPCR.  However, the MCF-7 cells did exhibit morphological changes 
consistent with apoptosis such as cell detachment, cell shrinkage and membrane blebbing 
after 24 hours of treatment with TFPs.  These changes suggest an alternate pathway may 
be activated in metastatic breast cancer cell lines that already overexpress p73.          
 To summarize the results of our experiments, the following points outline the 
conclusions of our research.   
 
A.  E2F-1/TatHA and E132/TatHA proteins can be effectively produced and 
purified using an optimized protocol combining strong denaturants, FPLC and 
dialysis. 
 
B.  E2F-1/TatHA, E132/TatHA and TatHA proteins transduced greater than 95%     
of cell lines tested as detected via immunocytochemistry. 
 
C.  Following 24 hours of protein treatment, E2F-1/TatHA repressed expression 
of hTERT by 3.5-fold in HCC1937 cells and by 4.0-fold in HCC1599 cells versus 
E132/TatHA and TatHA controls.  No differences were observed in cell lines with 
wildtype versus mutant BRCA1 genes. 
 
D.  Complete repression of hTERT was not achieved with E2F-1/TatHA 
treatment versus E132/TatHA and TatHA treatment of breast cancer cell lines.  
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However, 75% of hTERT expression was inhibited by E2F-1/TatHA treatment in 
the HCC1599 cell line. 
 
E.  Treatment of HCC1937 and HCC1599 cell lines with E2F-1/TatHA and   
E132/TatHA proteins resulted in greater than 2-fold induction of p73 gene       
expression.   
 
F.  Upregulation of the p53 responsive gene, p21
WAF1/CIP1
, was observed in breast 
cancer cell lines following E2F-1/TatHA and E132/TatHA treatment due to 
increased expression of p73.  In HCC1937 cells, E2F-1/TatHA and E132/TatHA 
increased p21
WAF1/CIP1
 gene expression by at least 3.3-fold versus a smaller 
induction of 1.4-fold in HCC1599 cells.   
 
G.  E2F-1/TatHA and E132/TatHA treatments revealed a diminished effect of p73 
overexpression to induce p21
WAF1/CIP1
 expression in the BRCA1 mutated cell line, 
HCC1599, which supports the importance of wildtype BRCA1 tumor suppressor 
proteins in the activation of p53-target genes.  Therapeutic treatment of p53-
mutated primary ductal breast tumors with E2F-1 Tat protein therapy would be 
more effective if tumors express wildtype BRCA1.  
 
H.  HCC1937 cells exhibited apoptotic activity following treatment with TFPs as 
detected by TUNEL-positive cells.  E2F-1/TatHA treatment resulted in 11.7% of 
TUNEL-positive cells and E132/TatHA resulted in 10.5% of TUNEL- positive 
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cells versus 0.46% of TUNEL-positive cells observed in TatHA control treatment 
groups.  It is estimated that approximately 10% of HCC1599 cells were TUNEL-
positive following treatment with E2F-1/TatHA and E132/TatHA. 
 
 Although the experiments investigating the effects of E2F-1/TatHA and 
E132/TatHA on hTERT and p73 have been evaluated separately, recent studies suggest a 
possible overlap in these pathways.  Beitzinger et al. (2006) recently reported that forced 
expression of p73 via E2F-1 results in downregulation of hTERT (15).  This study 
suggested two dose-dependent mechanisms for hTERT repression: a) high levels of E2F-
1 protein results in direct hTERT repression via the mechanisms supported by Crowe et 
al (2001) via binding two specific sites in the hTERT promoter (16), and b) low levels of 
E2F-1 protein results in indirect hTERT repression via TAp73 induction and the TAp73 
protein binding Sp1 sites in the hTERT core promoter inducing transcriptional repression 
(15).  Beitzinger et al. induced E2F-1 expression via 4-hydroxytamoxifen induction of an 
ER-E2F-1 plasmid transfected into cell lines (15).  Tamoxifen induction of their ER-E2F-
1 construct resulted in significant induction of the TAp73 promoter and direct repression 
of the hTERT promoter (15).  Interestingly, although their method of introducing E2F-1 
into cells is different from our Tat-mediated E2F-1 transduction, their results are 
consistent with the findings of our studies.       
 It is possible that induction of TAp73 could have contributed to hTERT 
repression in our cell lines via Sp1 binding sites in the hTERT promoter; however, the 
results from E132/TatHA treatment of cells for 24 hours did not reveal this phenomenon.  
In E2F-1/TatHA treated cells, hTERT was repressed approximately 4-fold, in other 
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words, only 25% of hTERT was expressed in E2F-1/TatHA treated cells versus the 100% 
expression in E132/TatHA and TatHA treated cell lines.  E132/TatHA did induce 
expression of p73 via the intact marked box domain as our studies revealed 2.2-fold 
(HCC1599 cells) and 2.0-fold (HCC1937 cells) increases in p73 expression.  The 
E132/TatHA induction of p73 did not appear to induce repression of hTERT in the 24-
hour treatment period.  However, it is conceivable that this effect could be detected 
following a longer course of treatment for 48 or 72 hours.  In HCC1599 and HCC1937 
cells treated with E2F-1/TatHA for 24 hours, as previously mentioned, a 2.7-fold 
(HCC1599) and 2.0-fold (HCC1937) increase in p73 was observed in combination to a 4-
fold repression of hTERT.  It is possible that the induction of p73 contributed to the E2F-
1 repression of hTERT, but it is more probable that this effect would be observed at 
greater treatment time points since induction of p73 by E132/TatHA treatment for 24 
hours did not demonstrate hTERT repression. 
 In summary, this research is the first to report the effects of biologically active 
E2F-1 Tat fusion proteins on gene expression in breast carcinoma cell lines.  These 
recombinant proteins rapidly transduced cells and either induced or repressed expression 
of target genes.  We conclude that E2F-1/TatHA is a moderately effective repressor of 
hTERT.  We also determined that both E2F-1/TatHA and E132/TatHA are effective 
inducers of transcriptionally active p73 tumor suppressor protein expression.  Likewise, 
the overexpression of p73 from E2F-1/TatHA and E132/TatHA is an efficient method of 
inducing expression of p21
WAF1/CIP1
.  Although it is feasible that elevated levels of p73 
could impact hTERT and further repress its transcriptional activation, at the 24 hour 
treatment time point, the hTERT repression in our experiments was only attributed to 
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high levels of transduced E2F-1/TatHA proteins.  Ultimately, treatment of breast cancer 
cell lines for 24 hours with E2F-1/TatHA and E132/TatHA proteins induced detectable 
apoptotic activity in approximately 10% of treated cells.  Importantly, this work supports 
our hypotheses that protein transduction with E2F-1 Tat fusion proteins would repress 
hTERT, induce expression of p73 and p21
WAF1/CIP1 
and ultimately provoke cancer cell 
death.   
 It appears that E2F-1/TatHA proteins are marginally effective inducers of 
apoptosis; however, the primary goal of any cancer therapy is to induce 100% cancer cell 
death.  It is more feasible to consider future investigations of E2F-1/TatHA proteins as 
part of a combination therapy for breast cancer.  The combination of E2F-1 Tat fusion 
proteins with chemotherapeutic agents could offer a multifaceted approach targeting both 
cancer cell division and the genetic alterations contributing to the development of 
immortalized breast tumor cells.   
Breast cancer will continue to impact at least 1 out of 8 women worldwide.  
Therefore, the development of alternative therapies is necessary to advance cancer 
treatment by targeting the genetic alterations underlying cancer development.  The 
concept of chemoprotein therapy, the combination of chemotherapeutic drugs with 
protein therapy, will offer a novel modality to reversibly impact gene expression in 
cancer cells to induce cell senescence and/or apoptosis.  Further in vitro and in vivo 
investigation of E2F-1 Tat fusion protein therapy in combination with common 
chemotherapeutic agents will spearhead novel approaches in cancer treatment.  Clearly, 
the complex effects of E2F-1 Tat fusion proteins must be further investigated via 
microarray analysis and further in vitro and in vivo experimentation.  Overall, the results 
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of this work suggest potential applications of E2F-1/TatHA protein therapy in 
















































1. Yang, Y., Ma, J., Song, Z., and Wu, M. HIV-1 TAT-mediated protein 
transduction and subcellular localization using novel expression vectors. FEBS 
Lett, 532: 36-44, 2002. 
 
2. Caron, N. J., Quenneville, S. P., and Tremblay, J. P. Endosome disruption 
enhances the functional nuclear delivery of Tat-fusion proteins. Biochem Biophys 
Res Commun, 319: 12-20, 2004. 
 
3. Wadia, J. S., Stan, R. V., and Dowdy, S. F. Transducible TAT-HA fusogenic 
peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. 
Nat Med, 10: 310-315, 2004. 
 
4. Campanero, M. R. and Flemington, E. K. Regulation of E2F through ubiquitin-
proteasome-dependent degradation: stabilization by the pRB tumor suppressor 
protein. Proc Natl Acad Sci U S A, 94: 2221-2226, 1997. 
 
5. Hallstrom, T. C. and Nevins, J. R. Specificity in the activation and control of 
transcription factor E2F-dependent apoptosis. Proc Natl Acad Sci U S A, 100: 
10848-10853, 2003. 
 
6. Stiewe, T. and Putzer, B. M. Role of the p53-homologue p73 in E2F1-induced 
apoptosis. Nat Genet, 26: 464-469, 2000. 
 
7. Stanelle, J., Stiewe, T., Theseling, C. C., Peter, M., and Putzer, B. M. Gene 
expression changes in response to E2F1 activation. Nucleic Acids Res, 30: 1859-
1867, 2002. 
 
8. Miro-Mur, F., Meiller, A., Haddada, H., and May, E. p73alpha expression induces 
both accumulation and activation of wt-p53 independent of the p73alpha 
transcriptional activity. Oncogene, 22: 5451-5456, 2003. 
 
9. Peters, U. R., Tschan, M. P., Kreuzer, K. A., Baskaynak, G., Lass, U., Tobler, A., 
Fey, M. F., and Schmidt, C. A. Distinct expression patterns of the p53-homologue 
p73 in malignant and normal hematopoiesis assessed by a novel real-time reverse 
transcription-polymerase chain reaction assay and protein analysis. Cancer Res, 
59: 4233-4236, 1999. 
 
10. Marabese, M., Vikhanskaya, F., Rainelli, C., Sakai, T., and Broggini, M. DNA 
damage induces transcriptional activation of p73 by removing C-EBPalpha 
repression on E2F1. Nucleic Acids Res, 31: 6624-6632, 2003. 
 
 183 
11. Vayssade, M., Haddada, H., Faridoni-Laurens, L., Tourpin, S., Valent, A., 
Benard, J., and Ahomadegbe, J. C. P73 functionally replaces p53 in Adriamycin-
treated, p53-deficient breast cancer cells. Int J Cancer, 116: 860-869, 2005. 
 
12. Zaika, A. I., Kovalev, S., Marchenko, N. D., and Moll, U. M. Overexpression of 
the wild type p73 gene in breast cancer tissues and cell lines. Cancer Res, 59: 
3257-3263, 1999. 
 
13. Zaika, A., Irwin, M., Sansome, C., and Moll, U. M. Oncogenes induce and 
activate endogenous p73 protein. J Biol Chem, 276: 11310-11316, 2001. 
 
14. Dominguez, G., Garcia, J. M., Pena, C., Silva, J., Garcia, V., Martinez, L., 
Maximiano, C., Gomez, M. E., Rivera, J. A., Garcia-Andrade, C., and Bonilla, F. 
DeltaTAp73 upregulation correlates with poor prognosis in human tumors: 
putative in vivo network involving p73 isoforms, p53, and E2F-1. J Clin Oncol, 
24: 805-815, 2006. 
 
15. Beitzinger, M., Oswald, C., Beinoraviciute-Kellner, R., and Stiewe, T. Regulation 
of telomerase activity by the p53 family member p73. Oncogene, 25: 813-826, 
2006. 
 
16. Crowe, D. L., Nguyen, D. C., Tsang, K. J., and Kyo, S. E2F-1 represses 
transcription of the human telomerase reverse transcriptase gene. Nucleic Acids 







KIMBERLY ANN ELLIOTT 
 
Candidate for the Degree of 
 
Doctor of Philosophy 
 
 
Thesis:    TRANSDUCTION OF E2F-1 TAT FUSION PROTEINS INTO   
  PRIMARY INVASIVE DUCTAL BREAST CARCINOMA CELL  
  LINES AND SUBSEQUENT EFFECTS ON GENE TRANSCRIPTION  
 
 




Personal Data:  Born in Butte, Montana, on December 22, 1979 to Leonard and 
Debbie Urick.  Married Byrne Elliott on March 3, 2006.  
 
Education:  Received Bachelor of Science degree from East Central University 
in Ada, Oklahoma in 2000.  Completed requirements for the Doctor of 
Philosophy in Biomedical Science and the Doctor of Osteopathic 
Medicine at Oklahoma State University Center for Health Sciences in 
Tulsa, Oklahoma in May, 2007. 
 
Experience:  Visiting Scholar, Center for Integrated Biosystems, Utah State 
University, Logan, Utah, February 2004-July 2005.  Auxiliary to the 
Oklahoma Osteopathic Associate Student Research Fellowship, 
Oklahoma State University Center for Health Sciences, Tulsa, 
Oklahoma, 2001.  McNair Scholars Program Summer Internship, 
National Risk Management Research Laboratory Subsurface and 
Remediation Division, United States Environmental Protection Agency 
at Robert S. Kerr Environmental Research Laboratory, Ada, Oklahoma, 
2000.  Research Assistant, Chemistry Department, East Central 
University, Ada, Oklahoma, 2000.   
 
Professional Memberships:  American Osteopathic College of Dermatology. 
American Association for Cancer Research.  American Medical 
Women's Association.  Student Osteopathic Medical Association.  
American College of Osteopathic Family Physicians.  Student 
Osteopathic Association of Radiology.  Student Osteopathic Internal 
Medicine Association.  Student Osteopathic Surgical Association. 
American Association for Cancer Research-Women in Cancer Research. 
 
 
Name: Kimberly Ann Elliott                                 Date of Degree: May, 2007 
 
Institution: Oklahoma State University        Location: Tulsa, Oklahoma 
 
Title of Study: TRANSDUCTION OF E2F-1 TAT FUSION PROTEINS INTO 
PRIMARY INVASIVE DUCTAL BREAST CARCINOMA CELL 
LINES AND SUBSEQUENT EFFECTS ON GENE TRANSCRIPTION 
 
Pages in Study: 183                 Candidate for the Degree of Doctor of Philosophy 
Major Field: Biomedical Science 
 
Scope and Method of Study:  Breast cancer cells harbor specific genetic alterations that 
contribute to their immortalized state, including overexpression of telomerase and 
mutations of the p53 tumor suppressor gene.  E2F-1 is a known transcriptional repressor 
of the catalytic subunit of telomerase (referred to as hTERT).  In p53 mutated cells, E2F-
1 possesses the ability to transactivate the p73 tumor suppressor pathway and p53-
homologues involved in cell cycle arrest such as p21
WAF1/CIP1
.  We investigated an 
alternative method of introducing the E2F-1 transcription factor via Tat-mediated protein 
transduction to effectively target and reversibly impact gene expression in breast cancer 
cell lines. Using affinity chromatography and strong denaturants, the E2F-1 Tat fusion 
proteins were isolated and purified via FPLC and dialysis.  Real-time RT-qPCR was 
utilized to assess the effects of E2F-1 Tat fusion protein treatment on gene expression of 
select breast cancer cell lines.  Specifically, we investigated repression of hTERT and 
induction of p73 and p21
WAF1/CIP1 
genes in HCC1937 and HCC1599 primary invasive 
ductal breast cancer cell lines.  We also monitored apoptotic activity in carcinoma cells 
with TUNEL assays following treatment with E2F-1 Tat fusion proteins.  
 
Findings and Conclusions:  The E2F-1 Tat fusion proteins effectively transduced greater 
than 95% of breast cancer cell lines.  Protein therapy with E2F-1/TatHA repressed 
expression of hTERT by 3.5-fold in HCC1937 cells and by 4.0-fold in HCC1599 cells 
versus control proteins. Treatment of HCC1937 and HCC1599 breast carcinoma cell lines 
with E2F-1 Tat fusion proteins resulted in a greater than 2-fold induction of p73 gene 
expression. Upregulation of the p53 responsive gene, p21
WAF1/CIP1
, was also observed in 
HCC1937 and HCC1599 cell lines following treatment with our E2F-1 Tat protein 
therapy.  A 3.3-fold induction of p21
WAF1/CIP1
 was observed in HCC1937 cells versus a 
smaller induction of 1.4-fold in HCC1599 cells, which was attributed to the presence of a 
BRCA1 mutation in the HCC1599 cell line.  Following 24 hours of treatment with our 
E2F-1 Tat fusion proteins, apoptotic activity was detected in approximately 10% of 
breast cancer cells versus control proteins.  Overall, our E2F-1 Tat protein therapy proved 
to be a moderately effective repressor of hTERT and activator of both p73 and 
p21
WAF1/CIP1
 resulting in detectable apoptotic activity.  This suggests a potential 
application of E2F-1 Tat protein therapy in cancer therapeutics to modulate gene 
expression in breast carcinomas.    
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